Anti-human papillomavirus (HPV) antigen-binding proteins and methods of use thereof

Abstract

To provide anti-human papillomavirus (HPV) antigen-binding proteins, and use methods thereof.SOLUTION: The present invention provides antigen-binding proteins that specifically bind to an HLA-displayed human papillomavirus (HPV) peptide, and therapeutic and diagnostic methods of using the binding proteins. There is a problem that although vaccines targeting the HPV L1 and L2 major capsid proteins of HPV-6, HPV-11, HPV-16 and HPV-18 subtypes have been developed to prevent infection, such vaccines cannot treat subjects having established lesions. The present invention provides means to solve such a problem of the prior art.SELECTED DRAWING: None

Description

[Technical Field]

[0001] Related Applications This application claims priority to U.S. Provisional Application No. 62 / 525,937, filed June 28, 2017, the entire contents of which are expressly incorporated herein by reference.

[0002] Sequence Listing This application has been filed electronically in ASCII format and contains a Sequence Listing, which is incorporated herein by reference in its entirety. The ASCII copy, created on June 27, 2018, is named 10355WO01_seqlisting.txt and is 253,600 bytes in size.

[0003] FIELD OF THE INVENTION The present invention relates to antigen binding proteins that specifically bind to HLA-displayed human papillomavirus (HPV) peptides, and to therapeutic and diagnostic methods using these binding proteins. [Background technology]

[0004] Background of the Invention Human papillomaviruses (HPV) are a group of small, non-enveloped DNA viruses that are extremely common worldwide. HPV is primarily transmitted by sexual contact, and the majority of people become infected with HPV soon after the onset of sexual activity.

[0005] There are over 170 types of HPV, some of which can cause warts or benign papillomas, and at least 13 others, of which can cause cancers, including cervical cancer, anogenital cancer (cancer of the anus, penis, vagina, and vulva), head / neck cancer, and oropharyngeal cancer, including cancer of the back of the throat, base of the tongue, and tonsils (also known as high-risk HPV). In fact, HPV is present in 20-40% of all head and neck squamous cell carcinomas (HNSCC) and 100% of cervical cancers.

[0006] Cervical cancer is the second most common cancer among women living in developing regions, with an estimated 445,000 new cases (84% of new cases worldwide) in 2012. Approximately 270,000 women died from cervical cancer in 2012, with more than 85% of these deaths occurring in low- and middle-income countries.

[0007] Approximately 70% of all cervical cancers and precancerous cervical lesions are caused by two HPV types (16 and 18). The development of cancer during persistent infection with high-risk HPV subtypes such as HPV16 or 18 is primarily due to the expression of two viral oncoproteins, E6 and E7, which are persistently expressed in lesions and presented on the cell surface by MHC class I, but not in normal cells. E6 and E7 promote genomic instability and cellular transformation by degrading the tumor suppressors p53 and Rb in a proteasome-dependent manner. Tumors arise several years after the initial cell immortalization event, and sustained expression of E6 and E7 is required for the maintenance of the transformed phenotype and for the prevention of cell growth arrest and / or apoptosis (McLaughlin-Drubin ME & Miinger K., Virology (2009) 384: 335-344).

[0008] Although vaccines that target HPV L1 and L2, which are the main capsid proteins of HPV-6, HPV-11, HPV-16 and HPV-18 subtypes, have been developed to prevent infection, these vaccines cannot treat the subjects with established lesions.Therefore, the highly invasive and unhealthy traditional methods such as surgery, radiation therapy and chemotherapy are still used to treat the subjects with cervical cancer.In addition, these treatments can benefit the subjects with early cervical cancer, but have limited usefulness for the patients with advanced or recurrent cervical cancer. Thus, there is an unmet need in the art for new therapeutic strategies to target HPV with high specificity and to treat cervical cancer and other cancers caused by HPV. [Prior art documents] [Non-patent literature]

[0009] [Non-Patent Document 1] McLaughlin-Drubin ME & Miinger K., Virology (2009) 384: 335-344 Summary of the Invention [Means for solving the problem]

[0010] Summary of the Invention The present invention provides antigen-binding proteins that specifically bind to a conformational epitope of the HLA-displayed human papillomavirus (HPV) 16E7 peptide (HLA-A2:HPV16E7). The antigen-binding proteins of the present invention bind with high specificity to HLA-displayed HPV16E7 and do not bind to HLA-displayed peptides that differ by one, two, three, four, five, or more amino acids. The antigen-binding proteins of the present invention enable specific targeting of HPV16E7 peptide-presenting cells (i.e., cells that present HPV16E7 peptides bound to MHC molecules, e.g., HLA-A2, on their surface), such as HPV16E7-expressing cancer cells, and in some embodiments, stimulate T cell activation, for example, to stimulate T cell-mediated killing of such cells. Furthermore, when fused to a detectable moiety, the antigen binding proteins of the present invention enable the diagnosis and prognosis of HPV16E7-positive diseases or disorders with high sensitivity to changes in the number and distribution of HPV16E7 peptide-presenting cells, which are a more valid measure of disease progression than circulating HPV16E7 levels.

[0011] The antigen-binding proteins of the invention can be antibodies, such as full-length antibodies (e.g., IgG1 or IgG4 antibodies), or can comprise only the antigen-binding portion of an antibody (e.g., a Fab, F(ab')2, or scFv fragment), and can be modified to affect functionality, for example, to eliminate residual effector function (Reddy et al., 2000, J. Immunol. 164: 1925-1933). In some embodiments, the antigen-binding proteins of the present invention may be antibodies or antigen-binding fragments thereof. In certain embodiments, the antigen-binding proteins may be bispecific.

[0012] In a first aspect, the present invention provides isolated recombinant antigen-binding proteins that specifically bind to a conformational epitope of an HLA-displayed human papillomavirus (HPV) 16 E7 peptide, such as an HLA-displayed peptide comprising amino acid residues 11-19 or 82-90 of HPV16 E7. In certain embodiments, the antigen-binding protein is an antibody. In some embodiments, the antibody is a fully human antibody.

[0013] Exemplary anti-HLA-A2:HPV16E7 antigen binding proteins of the present invention are listed in Tables 1 and 2 herein. Table 1 lists the amino acid sequence identifiers for the heavy chain variable region (HCVR), light chain variable region (LCVR), heavy chain complementarity determining regions (HCDR1, HCDR2, and HCDR3), and light chain complementarity determining regions (LCDR1, LCDR2, and LCDR3) of exemplary anti-HLA-A2:HPV16E7 antibodies. Table 2 lists the nucleic acid sequence identifiers for the HCVR, LCVR, HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, and LCDR3 of exemplary anti-HLA-A2:HPV16E7 antibodies.

[0014] The present invention provides antigen binding proteins comprising an HCVR comprising an amino acid sequence selected from any of the HCVR amino acid sequences listed in Table 1, or a substantially similar sequence thereof having at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity thereto.

[0015] The present invention also provides antigen binding proteins comprising an LCVR comprising an amino acid sequence selected from any of the LCVR amino acid sequences listed in Table 1, or a substantially similar sequence thereof having at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity thereto.

[0016] The present invention also provides antigen binding proteins comprising an HCVR and LCVR amino acid sequence pair (HCVR / LCVR) comprising a pair of any of the HCVR amino acid sequences listed in Table 1 with any of the LCVR amino acid sequences listed in Table 1. According to certain embodiments, the present invention provides antigen binding proteins comprising an HCVR / LCVR amino acid sequence pair contained in any of the exemplary anti-HLA-A2:HPV16E7 antigen binding proteins listed in Table 1. In certain embodiments, the HCVR / LCVR amino acid sequence pair is selected from the group consisting of SEQ ID NOs: 2 / 10, 18 / 26, 34 / 42, 50 / 58, 66 / 74, 82 / 90, 98 / 106, 114 / 122, 130 / 138, 146 / 154, 162 / 170, 178 / 186, 194 / 202, 210 / 202, 218 / 226, 234 / 242, 250 / 262, 260 / 270, 272 / 282, 284 / 292, 300 / 312, 316 / 322, 326 / 332, 336 / 342, 340 / 352, 342 / 352, 354 / 362, 360 / 370, 372 / 382, 374 / 382, 376 / 392, 384 / 402, 386 / 412, 388 / 422, 388 / 432, 388 / 442, 392 / 452, 400 / 462, 400 / 472, 400 / 482, 410 / 422, 410 / 432, 420 58, 266 / 274, 282 / 290, 298 / 306, 314 / 322, 330 / 338, 346 / 354, 362 / 370, 378 / 386, 394 / 402, 410 / 418, 426 / 434, 442 / 450, 458 / 466, 474 / 482, 490 / 498, 506 / 514, and 522 / 530. In certain embodiments, the HCVR / LCVR amino acid sequence pair is selected from one of SEQ ID NOs: 2 / 10 (e.g., H4sH17364N), 34 / 42 (e.g., H4sH17670P), 82 / 90 (e.g., H4sH17675P), 194 / 202 (e.g., H4sH17930N2), 282 / 290 (e.g., H4sH21064P), and 506 / 514 (e.g., H4sH17363N).

[0017] In certain embodiments, the present invention provides anti-HLA-A2:HPV16E7 antigen binding proteins comprising an HCVR and an LCVR, wherein the HCVR comprises an amino acid sequence listed in Table 1 with no more than five amino acid substitutions, and the LCVR comprises an amino acid sequence listed in Table 1 with no more than five amino acid substitutions. For example, the present invention provides anti-HLA-A2:HPV16E7 antigen binding proteins comprising an HCVR and an LCVR, wherein the HCVR comprises the amino acid sequence of SEQ ID NO: 194 with no more than five amino acid substitutions, and the LCVR comprises the amino acid sequence of SEQ ID NO: 202 with no more than five amino acid substitutions. In another exemplary embodiment, the invention provides an anti-HLA-A2:HPV16E7 antigen binding protein comprising an HCVR and an LCVR, wherein the HCVR comprises the amino acid sequence of SEQ ID NO: 194 with at least one amino acid substitution, and the LCVR comprises the amino acid sequence of SEQ ID NO: 202 with at least one amino acid substitution.

[0018] The present invention also provides antigen binding proteins comprising a heavy chain CDR1 (HCDR1) comprising an amino acid sequence selected from any of the HCDR1 amino acid sequences listed in Table 1, or a substantially similar sequence thereof having at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity.

[0019] The present invention also provides antigen binding proteins comprising a heavy chain CDR2 (HCDR2) comprising an amino acid sequence selected from any of the HCDR2 amino acid sequences listed in Table 1, or a substantially similar sequence thereof having at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity.

[0020] The present invention also provides antigen binding proteins comprising a heavy chain CDR3 (HCDR3) comprising an amino acid sequence selected from any of the HCDR3 amino acid sequences listed in Table 1, or a substantially similar sequence thereof having at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity.

[0021] The present invention also provides antigen binding proteins comprising a light chain CDR1 (LCDR1) comprising an amino acid sequence selected from any of the LCDR1 amino acid sequences listed in Table 1, or a substantially similar sequence thereof having at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity.

[0022] The present invention also provides antigen binding proteins comprising a light chain CDR2 (LCDR2) comprising an amino acid sequence selected from any of the LCDR2 amino acid sequences listed in Table 1, or a substantially similar sequence thereof having at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity.

[0023] The present invention also provides antigen binding proteins comprising a light chain CDR3 (LCDR3) comprising an amino acid sequence selected from any of the LCDR3 amino acid sequences listed in Table 1, or a substantially similar sequence thereof having at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity.

[0024] The present invention also provides antigen binding proteins comprising an HCDR3 and LCDR3 amino acid sequence pair (HCDR3 / LCDR3) comprising a pair of any of the HCDR3 amino acid sequences listed in Table 1 with any of the LCDR3 amino acid sequences listed in Table 1. According to certain embodiments, the present invention provides antigen binding proteins comprising an HCDR3 / LCDR3 amino acid sequence pair contained in any of the exemplary anti-HLA-A2:HPV16E7 antigen binding proteins listed in Table 1. In certain embodiments, the HCDR3 / LCDR3 amino acid sequence pair is selected from the group consisting of SEQ ID NOs: 8 / 16 (e.g., H4sH17364N), 40 / 48 (e.g., H4sH17670P), 88 / 96 (e.g., H4sH17675P), 200 / 208 (e.g., H4sH17930N2), 288 / 296 (e.g., H4sH21064P), and 512 / 520 (e.g., H4sH17363N).

[0025] The present invention also provides antigen binding proteins comprising an HCVR and an LCVR, wherein the HCVR comprises an HCDR1 comprising an amino acid sequence that differs by one amino acid from the amino acid sequence listed in Table 1, an HCDR2 comprising an amino acid sequence that differs by one amino acid from the amino acid sequence listed in Table 1, and an HCDR3 comprising an amino acid sequence that differs by one amino acid from the amino acid sequence listed in Table 1. In certain embodiments, the present invention provides antigen binding proteins comprising an HCVR and an LCVR, wherein the LCVR comprises an LCDR1 comprising an amino acid sequence that differs by one amino acid from the amino acid sequence listed in Table 1, an LCDR2 comprising an amino acid sequence that differs by one amino acid from the amino acid sequence listed in Table 1, and an LCDR3 comprising an amino acid sequence that differs by one amino acid from the amino acid sequence listed in Table 1. For example, the present invention provides an anti-HLA-A2:HPV16E7 antigen binding protein comprising an HCVR and an LCVR, wherein the HCVR comprises an HCDR1 comprising the amino acid sequence of SEQ ID NO: 196 or an amino acid sequence that differs by one amino acid from SEQ ID NO: 196, an HCDR2 comprising the amino acid sequence of SEQ ID NO: 198 or an amino acid sequence that differs by one amino acid from SEQ ID NO: 198, and an HCDR3 comprising the amino acid sequence of SEQ ID NO: 200 or an amino acid sequence that differs by one amino acid from SEQ ID NO: 200. In another exemplary embodiment, the present invention provides an antigen binding protein comprising an HCVR and an LCVR, wherein the LCVR comprises an LCDR1 comprising the amino acid sequence of SEQ ID NO: 204 or an amino acid sequence that differs by one amino acid from SEQ ID NO: 204, an LCDR2 comprising the amino acid sequence of SEQ ID NO: 206 or an amino acid sequence that differs by one amino acid from SEQ ID NO: 206, and an LCDR3 comprising the amino acid sequence of SEQ ID NO: 208 or an amino acid sequence that differs by one amino acid from SEQ ID NO: 208.

[0026] The present invention also provides antigen binding proteins comprising the set of six CDRs (i.e., HCDR1-HCDR2-HCDR3-LCDR1-LCDR2-LCDR3) contained in any of the exemplary antigen binding proteins listed in Table 1. In certain embodiments, the HCDR1-HCDR2-HCDR3-LCDR1-LCDR2-LCDR3 amino acid sequence set is selected from the group consisting of SEQ ID NOs: 4-6-8-12-14-16 (e.g., H4sH17364N), 36-38-40-44-46-48 (e.g., H4sH17670P), 84-86-88-92-94-96 (e.g., H4sH17675P), 196-198-200-204-206-208 (e.g., H4sH17930N2), 284-286-288-292-294-296 (e.g., H4sH21064P), and 508-510-512-516-518-520 (e.g., H4sH17363N).

[0027] In related embodiments, the invention provides antigen binding proteins that comprise a set of six CDRs (i.e., HCDR1-HCDR2-HCDR3-LCDR1-LCDR2-LCDR3) contained in an HCVR / LCVR amino acid sequence pair defined by any of the exemplary antigen binding proteins listed in Table 1. For example, the present invention includes antigen-binding proteins comprising a set of HCDR1-HCDR2-HCDR3-LCDR1-LCDR2-LCDR3 amino acid sequences contained in an HCVR / LCVR amino acid sequence pair selected from the group consisting of SEQ ID NOs: 2 / 10 (e.g., H4sH17364N), 34 / 42 (e.g., H4sH17670P), 82 / 90 (e.g., H4sH17675P), 194 / 202 (e.g., H4sH17930N2), 282 / 290 (e.g., H4sH21064P), and 506 / 514 (e.g., H4sH17363N).

[0028] Methods and techniques for identifying CDRs within HCVR and LCVR amino acid sequences are well known in the art and can be used to identify CDRs within the specified HCVR and / or LCVR amino acid sequences disclosed herein. Exemplary conventions that can be used to identify the boundaries of CDRs include, for example, the Kabat definition, the Chothia definition, and the AbM definition. Generally speaking, the Kabat definition is based on sequence variability, the Chothia definition is based on the location of structural loop regions, and the AbM definition is a compromise between the Kabat and Chothia approaches. See, e.g., Kabat, "Sequences of Proteins of Immunological Interest," National Institutes of Health, Bethesda, Md. (1991); Al-Lazikani et al., J. Mol. Biol. 273: 927-948 (1997); and Martin et al., Proc. Natl. Acad. Sci. USA 86: 9268-9272 (1989). Public databases also identify CDR sequences within antigen-binding proteins. It is available for

[0029] The present invention includes anti-HLA-A2:HPV16E7 antigen binding proteins with modified glycosylation patterns. In some embodiments, modifications to remove undesired glycosylation sites or antibodies lacking fucose moieties present on the oligosaccharide chains may be useful, for example, to enhance antibody-dependent cellular cytotoxicity (ADCC) function (see Shield et al. (2002) JBC 277: 26733). In other applications, complement-dependent cytotoxicity (CDC) may be enhanced. Galactosylation modifications can be performed to modify (CDC).

[0030] In certain embodiments, the antigen binding proteins of the invention are monoclonal antibodies comprising an HCVR and LCVR amino acid sequence pair (HCVR / LCVR) comprising a pair of any of the HCVR amino acid sequences listed in Table 1 and any of the LCVR amino acid sequences listed in Table 1. In certain embodiments, the monoclonal antibody comprises an Fc domain of an isotype selected from the group consisting of IgA, IgD, IgE, IgG, IgG1, IgG2, IgG3, IgG4, and IgM, and variants thereof.

[0031] The present invention provides an antigen-binding protein or antigen-binding fragment thereof comprising a heavy chain comprising an amino acid sequence selected from any of the HC amino acid sequences listed in Table 3, or a substantially similar sequence thereof having at least 90%, at least 95%, at least 98%, or at least 99% sequence identity thereto.

[0032] The present invention also provides an antigen-binding protein or antigen-binding fragment thereof comprising a light chain comprising an amino acid sequence selected from any of the LC amino acid sequences listed in Table 3, or a substantially similar sequence thereof having at least 90%, at least 95%, at least 98%, or at least 99% sequence identity thereto.

[0033] The present invention also provides antigen-binding proteins or antigen-binding fragments thereof comprising an HC and LC amino acid sequence pair (HC / LC) comprising a pair of any of the HC amino acid sequences listed in Table 3 with any of the LC amino acid sequences listed in Table 3. According to certain embodiments, the present invention provides antibodies or antigen-binding fragments thereof comprising an HC / LC amino acid sequence pair contained in any of the exemplary anti-PD-1 antibodies listed in Table 3. In certain embodiments, the HC / LC amino acid sequence pair is selected from the group consisting of SEQ ID NOs: 578 / 579, 580 / 581, 582 / 583, 584 / 585, 586 / 587, 588 / 589, 590 / 591, and 592 / 593.

[0034] In one aspect, the present invention provides an antigen-binding protein or antigen-binding fragment thereof that binds to an HLA-peptide complex, where the antigen-binding protein or antigen-binding fragment thereof contacts at least 60%, at least 70%, at least 80%, or at least 90% of the amino acid residues of the peptide contained in the HLA-peptide complex. In certain embodiments, the antigen-binding protein or antigen-binding fragment thereof "spans" or contacts all of the amino acid residues of the peptide contained in the HLA-peptide complex. In certain embodiments, the antigen-binding protein or antigen-binding fragment thereof binds to the HLA-peptide complex with high affinity and specificity, where the antigen-binding protein or antigen-binding fragment thereof contacts the entire length of the displayed peptide. "Contact," as used herein, includes direct or water-mediated hydrogen bonding, charge-charge interactions, or hydrophobic / van der Waals interactions. In one embodiment, the antigen-binding protein or antigen-binding fragment thereof binds to the HLA-A2-HPV16E7 11-19 peptide complex, wherein the antigen-binding protein binds to at least six of the ten amino acid residues of peptide 11-19 (SEQ ID NO: 538) and HLA-A2, thus spanning the entire HLA-A2-peptide complex. In certain embodiments, the antigen-binding protein or antigen-binding fragment thereof comprises the CDRs of the HCVR and the CDRs of the LCVR, wherein the HCVR and LCVR have amino acid sequences selected from the HCVR and LCVR sequences listed in Table 1, respectively. In one embodiment, the antigen-binding protein is a fully human antigen-binding protein. In certain embodiments, the fully human antigen-binding protein is not obtained using phage display methods and techniques. In one embodiment, the antigen-binding protein comprises the light chain variable region of the IGKV1-39 subtype.

[0035] In certain embodiments, the present invention provides an antigen binding protein or antigen-binding fragment thereof that binds to HLA-A2:HPV16E7 11-19 peptide, wherein the antigen binding protein binds to one or more amino acids of SEQ ID NO: 538. In one embodiment, the antigen binding protein binds to at least six amino acids of SEQ ID NO: 538. In one embodiment, the antigen binding protein binds to one or more amino acids selected from the group consisting of Y11, D14, L15, P17, and E18 of SEQ ID NO: 538.

[0036] In certain embodiments, the present invention provides antigen binding proteins that specifically bind to a conformational epitope of HLA-A2-presented human papillomavirus (HPV) 16 E7 peptide (HPV16 E7 peptide), wherein the conformational epitope comprises one or more amino acids of SEQ ID NO: 538. In certain embodiments, the conformational epitope comprises one or more amino acids selected from the group consisting of Y11, D14, L15, P17, and E18 of SEQ ID NO: 538.

[0037] The present invention also provides antigen-binding proteins that compete for specific binding to HLA-A2:HPV16E7 with an antigen-binding protein comprising the CDRs of an HCVR and the CDRs of an LCVR, wherein the HCVR and LCVR have amino acid sequences selected from the HCVR and LCVR sequences listed in Table 1, respectively.

[0038] The present invention also provides antigen binding proteins that cross-compete for binding to HLA-A2:HPV16E7 with a reference antigen binding protein comprising the CDRs of an HCVR and the CDRs of an LCVR, wherein the HCVR and LCVR have amino acid sequences selected from the HCVR and LCVR sequences listed in Table 1, respectively.

[0039] The present invention also provides antigen binding proteins that bind to the same epitope as a reference antigen binding protein comprising the CDRs of an HCVR and the CDRs of an LCVR, wherein the HCVR and LCVR have amino acid sequences selected from the HCVR and LCVR sequences listed in Table 1, respectively. In certain embodiments, the present invention provides antigen binding proteins that bind to the same epitope as a reference antigen binding protein comprising the CDRs of an HCVR and the CDRs of an LCVR, wherein the HCVR is selected from the group consisting of SEQ ID NOs: 2, 34, 82, 194, 282, and 504, and the LCVR is selected from the group consisting of SEQ ID NOs: 10, 42, 90, 202, 290, and 514.

[0040] In one embodiment, the present invention provides a recombinant, isolated antigen binding protein that specifically binds to a conformational epitope of human papillomavirus (HPV) 16 E7 peptide (HPV16 E7 peptide) presented by HLA-A2, wherein (a) the protein has a binding dissociation equilibrium constant (K) of less than about 20 nM for monomeric HLA-A2:HPV16 E7 11-19 peptide as measured by a surface plasmon resonance assay at 25°C. D (b) binds to the monomeric HLA-A2:HPV16E7 82-90 peptide with a binding dissociation equilibrium constant (K) of less than about 25 nM as measured by surface plasmon resonance assay at 25°C. D ) binds to cells expressing the HLA-A2:HPV16E7 11-19 peptide with an EC of less than about 6 nM as determined by a luminescence assay. 50 and does not bind to cells expressing predicted off-target peptides; (d) has an EC of less than about 1 nM on cells expressing the HLA-A2:HPV16E7 82-90 peptide as determined by a luminescence assay. 50 (e) an EC50 of less than about 30 nM on cells expressing the HLA-A2:HPV16E7 11-19 peptide, as determined by flow cytometry assay. 50(f) binds to cells expressing the HLA-A2:HPV16E7 82-90 peptide with an EC of less than about 75 nM as determined by flow cytometry assay. 50 and (g) the conformational epitope comprises one or more amino acids of SEQ ID NO: 538. As disclosed elsewhere herein, an "off-target peptide" refers to a peptide that differs from a target peptide (e.g., HPV16E7 11-19 peptide) by one, two, three, four, five or more amino acids.

[0041] In a second aspect, the present invention provides nucleic acid molecules encoding anti-HLA-A2:HPV16E7 antigen binding proteins. For example, the present invention provides nucleic acid molecules encoding any of the HCVR amino acid sequences listed in Table 1, and in certain embodiments, the nucleic acid molecule comprises a polynucleotide sequence selected from any of the HCVR nucleic acid sequences listed in Table 2, or a substantially similar sequence thereof having at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity thereto.

[0042] The present invention also provides nucleic acid molecules encoding any of the LCVR amino acid sequences listed in Table 1, and in certain embodiments, the nucleic acid molecule comprises a polynucleotide sequence selected from any of the LCVR nucleic acid sequences listed in Table 2, or a substantially similar sequence thereof having at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity thereto.

[0043] The present invention also provides nucleic acid molecules encoding any of the HCDR1 amino acid sequences listed in Table 1, and in certain embodiments, the nucleic acid molecule comprises a polynucleotide sequence selected from any of the HCDR1 nucleic acid sequences listed in Table 2, or a substantially similar sequence thereof having at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity thereto.

[0044] The present invention also provides nucleic acid molecules encoding any of the HCDR2 amino acid sequences listed in Table 1, and in certain embodiments, the nucleic acid molecule comprises a polynucleotide sequence selected from any of the HCDR2 nucleic acid sequences listed in Table 2, or a substantially similar sequence thereof having at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity thereto.

[0045] The present invention also provides nucleic acid molecules encoding any of the HCDR3 amino acid sequences listed in Table 1, and in certain embodiments, the nucleic acid molecule comprises a polynucleotide sequence selected from any of the HCDR3 nucleic acid sequences listed in Table 2, or a substantially similar sequence thereof having at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity thereto.

[0046] The present invention also provides nucleic acid molecules encoding any of the LCDR1 amino acid sequences listed in Table 1, and in certain embodiments, the nucleic acid molecule comprises a polynucleotide sequence selected from any of the LCDR1 nucleic acid sequences listed in Table 2, or a substantially similar sequence thereof having at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity thereto.

[0047] The present invention also provides nucleic acid molecules encoding any of the LCDR2 amino acid sequences listed in Table 1, and in certain embodiments, the nucleic acid molecule comprises a polynucleotide sequence selected from any of the LCDR2 nucleic acid sequences listed in Table 2, or a substantially similar sequence thereof having at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity thereto.

[0048] The present invention also provides nucleic acid molecules encoding any of the LCDR3 amino acid sequences listed in Table 1, and in certain embodiments, the nucleic acid molecule comprises a polynucleotide sequence selected from any of the LCDR3 nucleic acid sequences listed in Table 2, or a substantially similar sequence thereof having at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity thereto.

[0049] The present invention also provides nucleic acid molecules encoding HCVRs, wherein the HCVRs comprise a set of three CDRs (i.e., HCDR1-HCDR2-HCDR3), and the HCDR1-HCDR2-HCDR3 amino acid sequence set is defined by any of the exemplary anti-HLA-A2:HPV16E7 antigen binding proteins listed in Table 1.

[0050] The present invention also provides a nucleic acid molecule encoding an LCVR, wherein the LCVR comprises a set of three CDRs (i.e., LCDR1-LCDR2-LCDR3), and the LCDR1-LCDR2-LCDR3 amino acid sequence set is defined by any of the exemplary anti-HLA-A2:HPV16E7 antigen binding proteins listed in Table 1.

[0051] The present invention also provides nucleic acid molecules encoding both an HCVR and an LCVR, wherein the HCVR comprises the amino acid sequence of any of the HCVR amino acid sequences listed in Table 1, and the LCVR comprises the amino acid sequence of any of the LCVR amino acid sequences listed in Table 1. In certain embodiments, the nucleic acid molecule comprises a polynucleotide sequence selected from any of the HCVR nucleic acid sequences listed in Table 2, or a substantially similar sequence thereof having at least 90%, at least 95%, at least 98%, or at least 99% sequence identity thereto, and a polynucleotide sequence selected from any of the LCVR nucleic acid sequences listed in Table 2, or a substantially similar sequence thereof having at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity thereto. In certain embodiments according to this aspect of the invention, the nucleic acid molecule encodes an HCVR and an LCVR, wherein the HCVR and LCVR are both derived from the same anti-HLA-A2:HPV16 E7 antigen binding protein listed in Table 1.

[0052] The present invention provides nucleic acid molecules that encode any of the heavy chain amino acid sequences listed in Table 3. The present invention also provides nucleic acid molecules that encode any of the light chain amino acid sequences listed in Table 3.

[0053] The present invention also provides nucleic acid molecules encoding both a heavy chain (HC) and a light chain (LC), wherein the HC comprises the amino acid sequence of any of the HC amino acid sequences listed in Table 3, and the LC comprises the amino acid sequence of any of the LC amino acid sequences listed in Table 3.

[0054] In a related aspect, the present invention provides recombinant expression vectors capable of expressing a polypeptide, the recombinant expression vector comprising the heavy chain variable region and / or light chain variable region of an anti-HLA-A2:HPV16 E7 antigen binding protein. For example, the present invention includes recombinant expression vectors comprising any of the above-described nucleic acid molecules, i.e., nucleic acid molecules encoding any of the HCVR, LCVR, and / or CDR sequences listed in Table 1. The present invention also provides recombinant expression vectors capable of expressing a polypeptide, the recombinant expression vector comprising the heavy chain and / or light chain of an anti-HLA-A2:HPV16 E7 antigen binding protein. For example, the present invention includes recombinant expression vectors comprising any of the above-described nucleic acid molecules, i.e., nucleic acid molecules encoding any of the heavy or light chain sequences listed in Table 2. Also included within the scope of the present invention are host cells into which such vectors have been introduced, as well as methods for producing antigen binding proteins by culturing host cells under conditions that allow for the production of the antigen binding protein and recovering the antigen binding protein so produced.

[0055] In a third aspect, the invention provides pharmaceutical compositions comprising a therapeutically effective amount of a recombinant, isolated antigen-binding protein that specifically binds to a conformational epitope of an HLA-A2-presented HPV16E7 peptide (e.g., a peptide comprising amino acid residues 11-19 or 82-90 of HPV16E7) and a pharmaceutically acceptable carrier. In a related aspect, the invention features a composition that is a combination of an anti-HLA-A2:HPV16E7 antigen-binding protein and a second therapeutic agent. In one embodiment, the second therapeutic agent is any agent that can be advantageously combined with an anti-HLA-A2:HPV16E7 antigen-binding protein. Exemplary agents that can be advantageously combined with an anti-HLA-A2:HPV16E7 antigen-binding protein include, without limitation, other agents that bind to and / or modulate HPV replication or infection (including, for example, other antibodies or antigen-binding fragments thereof) and / or agents that modulate immune cell activation. Additional therapeutic agents that can be used in combination with the anti-HLA-A2:HPV16E7 antigen binding proteins of the invention are disclosed elsewhere herein.

[0056] In a fourth aspect, the present invention provides a method for treating a subject with an HPV-related disease or disorder, such as HPV16E7-positive cancer. The method comprises administering a therapeutically effective amount of an anti-HLA-A2:HPV16E7 antigen binding protein of the present invention or a pharmaceutical composition of the present invention to a subject in need thereof. The disorder to be treated is any disease or condition that is improved, ameliorated, inhibited, or prevented by the antigen binding proteins and compositions presented herein. In certain embodiments, the antigen binding protein (or pharmaceutical composition) of the present invention is administered to a subject in need thereof in combination with a second therapeutic agent. The second therapeutic agent can be selected from the group consisting of antibodies against T-cell co-inhibitors, antibodies against tumor cell antigens, antibodies against T-cell receptors, antibodies against epitopes on virally infected cells, cytotoxic agents, anti-cancer drugs, anti-viral drugs, anti-inflammatory drugs (e.g., corticosteroids), chemotherapeutic agents, surgery, radiation therapy, immunosuppressants, and any other drug or treatment known in the art. In certain embodiments, the second therapeutic agent may be an agent that serves to counteract or reduce any potential side effect(s) associated with the antigen binding protein of the invention, should such side effect(s) occur.

[0057] In certain embodiments, the present invention provides a method for suppressing the growth of HPV-associated cancer.For example, the present invention provides a method for suppressing tumor growth caused by primary tumor or metastatic tumor in a subject.In certain embodiments, the present invention provides a method for enhancing the survival (for example, progression-free survival or overall survival) of a subject with HPV-associated cancer.Examples of cancer include, but are not limited to, squamous cell carcinoma such as squamous cell carcinoma of the head and neck, cervical cancer, anogenital cancer, and oropharyngeal cancer.

[0058] In certain embodiments, the present invention provides methods for inhibiting or suppressing the growth of established tumors. The methods comprise administering to a subject in need thereof a pharmaceutical composition comprising a therapeutically effective amount of an antigen-binding protein of the present invention. In certain embodiments, the antigen-binding protein is administered in combination with a second therapeutic agent.

[0059] The antigen-binding protein, e.g., an antibody or antigen-binding fragment thereof, can be administered subcutaneously, intravenously, intradermally, intraperitoneally, orally, intramuscularly, or intracranially. The antigen-binding protein, e.g., an antibody or antigen-binding fragment thereof, can be administered at a dose of about 0.1 mg / kg to about 100 mg / kg of the subject's body weight.

[0060] In a fifth aspect, the present invention provides an isolated nucleic acid molecule encoding a chimeric antigen receptor (CAR). The CAR may comprise an extracellular binding domain that specifically binds to a conformational epitope of the human papillomavirus (HPV) 16 E7 peptide (HPV16 E7 peptide) presented by HLA-A2, e.g., amino acid residues 11-19 or 82-90 of HPV16 E7, a transmembrane domain, and an intracellular signaling domain. In one embodiment, the extracellular binding domain is an anti-HLA-A2:HPV16 E7 antigen-binding protein or an antigen-binding fragment thereof. Exemplary anti-HLA-A2:HPV16 E7 antigen-binding proteins of the present invention are any of the antigen-binding proteins described herein.

[0061] For example, in certain embodiments, an antigen binding protein suitable for use in a CAR of the invention comprises three heavy chain complementarity determining regions (CDRs) (HCDR1, HCDR2, and HCDR3) contained in any one of the heavy chain variable region (HCVR) sequences listed in Table 1; and three light chain CDRs (LCDR1, LCDR2, and LCDR3) contained in any one of the light chain variable region (LCVR) sequences listed in Table 1.

[0062] In other embodiments, an antigen binding protein suitable for use in a CAR of the invention comprises an HCVR having an amino acid sequence selected from the group consisting of the HCVR sequences listed in Table 1; and / or an LCVR having an amino acid sequence selected from the group consisting of the LCVR sequences listed in Table 1.

[0063] In some embodiments, an antigen binding protein suitable for use in a CAR of the invention comprises (a) an HCVR having an amino acid sequence selected from the group consisting of the HCVR sequences listed in Table 1; and (b) an LCVR having an amino acid sequence selected from the group consisting of the LCVR sequences listed in Table 1.

[0064] In one embodiment, an antigen binding protein suitable for use in a CAR of the invention comprises (a) an HCDR1 domain having an amino acid sequence selected from the group consisting of SEQ ID NOs: 4, 20, 36, 52, 68, 84, 100, 116, 132, 148, 164, 180, 196, 212, 220, 236, 252, 268, 284, 300, 316, 332, 348, 364, 380, 396, 412, 428, 444, 460, 476, 492, 508, and 524; (b) an HCDR1 domain having an amino acid sequence selected from the group consisting of SEQ ID NOs: 6, 22, 38, 54, (c) an HCDR2 domain having an amino acid sequence selected from the group consisting of SEQ ID NOs: 8, 24, 40, 56, 72, 88, 104, 120, 136, 152, 168, 184, 200, 216, 224, 240, 256, 272; , 288, 304, 320, 336, 352, 368, 384, 400, 416, 432, 448, 464, 480, 496, 512, and 528; (d) an HCDR3 domain having an amino acid sequence selected from the group consisting of SEQ ID NOs: 12, 28, 44, 60, 76, 92, 108, 124, 140, 156, 172, 188, 204, 228, 244, 260, 276, 292, 308, 324, 340, 356, 372, 388, 404, 420, 436, 452, 468, 484, 500 , 516, and 532; (e) an LCDR1 domain having an amino acid sequence selected from the group consisting of SEQ ID NOs: 14, 30, 46, 62, 78, 94, 110, 126, 142, 158, 174, 190, 206, 230, 246, 262, 278, 294, 310, 326, 342, 358, 374, 390, 406, 422, 438, 454, 470, 486, 502, 518, and 534; and (f) SEQ ID NO: 16.and an LCDR3 domain having an amino acid sequence selected from the group consisting of 32, 48, 64, 80, 96, 112, 128, 144, 160, 176, 192, 208, 232, 248, 264, 280, 296, 312, 328, 344, 360, 376, 392, 408, 424, 440, 456, 472, 488, 504, 520, and 536.

[0065] In further embodiments, antigen binding proteins suitable for use in the CAR of the invention are selected from the group consisting of SEQ ID NOs: 2 / 10, 18 / 26, 34 / 42, 50 / 58, 66 / 74, 82 / 90, 98 / 106, 114 / 122, 130 / 138, 146 / 154, 162 / 170, 178 / 186, 194 / 202, 210 / 202, 218 / 226, 234 / 242, 250 / 258, 266 / 274, 282 / 290, 298 / 306, 314 / 322, 330 / 338, 346 HCVR / LCVR amino acid sequence pairs selected from the group consisting of SEQ ID NOs: 2 / 10, 34 / 42, 82 / 90, 194 / 202, 282 / 290, and 506 / 514.

[0066] In some embodiments, the isolated antigen binding protein for use in the CAR of the invention is an scFv.

[0067] In other aspects, the present invention provides vectors comprising the isolated CAR nucleic acid molecules; and immune effector cells comprising such vectors.

[0068] In yet another aspect of the present invention, a method is provided for treating a subject having an HPV-related disease or disorder, such as an HPV16E7-positive cancer, e.g., a squamous cell carcinoma, e.g., cervical cancer, small cell carcinoma of the head and neck, anogenital cancer, and oropharyngeal cancer, comprising administering to the subject a population of immune effector cells comprising a CAR of the present invention.

[0069] In some embodiments, the present invention provides methods for detecting HPV16E7-positive cells, e.g., in a subject or a sample obtained from a subject, comprising contacting an antigen-binding protein of the present invention comprising a detectable moiety with cells, such as a cell sample obtained from a subject, or administering the protein to the subject, and detecting the presence of the detectable moiety.

[0070] Other embodiments will become apparent upon review of the detailed description. In certain embodiments, for example, the following are provided: (Item 1) 1. An isolated antigen-binding protein that specifically binds to a conformational epitope of human papillomavirus (HPV) 16 E7 peptide (HPV16 E7 peptide) presented by HLA-A2, wherein the conformational epitope comprises one or more amino acids of SEQ ID NO: 537 selected from the group consisting of Y11, D14, L15, P17 and E18. (Item 2) (a) A binding dissociation equilibrium constant (K) of less than about 20 nM for the monomeric HLA-A2:HPV16E7 11-19 peptide as measured by surface plasmon resonance assay at 25°C. D ) to join; (b) A binding dissociation equilibrium constant (K) of less than about 25 nM for the monomeric HLA-A2:HPV16E7 82-90 peptide as measured by surface plasmon resonance assay at 25°C. D ) to join; (c) EC of less than approximately 6 nM on cells expressing the HLA-A2:HPV16E7 11-19 peptide as determined by luminescence assay 50 binds to cells expressing predicted off-target peptides; (d) EC of less than about 1 nM on cells expressing the HLA-A2:HPV16E7 82-90 peptide as determined by a luminescence assay 50 binds to the target peptide and does not bind substantially to cells expressing the predicted off-target peptide; (e) EC of less than about 30 nM on cells expressing the HLA-A2:HPV16E7 11-19 peptide as determined by flow cytometry assay 50 Combine with; and (f) EC of less than about 75 nM on cells expressing the HLA-A2:HPV16E7 82-90 peptide as determined by flow cytometry assay 50 Join with 2. The isolated antigen-binding protein of item 1, having a property selected from the group consisting of: (Item 3) 2. The isolated antigen-binding protein of claim 1, wherein the HPV16E7 peptide comprises the amino acid sequence of YMLDLQPET (SEQ ID NO: 538). (Item 4) 4. The isolated antigen-binding protein of any one of paragraphs 1 to 3, wherein the protein is a full-length antibody, a Fab, a Fab', a (Fab')2, an Fv, a single-chain Fv (scFv), a T-body construct, or a CAR. (Item 5) 5. The isolated antigen-binding protein of any one of items 1 to 4, which is a human monoclonal antibody or an antigen-binding fragment thereof. (Item 6) 6. The isolated antigen-binding protein of any one of items 1 to 5, comprising three heavy chain complementarity-determining regions (CDRs) (HCDR1, HCDR2, and HCDR3) contained in any one of the heavy chain variable region (HCVR) sequences listed in Table 1; and three light chain CDRs (LCDR1, LCDR2, and LCDR3) contained in any one of the light chain variable region (LCVR) sequences listed in Table 1. (Item 7) 7. The isolated antigen-binding protein of any one of items 1 to 6, comprising an HCVR having an amino acid sequence selected from the group consisting of the HCVR sequences listed in Table 1. (Item 8) 8. The isolated antigen-binding protein of any one of items 1 to 7, comprising an LCVR having an amino acid sequence selected from the group consisting of the LCVR sequences listed in Table 1. (Item 9) 9. The isolated antigen-binding protein of any one of items 1 to 8, comprising: (a) a HCVR having an amino acid sequence selected from the group consisting of the HCVR sequences listed in Table 1; and (b) a LCVR having an amino acid sequence selected from the group consisting of the LCVR sequences listed in Table 1. (Item 10) (a) an HCDR1 domain having an amino acid sequence selected from the group consisting of SEQ ID NOs: 4, 20, 36, 52, 68, 84, 100, 116, 132, 148, 164, 180, 196, 212, 220, 236, 252, 268, 284, 300, 316, 332, 348, 364, 380, 396, 412, 428, 444, 460, 476, 492, 508, and 524; (b) an HCDR2 domain having an amino acid sequence selected from the group consisting of SEQ ID NOs: 6, 22, 38, 54, 70, 86, 102, 118, 134, 150, 166, 182, 198, 214, 222, 238, 254, 270, 286, 302, 318, 334, 350, 366, 382, ​​414, 430, 446, 462, 478, 494, 510, and 526; (c) an HCDR3 domain having an amino acid sequence selected from the group consisting of SEQ ID NOs: 8, 24, 40, 56, 72, 88, 104, 120, 136, 152, 168, 184, 200, 216, 224, 240, 256, 272, 288, 304, 320, 336, 352, 368, 384, 400, 416, 432, 448, 464, 480, 496, 512, and 528; (d) an LCDR1 domain having an amino acid sequence selected from the group consisting of SEQ ID NOs: 12, 28, 44, 60, 76, 92, 108, 124, 140, 156, 172, 188, 204, 204, 228, 244, 260, 276, 292, 308, 324, 340, 356, 372, 388, 404, 420, 436, 452, 468, 484, 500, 516, and 532; (e) an LCDR2 domain having an amino acid sequence selected from the group consisting of SEQ ID NOs: 14, 30, 46, 62, 78, 94, 110, 126, 142, 158, 174, 190, 206, 230, 246, 262, 278, 294, 310, 326, 342, 358, 374, 390, 406, 422, 438, 454, 470, 486, 502, 518, and 534; and (f) an LCDR3 domain having an amino acid sequence selected from the group consisting of SEQ ID NOs: 16, 32, 48, 64, 80, 96, 112, 128, 144, 160, 176, 192, 208, 232, 248, 264, 280, 296, 312, 328, 344, 360, 376, 392, 408, 424, 440, 456, 472, 488, 504, 520, and 536. 10. The isolated antigen-binding protein of any one of items 1 to 9, comprising: (Item 11) Sequence numbers 2 / 10, 18 / 26, 34 / 42, 50 / 58, 66 / 74, 82 / 90, 98 / 106, 114 / 122, 130 / 138, 146 / 154, 162 / 170, 178 / 186, 194 / 202, 210 / 202, 218 / 226, 234 / 242, 250 / 258, 266 / 274, 282 / 290, 298 / 306, 314 / 322, 33 11. The isolated antigen-binding protein of item 10, comprising an HCVR / LCVR amino acid sequence pair selected from the group consisting of 0 / 338, 346 / 354, 362 / 370, 378 / 386, 394 / 402, 410 / 418, 426 / 434, 442 / 450, 458 / 466, 474 / 482, 490 / 498, 506 / 514, and 522 / 530. (Item 12) 12. The isolated antigen-binding protein of item 11, comprising an HCVR / LCVR amino acid sequence pair selected from the group consisting of SEQ ID NOs: 2 / 10, 34 / 42, 82 / 90, 194 / 202, 282 / 290, and 506 / 514. (Item 13) 12. An isolated antigen-binding protein that competes for binding with the antigen-binding protein of item 11. (Item 14) 12. An isolated antigen-binding protein that binds to the same epitope as the antigen-binding protein of Item 11. (Item 15) 15. The isolated antigen-binding protein of any one of items 1 to 14, comprising a detectable moiety. (Item 16) 16. A pharmaceutical composition comprising an isolated antigen-binding protein that binds to HLA-A2:HPV16E7 according to any one of items 1 to 15 and a pharmaceutically acceptable carrier or diluent. (Item 17) 16. An isolated polynucleotide molecule comprising a polynucleotide sequence encoding the HCVR of the antigen-binding protein of any one of items 1 to 15. (Item 18) 16. An isolated polynucleotide molecule comprising a polynucleotide sequence encoding the LCVR of the antigen-binding protein of any one of items 1 to 15. (Item 19) 19. A vector comprising the polynucleotide molecule of item 17 or 18. (Item 20) A cell expressing the vector of item 19. (Item 21) A method of treating a subject having a disease or disorder associated with HPV16E7, comprising administering to the subject a therapeutically effective amount of the antigen-binding protein of any one of items 1 to 15 or the pharmaceutical composition of item 16, thereby treating the subject. (Item 22) 22. The method of claim 21, wherein the disease or disorder associated with HPV16E7 is HPV-associated cancer. (Item 23) 23. The method of claim 22, wherein the HPV-associated cancer is squamous cell carcinoma. (Item 24) 24. The method of claim 23, wherein the HPV-associated cancer is cervical cancer, anogenital cancer, head and neck cancer, or oropharyngeal cancer. (Item 25) 25. The method of any one of paragraphs 21 to 24, wherein the antigen binding protein is administered to the subject in combination with a second therapeutic agent. (Item 26) 26. The method of item 25, wherein the second therapeutic agent is selected from the group consisting of a PD-1 inhibitor, a CTLA-4 inhibitor, an antibody against a tumor-specific antigen, an antibody against a viral-infected cell antigen, a PD-L1 inhibitor, a CD20 inhibitor, a bispecific antibody against CD20 and CD3, a nutritional supplement such as an antioxidant, a VEGF antagonist, a chemotherapeutic agent, a cytotoxic agent, surgery, radiation, an NSAID, a corticosteroid, an anti-HPV vaccine, and any other treatment useful for ameliorating at least one symptom associated with the disease or disorder. (Item 27) 27. The method of any one of paragraphs 21 to 26, wherein the antigen binding protein is administered subcutaneously, intravenously, intradermally, intraperitoneally, orally, intramuscularly, or intracranially. (Item 28) 28. The method of any one of items 21 to 27, wherein the antigen-binding protein is administered at a dose of about 0.1 mg / kg body weight to about 100 mg / kg body weight of the subject. (Item 29) 1. An isolated nucleic acid molecule encoding a chimeric antigen receptor (CAR), wherein the CAR comprises an extracellular binding domain that specifically binds to a conformational epitope of human papillomavirus (HPV) 16 E7 peptide (HPV16 E7 peptide) presented by HLA-A2, a transmembrane domain, and an intracellular signaling domain. (Item 30) 30. The isolated nucleic acid molecule of claim 29, wherein the extracellular binding domain is an anti-HLA-A2:HPV16E7 antigen binding protein. (Item 31) 31. The isolated nucleic acid molecule of claim 30, wherein the isolated antigen-binding protein comprises three heavy chain complementarity-determining regions (CDRs) (HCDR1, HCDR2, and HCDR3) contained in any one of the heavy chain variable region (HCVR) sequences listed in Table 1; and three light chain CDRs (LCDR1, LCDR2, and LCDR3) contained in any one of the light chain variable region (LCVR) sequences listed in Table 1. (Item 32) 32. The isolated nucleic acid molecule of paragraph 30 or 31, wherein the isolated antigen binding protein comprises an HCVR having an amino acid sequence selected from the group consisting of the HCVR sequences listed in Table 1. (Item 33) 33. The isolated nucleic acid molecule of any one of paragraphs 30 to 32, wherein the isolated antigen-binding protein comprises an LCVR having an amino acid sequence selected from the group consisting of the LCVR sequences listed in Table 1. (Item 34) 34. The isolated nucleic acid molecule of any one of paragraphs 30 to 33, wherein the isolated antigen-binding protein comprises: (a) a HCVR having an amino acid sequence selected from the group consisting of the HCVR sequences listed in Table 1; and (b) a LCVR having an amino acid sequence selected from the group consisting of the LCVR sequences listed in Table 1. (Item 35) the isolated antigen binding protein comprises: (a) an HCDR1 domain having an amino acid sequence selected from the group consisting of SEQ ID NOs: 4, 20, 36, 52, 68, 84, 100, 116, 132, 148, 164, 180, 196, 212, 220, 236, 252, 268, 284, 300, 316, 332, 348, 364, 380, 396, 412, 428, 444, 460, 476, 492, 508, and 524; (b) an HCDR2 domain having an amino acid sequence selected from the group consisting of SEQ ID NOs: 6, 22, 38, 54, 70, 86, 102, 118, 134, 150, 166, 182, 198, 214, 222, 238, 254, 270, 286, 302, 318, 334, 350, 366, 382, ​​414, 430, 446, 462, 478, 494, 510, and 526; (c) an HCDR3 domain having an amino acid sequence selected from the group consisting of SEQ ID NOs: 8, 24, 40, 56, 72, 88, 104, 120, 136, 152, 168, 184, 200, 216, 224, 240, 256, 272, 288, 304, 320, 336, 352, 368, 384, 400, 416, 432, 448, 464, 480, 496, 512, and 528; (d) an LCDR1 domain having an amino acid sequence selected from the group consisting of SEQ ID NOs: 12, 28, 44, 60, 76, 92, 108, 124, 140, 156, 172, 188, 204, 204, 228, 244, 260, 276, 292, 308, 324, 340, 356, 372, 388, 404, 420, 436, 452, 468, 484, 500, 516, and 532; (e) an LCDR2 domain having an amino acid sequence selected from the group consisting of SEQ ID NOs: 14, 30, 46, 62, 78, 94, 110, 126, 142, 158, 174, 190, 206, 230, 246, 262, 278, 294, 310, 326, 342, 358, 374, 390, 406, 422, 438, 454, 470, 486, 502, 518, and 534; and (f) an LCDR3 domain having an amino acid sequence selected from the group consisting of SEQ ID NOs: 16, 32, 48, 64, 80, 96, 112, 128, 144, 160, 176, 192, 208, 232, 248, 264, 280, 296, 312, 328, 344, 360, 376, 392, 408, 424, 440, 456, 472, 488, 504, 520, and 536. 35. The isolated nucleic acid molecule of any one of items 30 to 34, comprising: (Item 36) The isolated antigen binding protein is selected from the group consisting of SEQ ID NOs: 2 / 10, 18 / 26, 34 / 42, 50 / 58, 66 / 74, 82 / 90, 98 / 106, 114 / 122, 130 / 138, 146 / 154, 162 / 170, 178 / 186, 194 / 202, 210 / 202, 218 / 226, 234 / 242, 250 / 258, 266 / 274, 282 / 290, 298 / 306, 314 36. The isolated nucleic acid molecule of any one of paragraphs 30 to 35, comprising an HCVR / LCVR amino acid sequence pair selected from the group consisting of: 322, 330 / 338, 346 / 354, 362 / 370, 378 / 386, 394 / 402, 410 / 418, 426 / 434, 442 / 450, 458 / 466, 474 / 482, 490 / 498, 506 / 514, and 522 / 530. (Item 37) 33. The isolated nucleic acid molecule of any one of paragraphs 30 to 32, wherein the isolated antigen-binding protein comprises an HCVR / LCVR amino acid sequence pair selected from the group consisting of SEQ ID NOs: 2 / 10, 34 / 42, 82 / 90, 194 / 202, 282 / 290, and 506 / 514. (Item 38) 38. The isolated nucleic acid molecule of any one of items 30 to 37, comprising any one of SEQ ID NOs: 540, 541, 542, 543, 544, or 545. (Item 39) 39. The isolated nucleic acid molecule of any one of paragraphs 30 to 38, wherein the isolated antigen-binding protein is an scFv. (Item 40) 40. A vector comprising the isolated nucleic acid molecule of any one of items 30 to 39. (Item 41) 41. An isolated immune effector cell comprising the vector of item 40. (Item 42) 42. The isolated immune effector cell of item 41, which is a T-body. (Item 43) 43. A method of treating a subject having a disease or disorder associated with HPV, comprising administering to said subject the immune effector cells of item 41 or 42. (Item 44) 44. The method of claim 43, wherein the HPV-associated disease or disorder is an HPV-associated cancer. (Item 45) 45. The method of claim 44, wherein the HPV-associated cancer is squamous cell carcinoma. (Item 46) 46. ​​The method of claim 45, wherein the HPV-associated cancer is cervical cancer, anogenital cancer, head and neck cancer, or oropharyngeal cancer. (Item 47) 47. The method of any one of paragraphs 43 to 46, wherein the antigen binding protein is administered to the subject in combination with a second therapeutic agent. DETAILED DESCRIPTION OF THE INVENTION

[0071] Detailed Description Before describing the present methods, it is to be understood that the invention is not limited to the particular methods and experimental conditions described, as such methods and conditions may vary. It is also to be understood that the terminology used herein is for the purpose of describing particular embodiments, and is not intended to be limiting, since the scope of the present invention will be limited only by the appended claims.

[0072] Unless otherwise defined, all scientific and technical terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs. Although any methods and materials similar or equivalent to those described herein can be used in the practice or testing of the present invention, the preferred methods and materials are described herein. All publications mentioned herein are incorporated by reference in their entirety.

[0073] The term "human papillomavirus" ("HPV") refers to a small, non-enveloped deoxyribonucleic acid (DNA) virus that infects skin or mucosal cells. The circular, double-stranded viral genome is approximately 8 kb in length. The genome encodes six early proteins involved in viral replication and two late proteins, L1 and L2, which are viral structural proteins. More than 170 HPV types have been identified and are designated numerically. Some HPV types, such as HPV-5, can establish a persistent infection throughout an individual's life without ever manifesting clinical symptoms. HPV types 1 and 2 can cause warts in some infected individuals. HPV types 6 and 11 can cause genital warts and respiratory papillomatosis. HPV types 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 68, 73, and 82 are considered to be oncogenic.

[0074] The term "HPV16E7" refers to the HPV16 early gene designated E7 and the protein translated from that gene.

[0075] The amino acid sequence of full-length HPV16E7 is provided in GenBank under accession number NP_041326.1 (SEQ ID NO: 537). The term "HPV16E7" includes recombinant HPV16E7 or a fragment thereof. The term also encompasses HPV16E7 or a fragment thereof coupled with a signal sequence, such as a histidine tag, mouse or human Fc, or ROR1. In certain embodiments, with respect to HLA-A2, the term includes HPV16E7 or a fragment thereof linked to or displayed by HLA-A2.

[0076] The term "HLA" refers to the human leukocyte antigen (HLA) system or complex, a complex of genes that encode major histocompatibility complex (MHC) proteins in humans. These cell surface proteins are involved in regulating the immune system in humans. HLA, corresponding to MHC class I (A, B, and C), present peptides from the inside of cells.

[0077] The term "HLA-A" refers to a group of human leukocyte antigens (HLA) encoded by the HLA-A locus. HLA-A is one of the three major types of human MHC class I cell surface receptors. The receptor is a heterodimer, composed of a heavy α chain and a smaller β chain. The α chain is encoded by a variant HLA-A gene, and the β chain (β2-microglobulin) is an invariant β2-microglobulin molecule.

[0078] The term "HLA-A2" refers to one particular class I major histocompatibility complex (MHC) allele group at the HLA-A locus; the α chain is HLA-A * It is encoded by the O2 gene, and the beta chain is encoded by the beta2-microglobulin or B2M locus.

[0079] The terms "antigen binding protein," "binding protein," or "binding molecule," as used herein, include molecules containing at least one antigen-binding site that specifically binds to a molecule of interest, such as a conformational epitope of the HLA-A2-presented human papillomavirus (HPV) 16 E7 peptide (HPV16 E7 peptide), e.g., a peptide displayed by HLA-A2 comprising amino acid residues 11-19 or 82-90. The binding protein can be an antibody, such as a full-length antibody or an antigen-binding fragment of an antibody, or a chimeric antigen receptor (CAR), or any other polypeptide, e.g., a receptor-antibody (Rab) protein.

[0080] The terms "HLA-A2:HPV16E7 antigen binding protein" or "HLA-A2:HPV16E7 antigen binding protein" and the like refer to an antigen binding protein, such as an antibody or antigen-binding portion thereof, that specifically binds to a conformational epitope by presentation of a peptide fragment of HPV16E7 by HLA-A2, e.g., amino acid residues 11-19 or amino acid residues 82-90. In certain embodiments, the conformational epitope is created by the HPV16E7 peptide presented by HLA-A2 on the surface of a cell.

[0081] The term "epitope" refers to an antigenic determinant that interacts with a specific antigen-binding site within the variable region of an antigen-binding protein, known as a paratope. A single antigen can have more than one epitope. Thus, different antigen-binding proteins may bind to different regions on an antigen and have different biological effects. The term "epitope" also refers to the site on an antigen to which B cells and / or T cells respond. An epitope also refers to the region of an antigen to which an antigen-binding protein binds. Epitopes can be defined as structural or functional. Functional epitopes are generally a subset of structural epitopes and contain residues that directly contribute to the affinity of the interaction. Epitopes can also be "conformational," i.e., composed of nonlinear amino acids. In certain embodiments, epitopes may include determinants that are chemically active surface groupings of molecules, such as amino acids, sugar side chains, phosphoryl groups, or sulfonyl groups, and in certain embodiments, may have specific three-dimensional structural characteristics, and / or specific charge characteristics.

[0082] In some embodiments of the invention, the binding protein is an antibody or antigen-binding fragment thereof, for example, a full-length antibody or antigen-binding fragment thereof.

[0083] The term "antibody," as used herein, refers to an immunoglobulin molecule (i.e., a "whole antibody molecule") composed of four polypeptide chains: two heavy (H) chains and two light (L) chains inter-connected by disulfide bonds, as well as multimers thereof (e.g., IgM) or antigen-binding fragments thereof. Each heavy chain contains a heavy chain variable region ("HCVR" or "V"). H ") and heavy chain constant region (domain C H 1. C H 2 and C H Each light chain is composed of a light chain variable region ("LCVR" or "V L ") and the light chain constant region (C L ) V H Area and V L The regions can be further subdivided into regions of hypervariability called complementarity-determining regions (CDRs) and interspersed with more conserved regions called framework regions (FRs). H and V L is composed of three CDRs and four FRs, arranged from the amino terminus to the carboxy terminus in the following order: FR1, CDR1, FR2, CDR2, FR3, CDR3, FR4. In certain embodiments of the present invention, the FRs of an antibody (or antigen-binding fragment thereof) may be identical to human germline sequences or may be naturally or artificially modified. An amino acid consensus sequence can be defined based on a parallel analysis of two or more CDRs.

[0084] Substitution of one or more CDR residues or omission of one or more CDRs is also possible. Antigen-binding proteins, such as antibodies, which can distribute one or two CDRs for binding have been described in the scientific literature. Padlan et al. (1995 FASEB J. 9: 133-139) analyzed the contact regions of antibodies with their antigens based on published crystal structures and found that: They concluded that only about one-fifth to one-third of the CDR residues actually contact the antigen. Padlan also found many antibodies in which one or two CDRs have no amino acids that contact the antigen (see also Vajdos et al. 2002 J Mol Biol 320: 415-428).

[0085] CDR residues that do not contact antigen can be identified empirically and / or by molecular modeling based on previous studies from regions of the Kabat CDRs outside the Chothia CDRs (e.g., residues H60-H65 of CDRH2 are often unnecessary). When a CDR or its residue(s) is omitted, it is typically replaced with an amino acid occupying the corresponding position in another human antibody sequence or a consensus of such sequences. The position of substitution within the CDR and the substituting amino acid can also be selected empirically. Empirical substitutions can be conservative or non-conservative.

[0086] The anti-HLA-A2:HPV16E7 antigen-binding proteins disclosed herein, such as fully human anti-HLA-A2:HPV16E7 monoclonal antibodies or antigen-binding fragments thereof, or CARs, may contain one or more amino acid substitutions, insertions, and / or deletions in the framework and / or CDR regions of the heavy and light chain variable domains compared to the corresponding germline sequences. Such mutations can be readily identified by comparing the amino acid sequences disclosed herein to germline sequences available, for example, from public antibody sequence databases. The present invention includes antigen-binding proteins, such as antibodies or antigen-binding fragments thereof, or CARs, derived from any of the amino acid sequences disclosed herein, in which one or more amino acids in one or more framework and / or CDR regions are mutated to the corresponding residue(s) in the germline sequence from which the antigen-binding protein is derived, or to the corresponding residue(s) in another human germline sequence, or to a conservative amino acid substitution of the corresponding germline residue(s) (such sequence changes are collectively referred to herein as "germline mutations"). Starting with the heavy and light chain variable region sequences disclosed herein, one of skill in the art can readily generate numerous antigen-binding proteins, e.g., antibodies or antigen-binding fragments thereof, or CARs, that contain one or more individual germline mutations or combinations thereof. In certain embodiments, V H Domain and / or V LAll of the framework and / or CDR residues within a domain are mutated back to the residues found in the original germline sequence from which the antigen-binding protein, e.g., antibody, is derived. In other embodiments, only certain residues are mutated back to the original germline sequence, e.g., only mutated residues found within the first 8 amino acids of FR1 or the last 8 amino acids of FR4, or only mutated residues found in CDR1, CDR2, or CDR3. In other embodiments, one or more of the framework and / or CDR residue(s) are mutated to the corresponding residue(s) in a different germline sequence (i.e., a different germline sequence from the germline sequence from which the antibody was originally derived). Furthermore, the antigen-binding proteins of the present invention, such as antibodies or antigen-binding fragments thereof, or CARs, can contain any combination of two or more germline mutations in the framework and / or CDR regions, where, for example, certain individual residues are mutated to the corresponding residues in a particular germline sequence, while certain other residues that differ from the original germline sequence are maintained or mutated to the corresponding residues in a different germline sequence. Once antigen-binding proteins, such as antibodies and antigen-binding fragments, containing one or more germline mutations are obtained, they can be easily tested for one or more desired properties, such as improved binding specificity, increased binding affinity, improved or enhanced antagonistic or agonistic biological properties (as the case may be), reduced immunogenicity, etc. Antigen-binding proteins, such as antibodies or antigen-binding fragments thereof, or CARs obtained in this general manner are encompassed within the scope of the present invention.

[0087] The present invention also includes antigen-binding proteins, e.g., fully human anti-HLA-A2:HPV16E7 monoclonal antibodies or antigen-binding fragments thereof, or CARs, comprising variants of any of the HCVR, LCVR, and / or CDR amino acid sequences disclosed herein with one or more conservative substitutions. For example, the present invention includes anti-HLA-A2:HPV16E7 antigen-binding proteins having HCVR, LCVR, and / or CDR amino acid sequences with 10 or fewer, 8 or fewer, 6 or fewer, 4 or fewer, etc., conservative amino acid substitutions compared to any of the HCVR, LCVR, and / or CDR amino acid sequences disclosed herein.

[0088] The term "human antibody," as used herein, is intended to include antibodies having variable and constant regions derived from human germline immunoglobulin sequences. Human monoclonal antibodies (mAbs) of the invention may include, for example, amino acid residues in the CDRs, particularly CDR3, that are not encoded by human germline immunoglobulin sequences (e.g., mutations introduced by random or site-specific mutagenesis in vitro or by somatic mutation in vivo). However, the term "human antibody," as used herein, does not include mAbs in which CDR sequences derived from the germline of another mammalian species (e.g., a mouse) have been grafted onto human FR sequences. This term encompasses antibodies recombinantly produced in non-human mammals or in the cells of non-human mammals. This term does not include antibodies isolated from or generated in human subjects.

[0089] The term "recombinant," as used herein, refers to antigen-binding proteins, e.g., antibodies or antigen-binding fragments thereof, of the present invention that are created, expressed, isolated, or obtained by techniques or methods known in the art as recombinant DNA technology, including, for example, DNA splicing and transgenic expression. The term refers, for example, to antigen-binding proteins, e.g., antibodies, expressed in a non-human mammal (including a transgenic non-human mammal, e.g., a transgenic mouse), or cellular (e.g., CHO cell) expression system, or isolated from a recombinant combinatorial human antibody library.

[0090] As used herein, the terms "chimeric antigen receptor" or "CAR" are used interchangeably herein and refer to a recombinant fusion protein comprising an extracellular domain capable of binding to an antigen (e.g., a conformational epitope of an HPV16E7 peptide displayed by HLA-A2, e.g., a peptide comprising amino acid residues 11-19 or 82-90 of HPV16E7), a transmembrane domain, and at least one intracellular signaling domain.

[0091] "Immune effector cell," as used herein, refers to any cell of the immune system that has one or more effector functions (e.g., cytotoxic cell-killing activity, secretion of cytokines, induction of ADCC and / or CDC). In one embodiment, immune effector cells used with the CARs described herein are T lymphocytes, particularly cytotoxic T cells (CTLs; CD8 + T cells) and helper T cells (HTL; CD4 +T cells). Other populations of T cells, such as naive T cells and memory T cells, are also useful in the present invention. As will be appreciated by those skilled in the art, other cells can also be used as immune effector cells in conjunction with the CARs described herein. Specifically, immune effector cells also include NK cells, NKT cells, neutrophils, and macrophages. Immune effector cells also include precursors of effector cells, and such precursor cells can be induced to differentiate into immune effector cells in vivo or in vitro. Thus, in this regard, immune effector cells can be derived from CD34+ cells derived from umbilical cord blood, bone marrow, or mobilized peripheral blood that differentiate into mature immune effector cells upon administration to a subject, or that can be induced to differentiate into mature immune effector cells in vitro. + Contained within the population are precursors of immune effector cells, such as hematopoietic stem cells (HSCs).

[0092] As disclosed herein, the term "off-target peptide" refers to a peptide that differs from a target peptide (e.g., HPV16 E7 11-19 peptide) by one, two, three, four, five, or more amino acids. In certain embodiments, the term includes peptides that differ from a target peptide by fewer than three amino acids or by three amino acids. For example, with respect to a 9-mer peptide, if one, two, or three amino acids are not identical to the target peptide, it is considered an "off-target" peptide. In certain embodiments, amino acid identity is expressed in terms of "degree of similarity" (DoS). If six or more amino acids in a 9-mer peptide are identical, the DoS is 6. In certain embodiments, a peptide with a DoS of 6 or greater is considered an "off-target" peptide. The term "off-target" peptide also refers to a peptide that is similar to a target peptide based on sequence homology, is predicted to bind to HLA-A2, and is contained in a protein expressed in essential normal tissues.

[0093] The terms "specifically binds" or "binds specifically to," and the like, mean that an antigen-binding protein, such as an antibody or antigen-binding fragment thereof, or a CAR, forms a complex with an antigen that is relatively stable under physiological conditions. Specific binding is defined as binding with an equilibrium dissociation constant of at least about 1×10 -8 M or less (e.g., K D (A smaller value indicates tighter binding.) Methods for determining whether two molecules specifically bind are well known in the art, and examples include, for example, equilibrium dialysis, surface plasmon resonance, and the like. As described herein, an antigen-binding protein, e.g., an antibody, has been identified by surface plasmon resonance, e.g., BIACORE™, to specifically bind to a conformational epitope of the human papillomavirus (HPV) 16 E7 peptide (HPV16E7 peptide) presented by HLA-A2, e.g., a peptide comprising amino acid residues 11-19 or 82-90 of HPV16E7.

[0094] The term "high affinity" antigen-binding protein, e.g., antibody, refers to an antigen-binding protein that binds to a conformational epitope of at least 10, as measured by surface plasmon resonance, e.g., BIACORE™, or solution affinity ELISA, to a conformational epitope of an HPV16E7 peptide presented by HLA-A2, e.g., a peptide comprising amino acid residues 11-19 or 82-90 of HPV16E7. -8 M; preferably 10 -9 M; more preferably 10 -10 M, and even more preferably 10 -11 M, and even more preferably 10 -12 K of M D The term "mAb" refers to an antigen-binding protein, such as a mAb, having a binding affinity represented by the formula:

[0095] The term "slow off rate," "Koff," or "kd" refers to the rate at which an antigen-binding protein binds to HLA-A2:HPV16E7 and has a binding affinity of 1×10 as determined by surface plasmon resonance, e.g., BIACORE™. -3 s -1 or less, preferably 1 x 10 -4 s -1 This means that the molecule dissociates with a rate constant equal to or less than this rate constant.

[0096] As used herein, the terms "antigen-binding portion" of an antigen-binding protein (e.g., an antibody), "antigen-binding fragment" of an antigen-binding protein (e.g., an antibody), and the like, include any naturally occurring, enzymatically obtainable, synthetic, or genetically engineered polypeptide or glycoprotein that specifically binds to an antigen to form a complex. The term "antigen-binding fragment" of an antibody, or "antibody fragment," as used herein, refers to one or more fragments of an antibody that retain the ability to bind to a conformational epitope of an HLA-A2-coupled HPV16E7 peptide presented by HLA-A2, for example, a peptide comprising amino acid residues 11-19 or 82-90 of HPV16E7.

[0097] In certain embodiments, the antigen binding proteins of the invention, e.g., antibodies or antibody fragments, or CARs, can be conjugated to a moiety such as a ligand, a detectable moiety, or a therapeutic moiety such as a cytotoxin, a second anti-HLA-A2:HPV16E7 antigen binding protein, an antibody against a tumor-specific antigen, an anti-cancer drug, or any other therapeutic moiety (an "immunoconjugate") useful for treating a disease or condition, including a disease or disorder associated with HPV, such as HPV16E7-positive cancer, or HPV infection, including chronic HPV infection.

[0098] An "isolated antigen-binding protein," e.g., an isolated antibody, as used herein, is intended to refer to an antigen-binding protein, e.g., an antibody, that is substantially free of other antigen-binding proteins, e.g., antibodies (Abs), having different antigen specificities (e.g., an isolated antibody that specifically binds to HLA-A2:HPV16E7 or a fragment thereof is substantially free of antigen-binding proteins, e.g., antibodies, that specifically bind to antigens other than the conformational epitope of the HPV16E7 peptide presented by HLA-A2).

[0099] The term "surface plasmon resonance," as used herein, refers to an optical phenomenon that allows for the analysis of real-time biomolecular interactions by detecting alterations in protein concentration within a biosensor matrix, for example, using the BIACORE™ system (Pharmacia Biosensor AB, Uppsala, Sweden and Piscataway, NJ).

[0100] "K D " as used herein is intended to refer to the equilibrium dissociation constant of a particular antigen-binding protein-antigen interaction.

[0101] The term "cross-compete," as used herein, refers to an antigen-binding protein, e.g., an antibody or antigen-binding fragment thereof, that binds to an antigen and inhibits or blocks the binding of another antigen-binding protein, e.g., an antibody or antigen-binding fragment thereof. This term also includes bidirectional competition between two antigen-binding proteins, e.g., antibodies, i.e., a first antigen-binding protein, e.g., an antibody, binds and blocks the binding of a second antigen-binding protein, e.g., an antibody, and vice versa. In certain embodiments, a first antigen-binding protein, e.g., an antibody, and a second antigen-binding protein, e.g., an antibody, may bind to the same epitope. Alternatively, the first and second antigen-binding proteins, e.g., antibodies, may bind to different but overlapping epitopes, such that binding of one antigen-binding protein, e.g., an antibody, inhibits or blocks binding of the second antigen-binding protein, e.g., antibody, for example, by steric hindrance. Cross-competition between antigen-binding proteins, e.g., antibodies, can be measured by methods known in the art, for example, by real-time, label-free biolayer interference assays. Cross-competition between two antigen-binding proteins, e.g., antibodies, can be expressed as the binding of a second antigen-binding protein, e.g., antibody, being less than the background signal due to self-binding (when the first and second antigen-binding proteins, e.g., antibodies, are the same antigen-binding protein, e.g., antibody). Cross-competition between two antigen-binding proteins, e.g., antibodies, can be expressed, for example, as the % binding of a second antigen-binding protein, e.g., antibody, being lower than baseline self-background binding (when the first and second antigen-binding proteins, e.g., antibodies, are the same antigen-binding protein, e.g., antibody).

[0102] The terms "substantial identity" or "substantially identical," when referring to a nucleic acid or fragment thereof, indicate nucleotide sequence identity over at least about 90%, and more preferably at least about 95%, 96%, 97%, 98%, or 99%, of the nucleotide bases as measured by any well-known sequence identity algorithm when optimally aligned with another nucleic acid (or its complementary strand), with appropriate nucleotide insertions or deletions, as discussed below. A nucleic acid molecule having substantial identity to a reference nucleic acid molecule can, in certain instances, encode a polypeptide having the same or substantially similar amino acid sequence as the polypeptide encoded by the reference nucleic acid molecule.

[0103] Sequence identity can be determined using algorithms, for example, the Needleman Wunsch algorithm for global alignments (Needleman and Wunsch 1970, J. Mol. Biol. 48: 443-453), or Smith & Wate for local alignments. The rman algorithm (Smith and Waterman 1981, J. Mol. Biol. 147: 195-197) can be used to calculate the rman algorithm. Another preferred algorithm is that of Dufresne et al. in Nature Biotechnology in 2002 (vol. 20, pp. 1269-71) and is used in the software GenePAST (GQ Life Sciences, Inc. Boston, MA).

[0104] When applied to polypeptides, the terms "substantial similarity" or "substantially similar" mean that two peptide sequences share at least 90% sequence identity, and even more preferably at least 95%, 96%, 97%, 98%, or 99% sequence identity, when optimally aligned, e.g., by the programs GAP or BESTFIT, using default gap weighting. Non-identical residue positions preferably differ by conservative amino acid substitutions. A "conservative amino acid substitution" is the replacement of an amino acid residue with another amino acid residue having a side chain (R group) with similar chemical properties (e.g., charge or hydrophobicity). Generally, conservative amino acid substitutions do not substantially alter the functional properties of a protein. When two or more amino acid sequences differ from each other by conservative substitutions, the percent or degree of similarity can be adjusted upward to correct for the conservative nature of the substitutions. Means for making this adjustment are well known to those of skill in the art. See, e.g., Pearson (1994) Methods Mol. Biol. 24: 307-331, incorporated herein by reference. Examples of groups of amino acids with side chains that have similar chemical properties include: 1) aliphatic side chains: glycine, alanine, valine, leucine, and isoleucine; 2) aliphatic hydroxyl side chains: serine and threonine; 3) amide-containing side chains: asparagine and glutamine; 4) aromatic side chains: phenylalanine, tyrosine, and tryptophan; 5) basic side chains: lysine, arginine, and histidine; 6) acidic side chains: aspartic acid and glutamic acid; and 7) sulfur-containing side chains: cysteine ​​and methionine. Preferred conservative amino acid substitution groups are valine-leucine-isoleucine, phenylalanine-tyrosine, lysine-arginine, alanine-valine, glutamic acid-aspartic acid, and asparagine-glutamine. Alternatively, a conservative replacement is any change for which the PAM250 log-likelihood matrix is ​​positive, as disclosed in Gonnet et al. (1992) Science 256: 1443 45, which is incorporated herein by reference. A "moderately conservative" replacement is any change for which the PAM250 log-likelihood matrix is ​​non-negative.

[0105] Sequence similarity for polypeptides is typically measured using sequence analysis software. Protein analysis software matches similar sequences using measures of similarity assigned to various substitutions, deletions, and other modifications, including conservative amino acid substitutions. For example, GCG software includes programs such as GAP and BESTFIT, which can be used with default parameters to determine sequence homology or sequence identity between closely related polypeptides, such as homologous polypeptides from different species of organisms, or between a wild-type protein and its mutant protein. See, e.g., GCG Version 6.1. Polypeptide sequences can also be compared using FASTA with default or recommended parameters; GCG Version 6.1. FASTA (e.g., FASTA2 and FASTA3) programs provide alignments and percent sequence identity of the regions of best overlap between the query and search sequences (Pearson (2000) supra). The sequences of the present invention can be compared with multiple polypeptides from different organisms. Another preferred algorithm for comparing a database containing multiple sequences is the computer program BLAST, particularly BLASTP or TBLASTN, using default parameters. See, for example, Altschul et al., "Blocking the Sequences of Multiple Sequences," in ... et al. (1990) J. Mol. Biol. 215: 403-410 and (1997) Nucleic Acids See Res. 25: 3389-3402.

[0106] The phrase "therapeutically effective amount" means an amount that produces a desired effect for which it is administered. The exact amount will depend on the purpose of the treatment, and will be ascertainable by one skilled in the art using known techniques (see, e.g., Lloyd (1999) The Art, Science and Technology of Pharmaceutical Compounding).

[0107] As used herein, the term "subject" refers to an animal, preferably a mammal, in need of reversal, prevention, and / or treatment of an HPV infection, or a disease or disorder, such as a disease or disorder associated with HPV, such as an HPV-associated cancer (e.g., HPV16E7-positive cancer). The term includes human subjects having or at risk of having an HPV-associated cancer, an HPV-associated disease or disorder, such as metastatic HPV-associated cancer, or an HPV infection.

[0108] As used herein, "anticancer agent" means any agent useful for treating, ameliorating, or inhibiting cancer, including, but not limited to, cytotoxins and agents such as antimetabolites, alkylating agents, anthracyclines, antibiotics, antimitotics, procarbazine, hydroxyurea, asparaginase, corticosteroids, cyclophosphamide, mitotane (O,P'-(DDD)), biologics (e.g., antibodies and interferons), and radioactive agents. As used herein, "cytotoxin or cytotoxic agent," which also refers to chemotherapeutic agents, means any agent that is detrimental to cells. Examples include Taxol® (paclitaxel), temozolamide, cytochalasin B, gramicidin D, ethidium bromide, emetine, cisplatin, mitomycin, etoposide, tenoposide, vincristine, vinblastine, colchicine, doxorubicin, daunorubicin, dihydroxy anthracin dione, mitoxantrone, mithramycin, actinomycin D, 1-dehydrotestosterone, glucocorticoids, procaine, tetracaine, lidocaine, propranolol, and puromycin and analogs or homologs thereof.

[0109] As used herein, the term "antiviral agent" refers to any drug or treatment used to treat, prevent, or reverse a viral infection in a host subject. The term "antiviral agent" includes, but is not limited to, zidovudine, lamivudine, abacavir, ribavirin, lopinavir, efavirenz, cobicistat, tenofovir, rilpivirine, analgesics, and corticosteroids.

[0110] Antigen-binding proteins, e.g., antibodies, against conformational epitopes of the HPV16E7 peptide presented by HLA-A2, e.g., peptides comprising amino acid residues 11-19 or residues 82-90 of HPV16E7 linked to HLA-A2, can be generated using an immunogen comprising any one of the following: In certain embodiments, antigen-binding proteins, e.g., antibodies, of the invention are obtained from mice immunized with the full-length native HPV16E7 protein (see NCBI Accession No. NP_041326.1) (SEQ ID NO: 537) or with a recombinant HPV16E7 peptide, such as a peptide comprising amino acid residues 11-19 (YMLDLQPET; SEQ ID NO: 538) of GenBank Accession No. NP_041326.1 (SEQ ID NO: 537) linked to HLA-A2 or amino acid residues 82-90 (LLMGTLGIV; SEQ ID NO: 539) of GenBank Accession No. NP_041326.1 (SEQ ID NO: 537).

[0111] Alternatively, HPV16E7 or a fragment thereof can be produced using standard biochemical techniques, engineered in the context of HLA-A2, and used as an immunogen.

[0112] In some embodiments, the immunogen can be a recombinant HPV16 E7 peptide expressed in E. coli or in any other eukaryotic or mammalian cell, such as Chinese hamster ovary (CHO) cells.

[0113] In certain embodiments, antigen-binding proteins that specifically bind to conformational epitopes of the HPV16E7 peptide presented by HLA-A2 can be prepared using the above regions, or fragments of the peptides extending from either the N-terminus or C-terminus, or both, of the designated regions described herein, for more than about 5 to about 20 amino acid residues. In certain embodiments, any combination of the above regions or fragments thereof can be used to prepare antigen-binding proteins, e.g., antibodies, specific for HLA-A2:HPV16E7.

[0114] Peptides can be modified to include the addition or substitution of certain residues for tagging or for conjugation with carrier molecules such as KLH. For example, cysteine ​​can be added to either the N-terminus or C-terminus of the peptide, or a linker sequence can be added to prepare the peptide for conjugation with KLH, for example, for immunization.

[0115] Non-limiting, exemplary in vitro assays for measuring binding activity are illustrated in the Examples herein. In Example 4, the binding affinity and kinetic constant of an antigen-binding protein, e.g., an antibody, specific to human anti-HLA-A2:HPV16E7 was determined by surface plasmon resonance, and measurements were performed on a Biacore4000 or T200 instrument. Examples 6 and 7 describe the binding of antibodies to cells overexpressing fragments of HPV16E7.

[0116] Antigen-binding proteins, such as antibodies, specific for HLA-A2:HPV16E7 may contain no additional label or moiety, or may contain an N-terminal or C-terminal label or moiety. In one embodiment, the label or moiety is biotin. In binding assays, the location of the label (if any) can determine the orientation of the peptide relative to the surface to which it binds. For example, when the surface is coated with avidin, a peptide containing N-terminal biotin will be oriented so that the C-terminal portion of the peptide is distal to the surface. In one embodiment, the label can be a radionuclide, a fluorescent dye, or an MRI-detectable label. In certain embodiments, such labeled antigen-binding proteins can be used in diagnostic assays, including imaging assays.

[0117] antigen-binding proteins The present invention provides antibodies or antigen-binding fragments thereof, and antigen-binding proteins, including CARs (e.g., nucleic acid molecules encoding CARs of the present invention) (described below). Unless otherwise indicated, the term "antibody," as used herein, is understood to encompass an antibody molecule comprising two immunoglobulin heavy chains and two immunoglobulin light chains (i.e., a "whole antibody molecule"), as well as antigen-binding fragments thereof. The terms "antigen-binding portion" of an antibody, "antigen-binding fragment" of an antibody, and the like, as used herein, include any naturally occurring, enzymatically obtainable, synthetic, or genetically engineered polypeptide or glycoprotein that specifically binds to an antigen to form a complex. The term "antigen-binding fragment" of an antibody, or "antibody fragment," as used herein, refers to one or more fragments of an antibody that retain the ability to specifically bind to a conformational epitope of the HPV16E7 peptide presented by HLA-A2. Antigen-binding proteins, such as antibody fragments, may include Fab fragments, F(ab')2 fragments, Fv fragments, dAb fragments, CDR-containing fragments, or isolated CDRs. Antigen-binding proteins, such as antigen-binding fragments of antibodies, can be obtained, for example, from whole antibody molecules using any suitable standard technique, such as proteolytic digestion or recombinant genetic engineering techniques involving the manipulation and expression of DNA encoding antibody variable and (optionally) constant domains. Such DNA is known and / or readily available, for example, from commercial sources, DNA libraries (including, for example, phage antibody libraries), or can be synthesized. The DNA can be sequenced and manipulated chemically or using molecular biology techniques, for example, to place one or more variable and / or constant domains into the appropriate configuration, or to introduce codons, create cysteine ​​residues, modify, add, or delete amino acids, etc.

[0118] Non-limiting examples of antigen-binding fragments of antibodies include (i) Fab fragments; (ii) F(ab')2 fragments; (iii) Fd fragments; (iv) Fv fragments; (v) single-chain Fv (scFv) molecules; (vi) dAb fragments; and (vii) minimal recognition units consisting of amino acid residues mimicking the hypervariable regions of an antibody (e.g., isolated complementarity-determining regions (CDRs) such as CDR3 peptides) or constrained FR3-CDR3-FR4 peptides. Other engineered molecules, such as domain-specific antibodies, single-domain antibodies, domain-deleted antibodies, chimeric antibodies, CDR-grafted antibodies, diabodies, triabodies, tetrabodies, minibodies, nanobodies (e.g., monovalent nanobodies, bivalent nanobodies, etc.), small modular immunopharmaceuticals (SMIPs), and shark variable IgNAR domains, are also encompassed by the term "antigen-binding fragment" as used herein.

[0119] An antigen-binding fragment of an antigen-binding protein (e.g., an antibody) generally comprises at least one variable domain. A variable domain can be of any size or amino acid composition and generally comprises at least one CDR contiguous with or in frame with one or more framework sequences. L V associated with the domain H In antigen-binding proteins with domains, V H Domains and V L The domains can be positioned in any suitable arrangement relative to each other. For example, the variable region can be a dimer, with the V H -V H , V H -V L or V L -V L Alternatively, the antigen-binding fragment of the antibody contains a monomeric V dimer. H Domain or V L It may contain domains.

[0120] In certain embodiments, an antigen-binding fragment of an antibody may contain at least one variable domain covalently linked to at least one constant domain. Non-limiting exemplary configurations of variable and constant domains that may be found in an antigen-binding fragment of an antigen-binding protein of the invention include: (i) a V H -C H 1;(ii)V H -C H 2;(iii)V H -C H 3;(iv)V H -C H 1-C H 2;(v)V H -C H 1-C H 2-C H 3;(vi)V H -C H 2-C H 3;(vii)V H -C L ;(viii)V L -C H 1;(ix)V L -C H 2;(x)V L -C H 3;(xi)V L -C H 1-C H 2;(xii)V L -C H 1-C H 2-C H 3;(xiii)V L -C H 2-C H 3; and (xiv) V L -C LIn any of the variable and constant domain configurations, including any of the exemplary configurations listed above, the variable and constant domains may be either directly linked to one another or may be linked by a complete or partial hinge or linker region. The hinge region may consist of at least two (e.g., 5, 10, 15, 20, 40, 60, or more) amino acids and provide a flexible or semi-flexible linkage between adjacent variable and / or constant domains within a single polypeptide molecule. Furthermore, antigen-binding fragments of antibodies of the present invention may comprise any of the variable and constant domain configurations listed above in non-covalent association with one another and / or with one or more monomeric V H Domain or V L It may comprise homodimers or heterodimers (or other multimers) with the domains (e.g., via disulfide bond(s)).

[0121] Like whole antibody molecules, antigen-binding proteins, e.g., antigen-binding fragments of antibodies, can be monospecific or multispecific (e.g., bispecific). Multispecific antigen-binding fragments of antibodies generally comprise at least two different variable domains, each capable of specifically binding to a separate antigen or a different epitope on the same antigen. Any multispecific antibody format, including the exemplary bispecific antibody formats disclosed herein, can be adapted for use in connection with the antigen-binding fragments of antibodies of the present invention using routine techniques available in the art.

[0122] Preparation of antigen-binding proteins Methods for producing antigen-binding proteins, such as human antibodies, in transgenic mice are known in the art. Any such known method can be used in connection with the present invention to generate human antibodies that specifically bind to a conformational epitope of the human papillomavirus (HPV) 16 E7 peptide (HPV16 E7 peptide) presented by HLA-A2.

[0123] Using VELOCIMMUNE® technology (see, e.g., U.S. Pat. No. 6,596,541, Regeneron Pharmaceuticals, VELOCIMMUNE®) or any other known method for generating antigen-binding proteins, e.g., monoclonal antibodies, a high-affinity antigen-binding protein, e.g., a chimeric antibody, against a conformational epitope of the HPV16E7 peptide presented by HLA-A2 is first isolated, having a human variable region and a mouse constant region. VELOCIMMUNE® technology involves generating transgenic mice whose genomes contain human heavy and light chain variable regions operably linked to endogenous mouse constant region loci, such that the mice produce antigen-binding proteins, e.g., antibodies, containing human variable regions and mouse constant regions in response to antigenic challenge. DNA encoding the antibody heavy and light chain variable regions is isolated and operably linked to DNA encoding human heavy and light chain constant regions. The DNA is then expressed in cells capable of expressing fully human antibodies.

[0124] Generally, VELOCIMMUNE® mice are challenged with an antigen of interest, and lymphoid cells (e.g., B cells) expressing antigen-binding proteins, such as antibodies, are collected from the mice. The lymphoid cells are fused with a myeloma cell line to prepare immortal hybridoma cell lines, which are then screened and selected to identify hybridoma cell lines that produce specific antibodies against the antigen of interest. DNA encoding the heavy and light chain variable regions can be isolated and linked to heavy and light chain constant regions of the desired isotype. Such antigen-binding proteins can be produced in cells such as CHO cells. Alternatively, DNA encoding antigen-specific antigen-binding proteins, such as chimeric antibodies, or the light and heavy chain variable domains can be isolated directly from antigen-specific lymphocytes.

[0125] First, a high-affinity antigen-binding protein, such as a chimeric antibody, is isolated with a human variable region and a mouse constant region. As in the following experimental section, the antigen-binding protein is characterized and selected for desirable properties, including affinity, selectivity, epitope, etc. The mouse constant region is replaced with a desired human constant region to generate an antigen-binding protein of the present invention, such as a fully human antibody, for example, a wild-type or modified IgG1 or IgG4. Meanwhile, the constant region selected can vary depending on the specific use, the properties of high-affinity antigen binding and target specificity present in the variable region.

[0126] bioequivalence Anti-HLA-A2:HPV16E7 antigen binding proteins of the present invention include proteins that have amino acid sequences that vary from that of the described antigen binding proteins, e.g., antibodies, but retain the ability to bind to a conformational epitope of the HPV16E7 peptide presented by HLA-A2. Such variant antigen binding proteins contain one or more amino acid additions, deletions, or substitutions when compared to the parent sequence, but exhibit essentially the same biological activity as that of the described antigen binding proteins. Similarly, DNA sequences encoding the antigen binding proteins of the present invention include sequences that contain one or more nucleotide additions, deletions, or substitutions when compared to the disclosed sequences, but encode antigen binding proteins that are essentially biologically equivalent to the antigen binding proteins of the present invention.

[0127] Two antigen-binding proteins or antibodies are considered bioequivalent if, for example, they are pharmaceutical equivalents or pharmaceutical substitutes that show no significant differences in the rate and extent of absorption when administered at the same molar dose, under similar experimental conditions, either in single or multiple doses. Some antigen-binding proteins or antibodies are considered equivalents or pharmaceutical substitutes if their extent of absorption is equivalent but their rate is not, and they can nevertheless be considered bioequivalent because such differences in rate of absorption are intentional, reflected in the labeling, not necessary, for example, to achieve effective body drug concentrations over long-term use, and are considered medically insignificant with respect to the particular drug being tested.

[0128] In one embodiment, two antigen binding proteins (or antibodies) are bioequivalent if there are no clinically meaningful differences in their safety, purity, or potency.

[0129] In one embodiment, two antigen binding proteins (or antibodies) are bioequivalent if a patient can switch between the reference product and the biologic one or more times without expecting clinically significant changes in immunogenicity or increased risk of adverse effects, including attenuation of efficacy, compared to continued treatment without such switching.

[0130] In one embodiment, two antigen binding proteins (or antibodies) are biologically equivalent if they both act by a common mechanism(s) of action for the condition(s) of use, to the extent such mechanism(s) are known.

[0131] Bioequivalence can be demonstrated by in vivo and / or in vitro methods. Measures of bioequivalence include, for example, (a) in vivo studies in humans or other mammals that measure the concentration of an antigen-binding protein or its metabolites in blood, plasma, serum, or other biological fluids as a function of time; (b) human in vivo studies. (c) in vitro studies that correlate with and reasonably predict in vivo bioavailability data; (d) well-controlled clinical trials that establish the safety, efficacy, or bioavailability or bioequivalence of the antigen binding protein; and (e) in vivo studies that measure the plausible acute pharmacological effects of the antigen binding protein (or its target) over time.

[0132] Biologically equivalent variants of the antigen-binding proteins (or antibodies) of the present invention can be constructed, for example, by making various substitutions of residues or sequences or by deleting terminal or internal residues or sequences that are not required for biological activity. For example, cysteine ​​residues that are not essential for biological activity can be deleted or replaced with other amino acids to prevent the formation of unnecessary or inappropriate intramolecular disulfide bridges upon renaturation. In other situations, biologically equivalent antigen-binding proteins may include antigen-binding protein variants that contain amino acid changes that alter the glycosylation characteristics of the antigen-binding protein, for example, mutations that eliminate or remove glycosylation.

[0133] Anti-HLA-A2:HPV16E7 antigen-binding proteins containing Fc variants According to certain embodiments of the present invention, there are provided anti-HLA-A2:HPV16E7 antigen binding proteins, e.g., antibodies, comprising an Fc domain comprising one or more mutations that enhance or attenuate binding of the antigen binding protein to the FcRn receptor at, e.g., acidic pH compared to neutral pH. For example, the present invention provides antibodies, e.g., antibodies, comprising an Fc domain comprising one or more mutations that enhance or attenuate binding of the antigen binding protein to the FcRn receptor at, e.g., acidic pH compared to neutral pH. H 2nd area or C HAnti-HLA-A2:HPV16E7 antigen binding proteins include those containing mutations in three regions, where the mutation(s) increase the affinity of the Fc domain for FcRn in acidic environments (e.g., in endosomes, where the pH ranges from about 5.5 to about 6.0). Such mutations can result in increased serum half-life of the antigen binding protein when administered to an animal. Non-limiting examples of such Fc modifications include, for example, modifications at positions 250 (e.g., E or Q); 250 and 428 (e.g., L or F); 252 (e.g., L / Y / F / W or T), 254 (e.g., S or T), and 256 (e.g., S / R / Q / E / D or T); or modifications at positions 428 and / or 433 (e.g., H / L / R / S / P / Q or K) and / or 434 (e.g., A, W, H, F or Y [N434A, N434W, N434H, N434F or N434Y]); or modifications at positions 250 and / or 428; or modifications at positions 307 or 308 (e.g., 308F, V308F), and 434. In one embodiment, the modifications include 428L (e.g., M428L) and 434S (e.g., N434S) modifications; 428L, 259I (e.g., V259I), and 308F (e.g., V308F) modifications; 433K (e.g., H433K) and 434 (e.g., 434Y) modifications; 252, 254, and 256 (e.g., 252Y, 254T, and 256E) modifications; 250Q and 428L modifications (e.g., T250Q and M428L); and 307 and / or 308 modifications (e.g., 308F or 308P). In yet another embodiment, the modifications include 265A (e.g., D265A) and / or 297A (e.g., N297A) modifications.

[0134] For example, the present invention provides 250Q and 248L (e.g., T250Q and M248L); 252Y, 254T and 256E (e.g., M252Y, S254T and T256E); 428L and 434S (e.g., M428L and N434S); 257I and 311I (e.g., P257I and Q311I); 257I and 434H (e.g., P257I and N434H); 3 The present invention includes anti-HLA-A2:HPV16 E7 antigen binding proteins comprising an Fc domain containing one or more pairs or groups of mutations selected from the group consisting of 76V and 434H (e.g., D376V and N434H); 307A, 380A and 434A (e.g., T307A, E380A and N434A); and 433K and 434F (e.g., H433K and N434F). In one embodiment, the present invention includes anti-HLA-A2:HPV16 E7 antigen binding proteins comprising an Fc domain containing the S108P mutation in the hinge region of IgG4 to promote dimer stabilization. All possible combinations of the aforementioned Fc domain mutations with other mutations within the antigen binding protein variable domains disclosed herein are intended to be within the scope of the present invention.

[0135] The present invention relates to chimeric heavy chain constant (C H ) region, wherein the chimeric C H The region contains C domains of more than one immunoglobulin isotype. H For example, the antigen-binding proteins of the present invention may comprise a segment derived from a C region derived from a human IgG1 molecule, a human IgG2 molecule, or a human IgG4 molecule. H Part or all of the 2 domain and C derived from human IgG1, IgG2, or IgG4 molecules H Chimeric C containing a combination of some or all of the three domains H According to certain embodiments, the antigen binding proteins of the present invention may comprise a chimeric C region having a chimeric hinge region. HFor example, the chimeric hinge may comprise a combination of an "upper hinge" amino acid sequence (amino acid residues 216 to 227 according to EU numbering) derived from a human IgG1, human IgG2, or human IgG4 hinge region and a "lower hinge" sequence (amino acid residues 228 to 236 according to EU numbering) derived from a human IgG1, human IgG2, or human IgG4 hinge region. According to certain embodiments, the chimeric hinge region comprises amino acid residues derived from the upper hinge of human IgG1 or human IgG4 and amino acid residues derived from the lower hinge of human IgG2. The chimeric C described herein H Antigen binding proteins comprising the region, in certain embodiments, exhibit altered Fc effector function without adversely affecting the therapeutic or pharmacokinetic properties of the antigen binding protein (see, e.g., U.S. Patent Application Publication No. 20140243504, the disclosure of which is incorporated herein by reference in its entirety).

[0136] Biological properties of antigen-binding proteins Generally, the antigen binding proteins of the present invention function by binding to a conformational epitope of the human papillomavirus (HPV) 16 E7 peptide (HPV16E7) peptide that is presented by HLA-A2.

[0137] The present invention includes anti-HLA-A2:HPV16E7 antigen binding proteins that bind with high specificity to HPV16E7 peptides in the context of HLA-A2. The anti-HLA-A2:HPV16E7 antigen binding proteins do not bind to HPV16E7 peptides in the absence of HLA-A2. Furthermore, the anti-HLA-A2:HPV16E7 antigen binding proteins do not bind to off-target peptides in the context of HLA-A2.

[0138] The present invention includes anti-HLA-A2:HPV16E7 antigen binding proteins that bind with high affinity to monomeric HLA-A2:HPV16E7 11-19 peptide. For example, the present invention provides antibodies that bind to monomeric HLA-A2:HPV16E7 11-19 peptide (e.g., at 25°C or 37°C) with a K of less than about 20 nM, as measured by surface plasmon resonance using, for example, the assay format defined in Example 4 herein. D In certain embodiments, the antigen binding protein binds to a monomeric HLA-A2:HPV16E7 11-19 peptide with a K of less than about 15 nM, less than about 12 nM, less than about 10 nM, less than about 5 nM, less than about 2 nM, less than about 1 nM, less than about 0.5 nM, less than about 0.1 nM, less than about 0.05 nM, or less than about 0.04 nM, as measured by surface plasmon resonance using, for example, the assay format defined in Example 4 herein, or a substantially similar assay. D Combine with.

[0139] The present invention provides compounds that bind to monomeric HLA-A2:HPV16E7 82-90 peptides with a K of less than about 25 nM (e.g., at 25° C. or 37° C.), as measured by surface plasmon resonance using, for example, the assay format defined in Example 4 herein, or a substantially similar assay. D In certain embodiments, the antigen binding protein binds to the monomeric HLA-A2:HPV16E7 82-90 peptide with a K of less than about 20 nM, less than about 15 nM, less than about 12 nM, less than about 10 nM, less than about 5 nM, less than about 2 nM, less than about 1 nM, less than about 0.5 nM, less than about 0.1 nM, less than about 0.05 nM, or less than about 0.04 nM, as measured by surface plasmon resonance using, for example, the assay format defined in Example 4 herein, or a substantially similar assay. D Combine with.

[0140] The present invention provides a method for treating HPV16E7 11-19 peptide-expressing cells with an EC of less than about 6 nM on cells expressing the HLA-A2:HPV16E7 11-19 peptide, as determined by the luminescence assay defined in Example 6 herein or a substantially similar assay. 50 and do not bind to cells expressing the predicted off-target peptide. In certain embodiments, the antigen binding protein has an EC of less than about 6 nM, less than about 5 nM, less than about 2 nM, less than about 1 nM, or less than about 0.5 nM to cells expressing the HLA-A2:HPV16E7 11-19 peptide, as determined by a luminescence assay or a substantially similar assay defined in Example 6 herein, e.g., using the assay format of Example 6 herein or a substantially similar assay. 50 It binds to cells expressing predicted off-target peptides and does not bind to cells expressing predicted off-target peptides.

[0141] The present invention provides a method for treating HPV16E7 82-90 peptide-expressing cells with an EC of less than about 1 nM on cells expressing the HLA-A2:HPV16E7 82-90 peptide, as determined by the luminescence assay defined in Example 6 herein or a substantially similar assay. 50 and do not bind to cells expressing the predicted off-target peptide. In certain embodiments, the antigen binding protein has an EC of less than about 1 nM, less than about 0.5 nM, less than about 0.2 nM, or less than about 0.01 nM to cells expressing the HLA-A2:HPV16E7 82-90 peptide, as determined by a luminescence assay defined in Example 6 herein or a substantially similar assay, e.g., using the assay format of Example 6 herein or a substantially similar assay. 50 It binds to cells expressing predicted off-target peptides and does not bind to cells expressing predicted off-target peptides.

[0142] The present invention provides a method for treating HPV16E7 11-19 peptide-expressing cells with an EC of less than about 30 nM on cells expressing the HLA-A2:HPV16E7 11-19 peptide, as measured by a flow cytometry assay as defined in Example 7 herein or a substantially similar assay. 50In certain embodiments, the antigen binding protein has an EC50 of less than about 25 nM, less than about 20 nM, less than about 15 nM, less than about 10 nM, less than about 5 nM, less than about 2 nM, less than about 1 nM, or less than about 0.5 nM for cells expressing the HLA-A2:HPV16E7 11-19 peptide, as measured by, for example, a flow cytometry assay using the assay format of Example 7 herein, or a substantially similar assay. 50 Combine with.

[0143] The present invention provides a method for treating HPV16E7 82-90 peptide-expressing cells with an EC of less than about 75 nM on cells expressing the HLA-A2:HPV16E7 82-90 peptide, as measured by a flow cytometry assay as defined in Example 7 herein or a substantially similar assay. 50 In certain embodiments, the antigen binding protein binds to cells expressing the HLA-A2:HPV16E7 82-90 peptide with an EC of less than about 75 nM, less than about 70 nM, less than about 65 nM, less than about 60 nM, less than about 55 nM, less than about 50 nM, less than about 45 nM, less than about 40 nM, less than about 35 nM, less than about 30 nM, less than about 25 nM, less than about 20 nM, less than about 15 nM, less than about 10 nM, less than about 5 nM, less than about 2 nM, less than about 1 nM, or less than about 0.5 nM, as measured by a flow cytometry assay, e.g., using the assay format of Example 7 herein, or a substantially similar assay. 50 Combine with.

[0144] In certain embodiments, the antigen-binding proteins of the present invention, when administered prophylactically to a subject in need thereof, are useful in inhibiting tumor growth or delaying the progression of cancer, and can increase the survival of the subject. For example, administration of the antigen-binding proteins of the present invention can lead to the shrinkage of a primary tumor and can prevent the development of metastasis or secondary tumors. In certain embodiments, the antigen-binding proteins of the present invention, when administered therapeutically to a subject in need thereof, are useful in inhibiting tumor growth and can increase the survival of the subject. For example, administration of a therapeutically effective amount of the antigen-binding proteins of the present invention to a subject can lead to the shrinkage and disappearance of an established tumor in the subject.

[0145] In one embodiment, the present invention provides an isolated recombinant antigen binding protein that binds to a conformational epitope of the HPV16E7 peptide presented by HLA-A2, wherein the antigen binding protein exhibits one or more of the following properties: (i) SEQ ID NOs: 2, 18, 34, 50, 66, 82, 98, 114, 130, 146, 162, 178, 194, 210, 218, 234, 250, 266, 282, 298, 314, 330, 346, 362, 370, 380, 390, 400, 410, 420, 430, 440, 450, 460, 470, 480, 490, 510, 520, 530, 540, 550, 560, 570, 580, 590, 610, 620, 630, 640, 650, 660, 670, 680, 690, 700, 710, 720, 730, 740, 750, 760, 770, 780, 790, 800, 810, 820, 830, 840, 850, 860, 870, 880, 890, 900, 910, 920, 930, 940, 950, 960, 970, 980, 990, 1000, 1010, 1020, 1030, 104 (ii) HCVRs having an amino acid sequence selected from the group consisting of SEQ ID NOs: 10, 26, 42, 58, 74, 90, 106, 122, 138, 154, 170, 186, 202, 226, 232, 242, 258, 264, 274, 282, 290, 306, 310, 326, 332, 342, 358, 364, 374, 382, ​​394, 410, 426, 442, 458, 474, 490, 506, and 522, or a substantially similar sequence thereof having at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity; (iii) SEQ ID NOs: 8, 24, 40, 56, 72, 88, 104, 120, 136, 152, an HCDR3 domain having an amino acid sequence selected from the group consisting of 168, 184, 200, 216, 224, 240, 256, 272, 288, 304, 320, 336, 352, 368, 384, 400, 416, 432, 448, 464, 480, 496, 512, and 528, or a substantially similar sequence thereof having at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity;and an LCDR3 domain having an amino acid sequence selected from the group consisting of SEQ ID NOs: 16, 32, 48, 64, 80, 96, 112, 128, 144, 160, 176, 192, 208, 232, 248, 264, 280, 296, 312, 328, 344, 360, 376, 392, 408, 424, 440, 456, 472, 488, 504, 520, and 536, or a substantially similar sequence thereof having at least 90%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% sequence identity. (iv) an HCDR1 domain having an amino acid sequence selected from the group consisting of SEQ ID NOs: 4, 20, 36, 52, 68, 84, 100, 116, 132, 148, 164, 180, 196, 212, 220, 236, 252, 268, 284, 300, 316, 332, 348, 364, 380, 396, 412, 428, 444, 460, 476, 492, 508, and 524, or a substantially similar sequence thereof having at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity. a LCDR1 domain having an amino acid sequence selected from the group consisting of SEQ ID NOs: 12, 28, 44, 60, 76, 92, 108, 124, 140, 156, 172, 188, 204, 228, 244, 260, 276, 292, 308, 324, 340, 356, 372, 388, 404, 420, 436, 452, 468, 484, 500, 516, and 532, or a substantially similar sequence thereof having at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity; and an LCDR2 domain having an amino acid sequence selected from the group consisting of SEQ ID NOs: 14, 30, 46, 62, 78, 94, 110, 126, 142, 158, 174, 190, 206, 230, 246, 262, 278, 294, 310, 326, 342, 358, 374, 390, 406, 422, 438, 454, 470, 486, 502, 518, and 534, or a substantially similar sequence thereof having at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity;(v) binds to monomeric HLA-A2:HPV16E7 11-19 peptide with a binding dissociation equilibrium constant (KD) of less than about 20 nM as measured by a surface plasmon resonance assay at 25°C; (vi) binds to monomeric HLA-A2:HPV16E7 82-90 peptide with a binding dissociation equilibrium constant (KD) of less than about 25 nM as measured by a surface plasmon resonance assay at 25°C; (vii) binds to cells expressing HLA-A2:HPV16E7 11-19 peptide with an EC50 of less than about 6 nM as measured by a luminescence assay, and does not bind to cells expressing predicted off-target peptides; (viii) binds to HLA-A2:HPV16E7 (ix) binds to cells expressing the HLA-A2:HPV16E7 11-19 peptide with an EC50 of less than about 30 nM as determined by a flow cytometry assay; (x) binds to cells expressing the HLA-A2:HPV16E7 82-90 peptide with an EC50 of less than about 75 nM as determined by a flow cytometry assay; (xi) does not bind to off-target peptides displayed by HLA-A2 that differ from SEQ ID NO:538 by one, two, three, four, five or more amino acids; and (xii) does not bind to off-target peptides displayed by HLA-A2 that differ from SEQ ID NO:539 by one, two, three, four, five or more amino acids.

[0146] The antigen binding proteins of the present invention may have one or more of the above biological properties, or any combination thereof. Other biological properties of the antigen binding proteins of the present invention will be apparent to those of skill in the art from a review of this disclosure, including the Examples herein.

[0147] Epitope mapping and related techniques The present invention includes anti-HLA-A2:HPV16E7 antigen binding proteins that interact with one or more amino acids found within one or more domains of the HPV16E7 peptide displayed by HLA-A2. The epitope may consist of multiple non-contiguous amino acids (or amino acid sequences) (e.g., conformational epitopes) located within either or both of the aforementioned domains of the HPV16E7 molecule.

[0148] A variety of techniques known to those skilled in the art can be used to determine whether an antigen binding protein "interacts with one or more amino acids" within a polypeptide or protein. Exemplary techniques include, for example, those described in Antibodies, Harlow and Lane (Cold Other methods include conventional cross-blocking assays, such as those described in (Spring Harbor Press, Cold Spring Harbor, NY). Other methods include alanine scanning mutagenesis analysis, peptide blot analysis (Reineke (2004) Methods Mol. Biol. 248: 443-63). These include peptide cleavage analysis, crystallographic studies, and NMR analysis. Additionally, methods such as epitope excision, epitope extraction, and chemical modification of antigens are available (Tomer (2000) Prot. Sci. 9: 487-496). Another method that can be used to identify amino acids within a peptide is hydrogen / deuterium exchange, detected by mass spectrometry. Generally speaking, hydrogen / deuterium exchange involves labeling a protein of interest with deuterium and then binding an antigen-binding protein to the deuterium-labeled protein. The protein / antigen-binding protein complex is then transferred to water, where exchangeable protons within amino acids protected by the antigen-binding protein complex undergo back-exchange from deuterium to hydrogen at a slower rate than exchangeable protons within amino acids that are not part of the interface. As a result, amino acids that form part of the protein / antigen-binding protein interface may retain deuterium and therefore exhibit a relatively high mass compared to amino acids not included in the interface. After dissociation of the antigen-binding protein, the target protein is subjected to protease cleavage and mass spectrometry, thereby revealing deuterium-labeled residues corresponding to the specific amino acids with which the antigen-binding protein interacts. See, for example, Ehring (1999). See Analytical Biochemistry 267: 252-259; Engen and Smith (2001) Anal. Chem. 73: 256A-265A.

[0149] The term "epitope" refers to a site on an antigen to which B cells and / or T cells respond. B cell epitopes can be formed both by contiguous amino acids or by non-contiguous amino acids juxtaposed by tertiary folding of a protein. Epitopes formed by contiguous amino acids generally are retained upon exposure to denaturing solvents, whereas epitopes formed by tertiary folding generally disappear upon treatment with denaturing solvents. Epitopes generally contain at least three, more usually at least five or 8-10 amino acids in a unique spatial conformation.

[0150] Modification-assisted profiling (MAP), also known as antigen structure-based antibody profiling (ASAP), is a method for categorizing multiple monoclonal antigen-binding proteins, e.g., antibodies (mAbs), directed against the same antigen according to the similarity of their binding profiles to chemically or enzymatically modified antigen surfaces (see US2004 / 0101920, expressly incorporated herein by reference in its entirety). Each category can reflect a unique epitope that is either distinctly different from or partially overlaps with the epitopes represented by other categories. This technique allows for rapid filtering of genetically identical antigen-binding proteins, thus focusing characterization on genetically distinct antigen-binding proteins. When applied to hybridoma screening, MAP facilitates the identification of rare hybridoma clones that produce antigen-binding proteins with desired properties. MAP can be used to sort the antigen-binding proteins of the present invention into groups of antigen-binding proteins that bind to different epitopes.

[0151] The present invention includes anti-HLA-A2:HPV16E7 antigen binding proteins that bind to the same epitope or a portion of the epitope as any of the specific exemplary antigen binding proteins set forth in Table 1 herein, or an antigen binding protein having the CDR sequences of any of the exemplary antigen binding proteins set forth in Table 1. Similarly, the present invention also includes anti-HLA-A2:HPV16E7 antigen binding proteins that compete with any of the specific exemplary antigen binding proteins set forth in Table 1 herein, or an antigen binding protein having the CDR sequences of any of the exemplary antigen binding proteins set forth in Table 1, for binding to HLA-A2:HPV16E7 or a fragment thereof.

[0152] Whether an antigen-binding protein binds to the same epitope as a reference anti-HLA-A2:HPV16E7 antigen-binding protein or competes for binding can be easily determined using routine methods known in the art. For example, to determine whether a test antigen-binding protein binds to the same epitope as a reference anti-HLA-A2:HPV16E7 antigen-binding protein of the present invention, the reference antigen-binding protein is allowed to bind to an HLA-A2:HPV16E7 protein or peptide under saturating conditions. The ability of the test antigen-binding protein to bind to an HLA-A2:HPV16E7 molecule is then evaluated. If the test antigen-binding protein can bind to HLA-A2:HPV16E7 after saturating binding with the reference anti-HLA-A2:HPV16E7 antigen-binding protein, it can be concluded that the test antigen-binding protein binds to a different epitope than the reference anti-HLA-A2:HPV16E7 antigen-binding protein. On the other hand, if the test antigen binding protein is unable to bind to the HLA-A2:HPV16E7 protein after saturation binding with the reference anti-HLA-A2:HPV16E7 antigen binding protein, then the test antigen binding protein likely binds to the same epitope as the reference anti-HLA-A2:HPV16E7 antigen binding protein of the invention.

[0153] To determine whether an antigen binding protein competes for binding with a reference anti-HLA-A2:HPV16E7 antigen binding protein, the above binding methodology is performed in two directions: in the first direction, the reference antigen binding protein is allowed to bind to the HLA-A2:HPV16E7 protein under saturating conditions, and then the binding of the test antigen binding protein to the HLA-A2:HPV16E7 molecule is assessed. In the second direction, the test antigen binding protein is allowed to bind to the HLA-A2:HPV16E7 molecule under saturating conditions, and then the binding of the reference antigen binding protein to the HLA-A2:HPV16E7 molecule is assessed. If in both directions only the first (saturating) antigen binding protein is able to bind to the HLA-A2:HPV16E7 molecule, then it is concluded that the test and reference antigen binding proteins compete for binding to HLA-A2:HPV16E7. As will be appreciated by those of skill in the art, an antigen binding protein that competes for binding with a reference antigen binding protein may not necessarily bind to the same epitope as the reference antigen binding protein, and may be sterically blocked by binding to an overlapping or adjacent epitope.

[0154] Two antigen-binding proteins bind to the same or overlapping epitopes if each competitively inhibits (blocks) the binding of the other to the antigen. That is, a 1-fold, 5-fold, 10-fold, 20-fold, or 100-fold excess of one antigen-binding protein inhibits the binding of the other by at least 50%, but preferably 75%, 90%, or even 99%, as measured in a competitive binding assay (see, e.g., Junghans et al., Cancer Res. 1990 50: 1495-1502). Alternatively, two antigen-binding proteins have the same epitope if essentially all of the amino acid mutations in the antigen that reduce or eliminate binding of one antigen-binding protein also reduce or eliminate binding of the other. Two antigen-binding proteins have overlapping epitopes if some of the amino acid mutations that reduce or eliminate binding of one antigen-binding protein also reduce or eliminate binding of the other.

[0155] Additional routine experiments (e.g., peptide mutations and binding analysis) can then be performed to confirm whether the observed lack of binding of the test antigen-binding protein is indeed due to binding to the same epitope as the reference antigen-binding protein, or whether steric blocking (or another phenomenon) is responsible for the observed lack of binding. These types of experiments can be performed using ELISA, RIA, surface plasmon resonance, flow cytometry, or any other quantitative or qualitative antigen-binding protein binding assay available in the art.

[0156] Immunoconjugates The present invention encompasses anti-HLA-A2:HPV16E7 antigen-binding proteins conjugated to a therapeutic moiety, such as a cytotoxin or chemotherapeutic agent, for treating cancer ("immunoconjugates"). As used herein, the term "immunoconjugate" refers to an antigen-binding protein chemically or biologically linked to a cytotoxin, radioactive agent, cytokine, interferon, target or reporter moiety such as a detectable moiety, enzyme, toxin, peptide or protein, or therapeutic agent. The antigen-binding protein can be linked to the cytotoxin, radioactive agent, cytokine, interferon, target or reporter moiety, enzyme, toxin, peptide, or therapeutic agent anywhere along the molecule, so long as it is capable of binding to its target. Examples of immunoconjugates include antigen-binding protein-drug conjugates and antigen-binding protein-toxin fusion proteins. In one embodiment, the agent can be a second, different antibody against HPV16E7 or HLA-A2:HPV16E7. In certain embodiments, the antigen-binding protein can be conjugated with an agent specific to tumor cells or virus-infected cells, i.e., HPV-infected cells. The type of therapeutic moiety that can be conjugated to the anti-HLA-A2:HPV16E7 antigen-binding protein takes into account the condition to be treated and the desired therapeutic effect to be achieved. Examples of suitable agents for forming immunoconjugates are known in the art; see, for example, PCT Publication No. WO05 / 103081.

[0157] Chimeric antigen receptor (CAR) Chimeric antigen receptors (CARs) redirect T cell specificity toward antibody-recognized antigens expressed on the surface of cancer cells, while T cell receptors (TCRs) broaden the targeting spectrum to include intracellular tumor antigens. CAR-redirected T cells specific for the B cell differentiation antigen CD19 have shown dramatic efficacy in treating B cell malignancies, while TCR-redirected T cells have shown benefit in patients with solid tumors. Stauss et al. have described therapeutic T cells for use in the treatment of cancer. Strategies for modifying CARs and TCRs, for example, to enhance antigen-specific effector function and limit the toxicity of engineered T cells, have been described (Current Opinion in Pharmacology 2015, 24: 113-118).

[0158] One aspect of the present invention includes chimeric antigen receptors (CARs) specific for HPV16E7 peptides displayed on the surface of tumor cells by HLA-A2, such as peptides comprising amino acid residues 11-19 or 82-90 of HPV16E7. In one embodiment of the present invention, the CARs described herein comprise an extracellular target-specific binding domain, a transmembrane domain, an intracellular signaling domain (e.g., a signaling domain derived from CD3 zeta or FcR gamma), and / or one or more costimulatory signaling domains derived from costimulatory molecules such as, but not limited to, CD28, CD137, CD134, or CD278. In one embodiment, the CARs comprise a hinge or spacer region between the extracellular binding domain and the transmembrane domain, such as a CD8 alpha hinge. In another embodiment of the present invention, the CARs described herein comprise an extracellular target-specific binding domain and a T cell receptor constant domain ("T-body construct").

[0159] It should be understood that for use in any of the CARs described herein, the extracellular target-specific binding domain can comprise the Fab, Fab', (Fab')2, Fv, or single-chain Fv (scFv) of the antigen-binding proteins of the invention.

[0160] As used herein, the binding domain or extracellular domain of a CAR provides the CAR with the ability to bind to a target antigen of interest. A binding domain can be any protein, polypeptide, oligopeptide, or peptide capable of specifically recognizing and binding to a biomolecule (e.g., a cell surface receptor or tumor protein, or a component thereof). A binding domain includes any naturally occurring, synthetic, semi-synthetic, or recombinantly produced binding partner for a biomolecule of interest. For example, as further described herein, a binding domain can be an antibody light chain and heavy chain variable region, or the light chain and heavy chain variable region can be joined together in either direction into a single chain (e.g., VL-VH or VH-VL). Various assays for identifying a binding domain of the present disclosure that specifically binds to a particular target are known and are described herein, including Western blot, ELISA, flow cytometry, or surface plasmon resonance analysis (e.g., using BIACORE analysis). The target can be any antigen of clinical interest against which it is desirable to elicit an effector immune response that results in tumor killing. In one embodiment, the target antigen of the binding domain of the chimeric antigen receptor is a conformational epitope of the HPV16E7 peptide presented by HLA-A2 on the surface of tumor cells, such as a peptide comprising amino acid residues 11-19 or 82-90 of HPV16E7.

[0161] Exemplary binding domains include antigen-binding fragments of antibodies such as scFv, scTCR, extracellular domains of receptors, ligands of cell surface molecules / receptors or receptor-binding domains thereof, and antigen-binding proteins such as tumor-binding proteins. In certain embodiments, the antigen-binding domain included in the CAR of the present invention can be a variable region (Fv), CDR, Fab, scFv, VH, VL, domain antibody variant (dAb), camelid antibody (VHH), fibronectin 3 domain variant, ankyrin repeat variant, and other antigen-specific binding domains derived from other protein scaffolds.

[0162] In one embodiment, the binding domain of the CAR is an anti-HLA-A2:HPV16E7 single-chain antibody (scFv), which can be a mouse scFv, a human scFv, or a humanized scFv. Single-chain antibodies can be cloned from the V-region genes of hybridomas specific to the desired target. Techniques that can be used to clone the variable heavy (VH) and variable light (VL) chains are described, for example, in Orlandi et al., PNAS, 1989; 86: 3833-3837. Thus, in certain embodiments, the binding domain is derived from an antibody. The binding domain may be a fragment of an antibody or the genetically engineered product of one or more fragments of an antibody, which fragment is responsible for binding to an antigen.

[0163] In certain embodiments, the CAR of the present invention may include linkers between various domains, attached with appropriate spacing and conformation of the molecule. For example, in one embodiment, there may be a linker between the VH or VL binding domains, which may be between 1 and 10 amino acids in length. In other embodiments, the linker between any of the domains of the chimeric antigen receptor may be between 1 and 20 amino acids in length. In this regard, the linker may be 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20 amino acids in length. In further embodiments, the linker may be 21, 22, 23, 24, 25, 26, 27, 28, 29, or 30 amino acids in length. Linkers of lengths inclusive of the numbers recited herein, e.g., 10-30 amino acids, are also encompassed herein.

[0164] In certain embodiments, linkers suitable for use in the CARs described herein are flexible linkers. Suitable linkers can be readily selected and can be of any of a variety of suitable lengths, such as from 1 amino acid (e.g., Gly) to 20 amino acids, from 2 to 15 amino acids, from 3 to 12 amino acids, including 4 to 10 amino acids, 5 to 9 amino acids, 6 to 8 amino acids, or 7 to 8 amino acids, and can be 1 amino acid, 2 amino acids, 3 amino acids, 4 amino acids, 5 amino acids, 6 amino acids, or 7 amino acids.

[0165] Exemplary flexible linkers include glycine polymers (G), glycine-serine polymers (where n is an integer of at least 1), glycine-alanine polymers, alanine-serine polymers, and other flexible linkers known in the art. Glycine and glycine-serine polymers are relatively unstructured and can therefore function as neutral tethers between domains of fusion proteins such as the CARs described herein. Glycine has greater access to the phi-psi space than alanine and is much less restricted than residues with longer side chains (see Scheraga, Rev. Computational Chem. 11173-142 (1992)). CAR design can include all or part of a flexible linker; thus, those skilled in the art will understand that the linker can include a flexible linker as well as one or more moieties that confer a less flexible structure to produce the desired CAR structure.

[0166] The binding domain of a CAR may be followed by a "spacer" or "hinge," which refers to a region that moves the antigen-binding domain away from the effector cell surface to allow proper cell-cell contact, antigen binding, and activation (Patel et al., Gene Therapy, 1999; 6: 412-419). The hinge region in a CAR generally binds the transmembrane (TM) domain. The hinge region is located between the ligation domain and the binding domain. In certain embodiments, the hinge region may be an immunoglobulin hinge region, and may be a wild-type immunoglobulin hinge region or a modified wild-type immunoglobulin hinge region. Other exemplary hinge regions used in the CARs described herein include hinge regions derived from the extracellular domains of type 1 membrane proteins such as CD8 alpha, CD4, CD28, and CD7, which may be the wild-type hinge region derived from these molecules or may be modified. In one embodiment, the hinge region comprises a CD8 alpha hinge.

[0167] The "transmembrane" region or domain is the portion of a CAR that anchors the extracellular binding moiety to the plasma membrane of an immune effector cell, facilitating binding of the binding domain to a target antigen. The transmembrane domain may be a CD3 zeta transmembrane domain, although other transmembrane domains can be used, including those obtained from CD8 alpha, CD4, CD28, CD45, CD9, CD16, CD22, CD33, CD64, CD80, CD86, CD134, CD137, and CD154. In one embodiment, the transmembrane domain is that of CD137. In certain embodiments, the transmembrane domain is synthetic, and in that case, contains primarily hydrophobic residues such as leucine and valine.

[0168] The term "intracellular signaling domain" refers to a portion of a chimeric antigen receptor protein involved in transmitting a message of effective CAR binding to a target antigen inside an immune effector cell to elicit an effector cell function, such as cytotoxic activity, including activation, cytokine production, proliferation, and release of cytotoxic factors toward a target cell to which the CAR is bound, or other cellular responses elicited by antigen binding to the extracellular CAR domain. The term "effector function" refers to a specialized function of a cell. The effector function of a T cell can be, for example, supportive activities including cytolytic activity or cytokine secretion. Thus, the term "intracellular signaling domain" refers to a portion of a protein that transmits an effector function signal and directs the cell to perform a specialized function. Typically, the entire intracellular signaling domain can be used, but in many cases, it is not necessary to use the entire domain. A truncated portion of the intracellular signaling domain can be used in place of the entire domain, so long as such a truncated portion transmits the effector function signal. The term intracellular signaling domain is intended to include any truncated portion of the intracellular signaling domain sufficient to transmit an effector function signal. The intracellular signaling domain, also known as the "signal transduction domain," is generally derived from a portion of the human CD3 or FcRy chain.

[0169] It is known that signals generated by the T cell receptor alone are insufficient for full activation of T cells, and that secondary or costimulatory signals are also required. Thus, T cell activation can be said to be mediated by two distinct classes of cytoplasmic signaling sequences: those that initiate antigen-dependent primary activation through the T cell receptor (primary cytoplasmic signaling sequences), and those that act in an antigen-independent manner to provide secondary or costimulatory signals (secondary cytoplasmic signaling sequences). Primary cytoplasmic signaling sequences regulate the primary activation of the T cell receptor complex in either an inhibitory or inhibitory manner. Primary cytoplasmic signaling sequences that act in a costimulatory manner may contain signaling motifs known as immunoreceptor tyrosine-based activation motifs or ITAMs.

[0170] Examples of ITAMs containing primary cytoplasmic signaling sequences of particular use in the present invention include those derived from TCR zeta, FcR gamma, FcR beta, CD3 gamma, CD3 delta, CD3 epsilon, CD5, CD22, CD79a, CD79b, and CD66d. In some specific embodiments, the intracellular signaling domain of the anti-HLA-A2:HPV16E7 CARs described herein is derived from CD3 zeta or FcR gamma.

[0171] As used herein, the term "costimulatory signaling domain" or "costimulatory domain" refers to a portion of a CAR that contains the intracellular domain of a costimulatory molecule. A costimulatory molecule is a cell surface molecule other than an antigen receptor or an Fc receptor that provides a second signal necessary for efficient activation and function of T lymphocytes upon antigen binding. Examples of such costimulatory molecules include ligands that specifically bind to CD27, CD28, 4-1BB (CD137), OX40 (CD134), CD30, CD40, PD-1, ICOS (CD278), LFA-1, CD2, CD7, LIGHT, NKD2C, B7-H2, and CD83. Thus, although the present disclosure provides exemplary costimulatory domains derived from CD3 zeta and 4-1BB, other costimulatory domains are also contemplated for use with the CARs described herein. The inclusion of one or more costimulatory signaling domains can enhance the efficacy and expansion of T cells expressing a CAR receptor. The intracellular signaling and costimulatory signaling domains can be linked in tandem to the carboxyl terminus of the transmembrane domain in any order.

[0172] While scFv-based CARs engineered to contain signaling domains derived from CD3 or FcR gamma have been shown to deliver potent signals for T cell activation and effector function, they are not sufficient to elicit signals that promote T cell survival and expansion in the absence of concomitant costimulatory signals. Other CARs containing binding domains, hinges, transmembrane, and signaling domains derived from CD3 zeta or FcR gamma, along with one or more costimulatory signaling domains (e.g., intracellular costimulatory domains derived from CD28, CD137, CD134, and CD278), can more effectively direct antitumor activity and increase cytokine secretion, lytic activity, survival, and proliferation of CAR-expressing T cells in vitro and in animal models and cancer patients (Milone et al., Molecular Therapy, 2009; 17: 1453-1464; Zhong et al., Molecular Therapy, 2010; 18: 413-420; Carpenito et al., PNAS, 2009; 106: 3360-3365)。

[0173] In one embodiment, an HLA-A2:HPV16E7 CAR of the invention comprises (a) an anti-HLA-A2:HPV16E7 scFv as a binding domain (e.g., an scFv having a binding region (e.g., CDR or variable domain) from any one or more of the HLA-A2:HPV16E7 antibodies listed in Table 1), (b) a hinge region derived from human CD8 alpha, (c) a human CD8 alpha transmembrane domain, and (d) a human T-cell receptor CD3 zeta chain (CD3) intracellular signaling domain, and optionally one or more costimulatory signaling domains derived from CD28, CD137, CD134, and CD278. In one embodiment, the different protein domains are arranged from amino-terminus to carboxyl-terminus in the following order: binding domain, hinge region, and transmembrane domain. The intracellular signaling domain and optional costimulatory signaling domain are linked in tandem to the transmembrane carboxy-terminus in any order to form a single-chain chimeric polypeptide. In one embodiment, the nucleic acid construct encoding the HLA-A2:HPV16E7 CAR is a chimeric nucleic acid molecule comprising a nucleic acid molecule comprising different coding sequences, for example, a coding sequence for a (5' to 3') human anti-HLA-A2:HPV16E7 scFv, a coding sequence for a human CD8 alpha-hinge, a coding sequence for a human CD8 alpha transmembrane domain, and a coding sequence for a CD3 zeta intracellular signaling domain. In another embodiment, the nucleic acid construct encoding the HLA-A2:HPV16E7 CAR is a chimeric nucleic acid molecule comprising a nucleic acid molecule comprising different coding sequences, for example, a coding sequence for a (5' to 3') human anti-HLA-A2:HPV16E7 scFv, a coding sequence for a human CD8 alpha-hinge, a coding sequence for a human CD8 alpha transmembrane domain, a coding sequence for a CD137 costimulatory domain, and a coding sequence for a CD3 zeta costimulatory domain.In certain embodiments, the nucleic acid construct encoding the HLA-A2:HPV16E7 CAR is a chimeric nucleic acid molecule comprising a nucleic acid molecule comprising different coding sequences, for example, a (5' to 3') coding sequence for a human anti-HLA-A2:HPV16E7 scFv, a coding sequence for a human CD8 alpha-hinge, a coding sequence for a human CD8 alpha transmembrane domain, a coding sequence for a CD137 costimulatory domain, and a coding sequence for a CD3 zeta costimulatory domain, wherein the anti-HLA-A2:HPV16E7 scFv is selected from the group consisting of SEQ ID NOs: 2, 34, 82, 194, 282, and 506. H and V selected from the group consisting of SEQ ID NOs: 10, 42, 90, 202, 290 and 514 L In some embodiments, the invention comprises a nucleic acid molecule encoding an HLA-A2:HPV16E7 CAR selected from the group consisting of SEQ ID NOs: 540, 541, 542, 543, 544, and 545.

[0174] In certain embodiments, the polynucleotide encoding the CAR described herein is inserted into a vector. As used herein, the term "vector" refers to a vehicle into which a polynucleotide encoding a protein can be covalently inserted to effect expression of the protein and / or cloning of the polynucleotide. Such vectors can also be referred to as "expression vectors." An isolated polynucleotide can be inserted into a vector using any suitable method known in the art, for example, but not limited to, digesting the vector with an appropriate restriction enzyme and then ligating it with an isolated polynucleotide having a matching restriction end. Expression vectors have the ability to incorporate and express heterologous or modified nucleic acid sequences that encode at least a portion of a gene product that can be transcribed in a cell. In most cases, the RNA molecule is then translated into a protein. Expression vectors can contain various regulatory sequences, referred to as nucleic acid sequences necessary for the transcription, and sometimes translation, of an operably linked coding sequence in a particular host organism. In addition to regulatory sequences that govern transcription and translation, vectors and expression vectors can also contain nucleic acid sequences that perform other functions and are discussed below. An expression vector may contain additional elements, for example, it may have two replication systems, thus allowing it to be maintained in two organisms, for example, in human cells for expression and in a prokaryotic host for cloning and amplification.

[0175] The expression vector may have necessary 5' upstream and 3' downstream regulatory elements for efficient gene transcription and translation in its respective host cell, such as promoter sequences such as the CMV, PGK, and EF1 alpha promoters, ribosome recognition and binding TATA boxes, and 3' UTRAAUAAA transcription termination sequences. Other suitable promoters include constitutive promoters such as the simian virus 40 (SV40) early promoter, mouse mammary tumor virus (MMTV), HIV LTR promoter, MoMuLV promoter, avian leukosis virus promoter, EBV immediate early promoter, and Rous sarcoma virus promoter. Human gene promoters, including but not limited to, actin promoter, myosin promoter, hemoglobin promoter, and creatine kinase promoter, can also be used. In certain embodiments, inducible promoters are also contemplated as part of vectors expressing chimeric antigen receptors. This provides a molecular switch that can turn on or off the expression of the polynucleotide sequence of interest. Examples of inducible promoters include, but are not limited to, a metallothionein promoter, a glucocorticoid promoter, a progesterone promoter, or a tetracycline promoter.

[0176] The expression vector may have additional sequences, such as hexa-histidine, c-Myc, and FLAG tags, that are incorporated into the expressed CAR. Thus, the expression vector may be engineered to contain 5' and 3' untranslated regulatory sequences, which may sometimes function as enhancer sequences, promoter regions, and / or terminator sequences, which can facilitate or enhance the efficient transcription of the nucleic acid(s) of interest carried in the expression vector. The expression vector may also be engineered for replication and / or expression functionality (e.g., transcription and translation) in a specific cell type, cell location, or tissue type. The expression vector may include a selectable marker for maintaining the vector in a host or recipient cell.

[0177] Examples of vectors are plasmids, autonomously replicating sequences, and transposable elements.Further exemplary vectors include, but are not limited to, plasmids, phagemids, cosmids, artificial chromosomes such as yeast artificial chromosomes (YACs), bacterial artificial chromosomes (BACs) or P1-derived artificial chromosomes (PACs), bacteriophages such as lambda phage or M13 phage, and animal viruses.Examples of animal virus categories that are useful as vectors include, but are not limited to, retroviruses (including lentiviruses), adenoviruses, adeno-associated viruses, herpesviruses (such as herpes simplex viruses), poxviruses, baculoviruses, papillomaviruses, and papovaviruses (such as SV40). Examples of expression vectors are the Lenti-X™ bicistronic expression system (Neo) vector (Clontrch), pClneo vector (Promega) for expression in mammalian cells; pLenti4 / V5-DEST™, pLenti6 / V5-DEST™, and pLenti6.2N5-GW / lacZ (Invitrogen) for lentivirus-mediated gene transfer and expression in mammalian cells. To express the chimeric protein in mammalian cells, the coding sequence of the CAR disclosed herein can be ligated into such an expression vector.

[0178] In certain embodiments, the nucleic acid encoding the CAR of the present invention is provided within a viral vector. The viral vector can be derived from a retrovirus, lentivirus, or foamy virus. As used herein, the term "viral vector" refers to a nucleic acid vector construct that contains at least one element of viral origin and can be packaged into a viral vector particle. The viral vector can include coding sequences for various chimeric proteins described herein in place of non-essential viral genes. The vector and / or particle can be used to transfer DNA, RNA, or other nucleic acids into cells either in vitro or in vivo. Many forms of viral vectors are known in the art.

[0179] In certain embodiments, the viral vector that contains the coding sequence of CAR described herein is retroviral vector or lentiviral vector.The term " retroviral vector " refers to the vector that contains the structural and functional genetic elements that are mainly derived from retrovirus.The term " lentiviral vector " refers to the vector that contains the structural and functional genetic elements outside of LTR that are mainly derived from lentivirus.

[0180] Retroviral vectors for use herein can be derived from any known retrovirus (e.g., C-type retroviruses, such as Moloney murine sarcoma virus (MoMSV), Harvey murine sarcoma virus (HaMuSV), mouse mammary tumor virus (MuMTV), gibbon ape leukemia virus (GaLV), feline leukemia virus (FLV), spumavirus, Friend, murine stem cell virus (MSCV), and Rous sarcoma virus (RSV)). Retroviruses of the present invention also include human T-cell leukemia viruses, HTLV-1 and HTLV-2, and the lentivirus family of retroviruses, such as human immunodeficiency virus, HIV-1, HIV-2, simian immunodeficiency virus (SIV), feline immunodeficiency virus (FIV), equine immunodeficiency virus (EIV), and other classes of retroviruses.

[0181] As used herein, lentiviral vector refers to a vector derived from lentivirus, a group (or genus) of retroviruses that cause slowly developing diseases. Viruses in this group include HIV (human immunodeficiency virus; including HIV types 1 and 2); visna-maedi; caprine arthritis-encephalitis virus; equine infectious anemia virus; feline immunodeficiency virus (FIV); bovine immunodeficiency virus (BIV); and simian immunodeficiency virus (SIV). Preparation of recombinant lentiviruses is described in detail in Dull et al. and Zufferey et al. (Dull et al., J. Virol., 1998; 72: 1998). 8463-8471 and Zufferey et al., J. Virol. 1998; 72: 9873-9880) This can be achieved using the method.

[0182] Retroviral vectors (i.e., both lentiviral and non-lentiviral vectors) for use in the present invention can be formed by combining the desired DNA sequences in the order and orientation described herein using standard cloning techniques (Current Protocols in Molecular Biology, Ausubel, FM et al. (eds.) Greene Publishing Associates, (1989), Sections 9.10-9.14 and other standard laboratory manuals; Eglitis, et al. (1985) Science 230: 1395-1398; Danos and Mulligan (1988) Proc. Natl. Acad. Sci. USA 85: 6460-6464; Wilson et al. (1988) Proc. Natl. Acad. Sci. USA 85: 3014-3018; Armentano et al. (1990) Proc. Natl. Acad. Sci. USA 87: 6141-6145; Huber et al. (1991) Proc. Natl. Acad. Sci. USA 88: 8039-8043; Ferry et al. (1991) Proc. Natl. Acad. Sci. USA 88: 8377-8381; Chowdhury et al. (1991) Science 254: 1802-1805; van Beusechem et al. (1992) Proc. Natl. Acad. Sci. USA 89: 7640-7644; Kay et al. (1992) Human Gene Therapy 3: 641-647; Dai et al. (1992) Proc. Natl. Acad. Sci. USA 89: 10892-10895; Hwu et al. (1993) J. Immunol 150: 4104-4115; U.S. Patent No. No. 4,868,116; U.S. Pat. No. 4,980,286; PCT Application WO89 / 07136; PCT Application WO89 / 02468; PCT Application WO89 / 05345; and PCT Application WO92 / 07573).

[0183] Suitable sources for obtaining retroviral sequences (i.e., both lentiviral and non-lentiviral sequences) for use in forming vectors include, for example, genomic RNA and cDNA available from commercial sources, including Type Culture Collection (ATCC), Rockville, Md. Sequences can also be chemically synthesized.

[0184] To express the HLA-A2:HPV16E7 CAR, a vector can be introduced into a host cell to allow expression of the polypeptide in the host cell. The expression vector can contain various elements for regulating expression, including, but not limited to, a promoter sequence, a transcription initiation sequence, an enhancer sequence, a selection marker, and a signal sequence. These elements can be selected as needed by those skilled in the art, as described above. For example, a promoter sequence can be selected to promote transcription of the polynucleotide in the vector. Suitable promoter sequences include, but are not limited to, T7 promoter, T3 promoter, SP6 promoter, beta-actin promoter, EF1a promoter, CMV promoter, and SV40 promoter. An enhancer sequence can be selected to enhance transcription of the polynucleotide. A selection marker can be selected to allow selection of a host cell into which the vector has been inserted from a host into which the vector has not been inserted; for example, the selection marker can be a gene that confers antibiotic resistance. A signal sequence can be selected to allow the expressed polypeptide to be transported out of the host cell.

[0185] For cloning polynucleotides, a vector is introduced into a host cell (isolated host cell) to allow the vector itself to replicate, thereby amplifying copies of the polynucleotide contained in the vector. Cloning vectors generally contain sequence components, including, but not limited to, a replication origin, a promoter sequence, a transcription initiation sequence, an enhancer sequence, and a selection marker. These elements can be selected by those skilled in the art as needed. For example, a replication origin can be selected to promote the autonomous replication of the vector in the host cell.

[0186] In certain embodiments, the present disclosure provides an isolated host cell containing the vector provided herein. Host cells containing the vector may be useful for expressing or cloning the polynucleotide contained in the vector. Suitable host cells may include, but are not limited to, prokaryotic cells, fungal cells, yeast cells, or higher eukaryotic cells such as mammalian cells. Suitable prokaryotic cells for this purpose include, but are not limited to, eubacteria, such as gram-negative or gram-positive organisms, for example, Enterobacteriaceae, for example, Escherichia, for example, E. coli, Enterobacter, Erwinia, Klebsiella, Proteus, Salmonella, for example, Salmonella typhimurium, Serratia, for example, Serratia marcescans, and Shigella, as well as Bacilli, such as B. subtilis and B. licheniformis, Pseudomonas, such as P. aeruginosa, and Streptomyces.

[0187] The CAR of the present invention is introduced into host cells using transfection and / or transduction techniques known in the art. As used herein, the terms "transfection" and "transduction" refer to the process by which an exogenous nucleic acid sequence is introduced into a host cell. The nucleic acid can be integrated into the host cell DNA or maintained extrachromosomally. The nucleic acid can be transiently maintained or stably introduced. Transfection can be achieved by various means known in the art, including, but not limited to, calcium phosphate-DNA coprecipitation, DEAE-dextran-mediated transfection, polybrene-mediated transfection, electroporation, microinjection, liposome fusion, lipofection, protoplast fusion, retroviral infection, and biolistics. Transduction refers to the delivery of a gene(s) using a viral or retroviral vector by viral infection rather than by transfection. In certain embodiments, the retroviral vector is transduced into a virion by a packaging vector and then contacted with a cell. For example, a nucleic acid encoding an anti-HLA-A2:HPV16E7 CAR carried in a retroviral vector can be transduced into cells by infection and proviral integration.

[0188] As used herein, the terms "genetically engineered" or "genetically modified" refer to the addition of extra genetic material in the form of DNA or RNA to the total genetic material in a cell. The terms "genetically modified cell," "modified cell," and "redirected cell" are used interchangeably.

[0189] In particular, the CAR of the present invention is introduced into and expressed in immune effector cells to redirect the specificity of the immune effector cells to a target antigen of interest, e.g., a conformational epitope of the HPV16E7 peptide displayed by HLA-A2, e.g., amino acid residues 11-19 or 82-90.

[0190] The present invention provides a method for producing immune effector cells that express a CAR described herein. In one embodiment, the method comprises transfecting or transducing immune effector cells isolated from a subject, such as a subject with a disease or disorder associated with HPV16E7, so that the immune effector cells express one or more CARs described herein. In certain embodiments, immune effector cells are isolated from an individual and genetically modified without further manipulation in vitro. Such cells can then be directly re-administered to the individual. In a further embodiment, immune effector cells are first activated in vitro, stimulated to proliferate, and then genetically modified to express a CAR. In this regard, immune effector cells can be cultured before or after genetic modification (i.e., transduced or transfected to express a CAR described herein).

[0191] Before the immune effector cells described herein are manipulated in vitro or genetically modified, the source of cells can be obtained from a subject.In particular, for use with CAR described herein, immune effector cells include T cells.Such recombinant T cells are referred to herein as "T-body".

[0192] In one embodiment of the invention, a T-body comprises a CAR of the invention comprising an extracellular target-specific binding domain, a transmembrane domain, an intracellular signaling domain (such as, for example, a signaling domain derived from CD3 zeta or FcR gamma), and / or one or more costimulatory signaling domains derived from a costimulatory molecule, for example, but not limited to, CD28, CD137, CD134, or CD278. In another embodiment of the invention, a T-body comprises a CAR of the invention comprising an extracellular target-specific binding domain, a transmembrane domain, a hinge or spacer region between the extracellular binding domain and the transmembrane domain, an intracellular signaling domain (such as, for example, a signaling domain derived from CD3 zeta or FcR gamma), and / or one or more costimulatory signaling domains derived from a costimulatory molecule. In yet another embodiment of the invention, a T-body comprises a T-body construct CAR comprising an extracellular target-specific binding domain and a T cell receptor constant domain. An extracellular target-specific binding domain suitable for use in a T-body, including any of the CARs described herein, can comprise a Fab, Fab', (Fab')2, Fv, or single-chain Fv (scFv) of an antigen-binding protein of the invention.

[0193] T cells can be obtained from several sources, including peripheral blood mononuclear cells, bone marrow, lymph node tissue, umbilical cord blood, thymus tissue, tissue from an infection site, ascites, pleural effusion, spleen tissue, and tumors. In certain embodiments, T cells can be obtained from a unit of blood collected from a subject using any number of techniques known to those skilled in the art, such as Ficoll separation. In one embodiment, cells from an individual's circulating blood are obtained by apheresis. The apheresis product generally contains lymphocytes, including T cells, monocytes, granulocytes, B cells, other nucleated white blood cells, red blood cells, and platelets. In one embodiment, cells collected by apheresis can be washed to remove the plasma fraction and to place the cells in an appropriate buffer or medium for subsequent processing. In one embodiment, the cells are washed with PBS. In an alternative embodiment, the washed solution lacks calcium and may also lack magnesium, or may lack many, but not all, divalent cations. As will be appreciated by those skilled in the art, the washing step can be accomplished by methods known to those skilled in the art, such as by using a semi-automated flow-through centrifuge. After washing, the cells can be resuspended in various biocompatible buffers or other saline solutions, with or without buffers. In certain embodiments, undesirable components of the apheresis sample can be removed in the culture medium in which the cells are directly resuspended.

[0194] In certain embodiments, T cells are isolated from peripheral blood mononuclear cells (PBMCs) by lysing red blood cells and depleting monocytes, for example, by centrifugation through a PERCOLL™ gradient. Specific T cell subpopulations, such as CD28+ T cells, CD4+ T cells, CD8+ T cells, CD45RA+ T cells, and CD45RO+ T cells, can be further isolated by positive or negative selection techniques. For example, enrichment of T cell populations can be achieved by negative selection using a combination of antibodies directed against surface markers unique to the negatively selected cells. One method for use herein is cell sorting and / or selection by negative magnetic immunoadhesion or flow cytometry using a cocktail of monoclonal antibodies directed against cell surface markers present on the negatively selected cells. For example, to enrich CD4+ cells by negative selection, the monoclonal antibody cocktail typically includes antibodies against CD14, CD20, CD11b, CD16, HLA-DR, and CD8. Flow cytometry and cell sorting can also be used to isolate cell populations of interest for use in the present invention.

[0195] PBMCs can be directly used for genetic modification with CARs using the methods described herein. In certain embodiments, after PBMC isolation, T lymphocytes are further isolated, and in certain embodiments, both cytotoxic T cells and helper T lymphocytes can be sorted into naive T cell subpopulations, memory T cell subpopulations, and effector T cell subpopulations either before or after genetic modification and / or expansion. CD8+ cells can be obtained using standard methods. In some embodiments, CD8+ cells are further sorted into naive cells, central memory cells, and effector cells by identifying cell surface antigens associated with each of these types of CD8+ cells. In several embodiments, memory T cells exist in both the CD62L+ and CD62L- subsets of CD8+ peripheral blood lymphocytes. PBMCs are sorted into CD62L-CD8+ and CD62L+CD8+ fractions after staining with anti-CD8 and anti-CD62L antibodies. In some embodiments, expression of phenotypic markers of central memory T cells includes CD45RO, CD62L, CCR7, CD28, CD3, and CD127, and is negative for granzyme B. In some embodiments, central memory T cells are CD45RO+ T cells, CD62L+ T cells, and CD8+ T cells. In some embodiments, effector T cells are negative for CD62L, CCR7, CD28, and CD127, and positive for granzyme B and perforin. In some embodiments, naive CD8+ T lymphocytes are characterized by expression of phenotypic markers of naive T cells, including CD62L, CCR7, CD28, CD3, CD127, and CD45RA.

[0196] In certain embodiments, CD4+ T cells are further sorted into subpopulations. For example, CD4+ T helper cells can be sorted into naive cells, central memory cells, and effector cells by identifying cell populations with cell surface antigens. CD4+ lymphocytes can be obtained by standard methods. In some embodiments, naive CD4+ T lymphocytes are CD45RO- T cells, CD45RA+ T cells, and CD62L+ CD4+ T cells. In some embodiments, central memory CD4+ cells are CD62L-positive and CD45RO-positive. In some embodiments, effector CD4+ cells are CD62L- and CD45RO-negative.

[0197] Immune effector cells, such as T cells, can be genetically modified after isolation using known methods, or immune effector cells can be activated and expanded (or differentiated in the case of precursors) in vitro before genetic modification. In another embodiment, immune effector cells, such as T cells, are genetically modified with a chimeric antigen receptor described herein (e.g., transduced with a viral vector containing a nucleic acid encoding a CAR) and then activated and expanded in vitro. Methods for activating and expanding T cells are known in the art and are described, for example, in U.S. Pat. Nos. 6,905,874; 6,867,041; 6,797,514; WO2012079000; and US2016 / 0175358. Generally, such methods involve contacting PBMCs or isolated T cells with stimulatory and costimulatory agents, such as anti-CD3 and anti-CD28 antibodies, typically attached to beads or other surfaces, in a culture medium accompanied by appropriate cytokines, such as IL-2. Anti-CD3 and anti-CD28 antibodies attached to the same bead serve as "surrogate" antigen-presenting cells (APCs). In other embodiments, T cells can be activated and stimulated to proliferate using feeder cells and appropriate antibodies and cytokines, using methods such as those described in U.S. Patent No. 6,040,177; U.S. Patent No. 5,827,642; and WO2012129514.

[0198] The present invention provides a population of engineered immune effector cells for treating an HPV-associated disease or disorder, e.g., cancer, wherein the engineered immune effector cells comprise an HLA-A2:HPV16E7 CAR as disclosed herein.

[0199] CAR-expressing immune effector cells prepared as described herein can be utilized in methods and compositions for adoptive immunotherapy according to known techniques or variations thereof that will become apparent to those skilled in the art based on this disclosure. See, e.g., U.S. patent application to Gruenberg et al. See Publication No. 2003 / 0170238; U.S. Patent No. 4,649,499 to Rosenberg. See also No. 690,915.

[0200] In some embodiments, the cells are formulated by first harvesting them from their culture medium, then washing and concentrating them into a therapeutically effective amount using a medium and container system suitable for administration (a "pharmaceutically acceptable" carrier). Suitable infusion media can be any isotonic medium formulation, typically normal saline, Normosol R (Abbott), or Plasma-Lyte A (Baxter), although water or 5% dextrose in lactated Ringer's solution can also be used. The infusion medium can be supplemented with human serum albumin.

[0201] A therapeutically effective amount of cells in the composition is at least 2 cells (e.g., at least one CD8+ central memory T cell and at least one CD4+ helper T cell subset), or more generally, 10 2 More than 10 cells, and 6 Up to 10 8 pieces or 10 9 Contains 10 cells 10 The number of cells will depend on the intended end use of the composition, as well as the type of cells included therein.

[0202] The cells can be autologous or heterologous to the patient being treated. If desired, treatment can also include administration of mitogens (e.g., PHA) or lymphokines, cytokines, and / or chemokines (e.g., IFN-γ, IL-2, IL-12, TNF-α, IL-18, and TNF-β, GM-CSF, IL-4, IL-13, Flt3-L, RANTES, MIP1α, etc.) to enhance the induction of an immune response, as described herein.

[0203] The immune effector cell population expressing the CAR of the present invention can be administered alone or as a pharmaceutical composition in combination with other components, such as diluents and / or IL-2 or other cytokines or cell populations. Briefly, the pharmaceutical composition of the present invention can comprise the immune effector cell population expressing the CAR, such as T cells described herein, in combination with one or more pharmaceutically or physiologically acceptable carriers, diluents or excipients. Such compositions can include, for example, a buffer such as neutral buffered saline, phosphate buffered saline, carbohydrates such as glucose, mannose, sucrose, or dextran, mannitol, proteins, amino acids such as polypeptides or glycine, antioxidants, chelating agents such as EDTA or glutathione, adjuvants (e.g., aluminum hydroxide), and preservatives. The composition of the present invention is preferably formulated for intravenous administration.

[0204] The anti-tumor immune response induced in a subject by administering the CAR-expressing T cells described herein using the methods described herein or other methods known in the art can include a cellular immune response mediated by cytotoxic T cells, regulatory T cells, and helper T cell responses, which can kill infected cells. A humoral immune response can also be induced, which is primarily mediated by helper T cells, which can activate B cells and thus induce antibody production. Various techniques can be used to analyze the type of immune response induced by the composition of the present invention, and they are well described in the art; for example, see Current Protocols in Immunology, Edited by: John E. Coligan, Ada M. Kruisbeek, David H. Margulies, Ethan M. Shevach, Warren Strober (2001) John Wiley & Sons, NY, NY.

[0205] Accordingly, the present invention provides a method for treating an individual diagnosed with, suspected of having, or at risk of developing an HPV-associated disease or disorder, e.g., HPV16E7-positive cancer, comprising administering to the individual a therapeutically effective amount of immune effector cells expressing a CAR described herein.

[0206] In one embodiment, the present invention provides a method of treating a subject diagnosed with HPV16E7-positive cancer, comprising the steps of removing immune effector cells from the subject diagnosed with HPV16E7-positive cancer, genetically modifying the immune effector cells with a vector comprising a nucleic acid encoding a chimeric antigen receptor of the present invention, thereby generating a population of modified immune effector cells, and administering the population of modified immune effector cells to the same subject. In one embodiment, the immune effector cells comprise T cells.

[0207] Methods for administering the cell compositions described herein include any method effective to result in either the reintroduction of ex vivo genetically modified immune effector cells that directly express a CAR of the invention in a subject, or the reintroduction of precursors of genetically modified immune effector cells that differentiate into mature immune effector cells that express a CAR when introduced into a subject. One method involves transducing peripheral blood T cells ex vivo with a nucleic acid construct according to the invention and returning the transduced cells to the subject.

[0208] Therapeutic Administration and Formulations The present invention provides therapeutic compositions comprising an anti-HLA-A2:HPV16E7 antigen binding protein, e.g., an antibody or antigen-binding fragment thereof, or a CAR, of the present invention. Therapeutic compositions according to the present invention are administered with suitable carriers, excipients, and other agents incorporated into the formulation to provide improved mobility, delivery, tolerance, etc. Many suitable formulations can be found in the formulary known to all pharmacists: Remington's Pharmaceutical Sciences, Mack Publishing Company, Easton, PA. These formulations include, for example, Excipients include powders, pastes, ointments, jellies, waxes, oils, lipids, lipid (cationic or anionic)-containing vesicles (such as LIPOFECTIN™), DNA conjugates, anhydrous absorbent pastes, oil-in-water and water-in-oil emulsions, emulsions of carbowax (polyethylene glycols of various molecular weights), semi-solid gels, and semi-solid mixtures containing carbowax. See also Powell et al. "Compendium of excipients for parenteral formulations" PDA (1998) J Pharm Sci Technol 52: 238-311.

[0209] The dose of an antigen-binding protein, e.g., an antibody or antigen-binding fragment thereof, can vary depending on the age and size of the recipient, the target disease, condition, route of administration, etc. When using antigen-binding proteins of the present invention to treat or prevent a disease or disorder in an adult patient, it is generally advantageous to administer the antigen-binding protein of the present invention, e.g., an antibody or antigen-binding fragment thereof, in a single dose of about 0.1 to about 60 mg per kg of body weight, more preferably about 5 to about 60 mg, about 20 to about 50 mg, about 10 to about 50 mg, about 1 to about 10 mg, or about 0.8 to about 11 mg per kg of body weight. The frequency and duration of treatment can be adjusted depending on the severity of the condition. In certain embodiments, an antigen-binding protein of the present invention, e.g., an antibody or antigen-binding fragment thereof, can be administered as an initial dose of at least about 0.1 mg to about 800 mg, about 1 to about 500 mg, about 5 to about 300 mg, or about 10 to about 200 mg, up to about 100 mg, or up to about 50 mg. In certain embodiments, after the initial dose, a second or multiple subsequent doses of the antigen binding protein, e.g., an antibody or antigen-binding fragment thereof, can be administered in an amount that can be about the same as or less than the initial dose, where the subsequent doses are spaced apart by at least 1 to 3 days; at least 1 week, at least 2 weeks; at least 3 weeks; at least 4 weeks; at least 5 weeks; at least 6 weeks; at least 7 weeks; at least 8 weeks; at least 9 weeks; at least 10 weeks; at least 12 weeks; or at least 14 weeks.

[0210] Various delivery systems, such as encapsulation in liposomes, microparticles, microcapsules, recombinant cells capable of expressing mutant viruses, and receptor-mediated endocytosis, are known and can be used to administer the pharmaceutical compositions of the present invention (see, e.g., Wu et al. (1987) J. Biol. Chem. 262: 4429-4432). Methods of introduction include, but are not limited to, intradermal, transdermal, intramuscular, intraperitoneal, intravenous, subcutaneous, intranasal, epidural, and oral routes. The compositions can be administered by any convenient route, for example, by infusion or bolus injection, by absorption through epithelial or mucocutaneous linings (e.g., oral mucosa, rectal and intestinal mucosa, etc.), and can be administered together with other biologically active agents. Administration can be systemic or local. The pharmaceutical composition can also be delivered in vesicles, in particular liposomes (see, eg, Langer (1990) Science 249: 1527-1533).

[0211] The use of nanoparticles to deliver the antigen-binding proteins of the present invention, such as antibodies or antigen-binding fragments thereof, is also contemplated herein. Nanoparticles conjugated with antigen-binding proteins can be used for both therapeutic and diagnostic applications. Nanoparticles conjugated with antigen-binding proteins and methods of preparation and use are described by Arruebo, M., et al. 2009 ("Antibody-conjugated nanoparticles for biomedical applications" in J. Nanomat. Volume 2009, Article ID 439389, 24 pages, doi: 10.1155 / 2009 / 439389), which is incorporated herein by reference. Nanoparticles can be developed and conjugated with antigen binding protein contained in pharmaceutical compositions to target tumor cells or autoimmune tissue cells or virus-infected cells.Nanoparticles for drug delivery are also described in, for example, United States Patent No. 8,257,740 or United States Patent No. 8,246,995, each of which is incorporated herein in its entirety.

[0212] In certain circumstances, the pharmaceutical composition can be delivered in a sustained release system. In one embodiment, a pump can be used. In another embodiment, a polymeric material can be used. In yet another embodiment, the sustained release system can be placed in proximity to the target of the composition, thus requiring only a small systemic dose.

[0213] Injectable preparations may include dosage forms for intravenous, subcutaneous, intradermal, intracranial, intraperitoneal, and intramuscular injections, drip infusion, and the like. These injectable preparations can be prepared by generally known methods. For example, injectable preparations can be prepared by dissolving, suspending, or emulsifying the antigen-binding protein or its salt in a sterile aqueous or oily medium conventionally used for injections. Aqueous media for injections include, for example, physiological saline, isotonic solutions containing glucose and other adjuvants, and the like, which can be used in combination with appropriate solubilizers such as alcohols (e.g., ethanol), polyhydric alcohols (e.g., propylene glycol, polyethylene glycol), and nonionic surfactants [e.g., polysorbate 80, HCO-50 (polyoxyethylene (50 mol) addition product of hydrogenated castor oil)]. Oily media include, for example, sesame oil and soybean oil, which can be used in combination with solubilizers such as benzyl benzoate and benzyl alcohol. The injection thus prepared is preferably filled into an appropriate ampule.

[0214] The pharmaceutical composition of the present invention can be delivered subcutaneously or intravenously using a standard needle and syringe. Furthermore, for subcutaneous delivery, a pen delivery device is easily adapted to deliver the pharmaceutical composition of the present invention. Such a pen delivery device can be reusable or disposable. Reusable pen delivery devices generally utilize a replaceable cartridge containing the pharmaceutical composition. Once the pharmaceutical composition in the cartridge has been administered and the cartridge is empty, the empty cartridge can be easily discarded and replaced with a new cartridge containing the pharmaceutical composition. The pen delivery device can then be reused. Disposable pen delivery devices do not have a replaceable cartridge. Instead, disposable pen delivery devices are provided in a pre-filled state, with the pharmaceutical composition held in a reservoir within the device. Once the pharmaceutical composition is depleted and the reservoir is empty, the entire device is discarded.

[0215] Numerous reusable pen and autoinjector delivery devices are adapted for subcutaneous delivery of the pharmaceutical compositions of the present invention. Examples include, but are certainly not limited to, the AUTOPEN™ (Owen Mumford, Inc., Woodstock, UK), the DISETRONIC™ pen (Disetronic Medical Systems, Burghdorf, Switzerland), the HUMALOG MIX 75 / 25™ pen, the HUMALOG™ pen, the HUMALIN 70 / 30™ pen (Eli Lilly and Co., Indianapolis, IN), the NOVOPEN™ I, II, and III (Novo Nordisk, Copenhagen, Denmark), the NOVOPEN JUNIOR™ (Novo Nordisk, Copenhagen, Denmark), the BD™ pen (Becton Dickinson, Franklin Lakes, NJ), the OPTIPEN™, the OPTIPEN PRO™, the OPTIPEN™, to name just a few. STARLET™, and OPTICLIK™ (Sanofi-Aventis, Frankfurt, Germany). Examples of disposable pen delivery devices applicable to subcutaneous delivery of the pharmaceutical compositions of the present invention include, but are not limited to, the SOLOSTAR™ pen (Sanofi-Aventis), FLEXPEN™ (Novo Nordisk), and KWIKPEN™ (Eli Lilly), SURECLICK™ Autoinjector (Amgen, Thousand Oaks, CA), PENLET™ (Haselmeier, Stuttgart, Germany), EPIPEN (Dey, LP), and HUMIRA™ pen (Abbott Labs, Abbott Park, IL), to name just a few.

[0216] The above-mentioned pharmaceutical compositions for oral or parenteral use are advantageously prepared in a unit dosage form adapted to the dose of the active ingredient. Examples of such unit dosage forms include tablets, pills, capsules, injections (ampoules), and suppositories. The amount of antigen-binding protein contained is generally about 5 to about 500 mg per unit dosage form. In particular, injections preferably contain about 5 to about 100 mg of antigen-binding protein, and other dosage forms preferably contain about 10 to about 250 mg.

[0217] Therapeutic Uses of Antigen Binding Proteins The antibodies of the invention are useful, inter alia, for treating, preventing, and / or ameliorating any disease or disorder associated with or mediated by HPV 16. For example, the invention provides methods of treating HPV-associated diseases or disorders, such as HPV-associated cancers (e.g., HPV16E7-positive cancers) (tumor growth inhibition) and / or HPV infections, by administering to a patient in need of such treatment an anti-HLA-A2:HPV16E7 antigen binding protein (or a pharmaceutical composition comprising an anti-HLA-A2:HPV16E7 antigen binding protein) described herein, as well as anti-HLA-A2:HPV16E7 antigen binding proteins (or pharmaceutical compositions comprising an anti-HLA-A2:HPV16E7 antigen binding protein) for use in treating HPV-associated cancers (tumor growth inhibition) and / or HPV infections. The antigen binding proteins of the invention are useful for treating, preventing, and / or ameliorating a disease or disorder or condition, such as HPV-associated cancer or HPV infection, and / or ameliorating at least one symptom associated with such a disease, disorder, or condition. With respect to the methods of treatment described herein, the anti-HLA-A2:HPV16E7 antigen binding protein can be administered as a monotherapy (i.e., as the only therapeutic agent) or in combination with one or more additional therapeutic agents (examples of which are described elsewhere herein).

[0218] In some embodiments of the invention, the antibodies described herein are useful for treating subjects suffering from primary or recurrent cancers, including, but not limited to, HPV-associated cancers, e.g., squamous cell carcinomas such as squamous cell carcinoma of the head and neck, cervical cancer, anogenital cancer, and oropharyngeal cancer.

[0219] The antigen binding proteins can be used to treat early or late symptoms of HPV-associated cancer. In one embodiment, the antibodies of the present invention or fragments thereof can be used to treat advanced or metastatic cancer. The antigen binding proteins are useful in reducing, inhibiting, or shrinking tumor growth. In certain embodiments, treatment with the antigen binding proteins of the present invention leads to greater than 40%, greater than 50%, greater than 60%, greater than 70%, greater than 80%, or greater than 90% regression of tumors in a subject. In certain embodiments, the antigen binding proteins can be used to prevent tumor recurrence. In certain embodiments, the antigen binding proteins are useful in extending progression-free survival or overall survival in subjects with HPV-associated cancer. In some embodiments, the antibodies are useful in reducing toxicity resulting from chemotherapy or radiation therapy while maintaining long-term survival in patients with HPV-associated cancer.

[0220] In certain embodiments, the antigen binding proteins of the invention are useful for treating subjects suffering from chronic HPV infection, hi some embodiments, the antigen binding proteins of the invention are useful in reducing viral titers in the host.

[0221] One or more antibodies of the invention can be administered to alleviate or prevent or lessen the severity of one or more symptoms or conditions of a disease or disorder.

[0222] Also contemplated herein is the prophylactic use of one or more antibodies of the invention in patients at risk of developing a disease or disorder associated with HPV, such as HPV-associated cancer, and HPV infection.

[0223] In a further embodiment of the invention, the antibody is used to prepare a pharmaceutical composition for treating a patient suffering from a disease or disorder associated with HPV, such as an HPV-associated cancer, or an HPV infection. In another embodiment of the invention, the antibody is used as an adjunctive therapy with any other agent or any other treatment known to those skilled in the art to be useful for treating an HPV-associated cancer or an HPV infection.

[0224] Combination Therapies and Formulations The combination therapy can include an anti-HLA-A2:HPV16E7 antigen binding protein of the invention, such as a CAR of the invention (e.g., an immune effector cell comprising a CAR of the invention) or a pharmaceutical composition of the invention, and any additional therapeutic agent that can be advantageously combined with the antigen binding protein of the invention. The antigen binding proteins of the invention can be synergistically combined with one or more anti-cancer drugs or therapies used to treat or inhibit a disease or disorder associated with HPV16E7, such as HPV-positive cancer, e.g., squamous cell carcinoma, cervical cancer, anogenital cancer, head and neck cancer, or oropharyngeal cancer.

[0225] It is contemplated herein that the anti-HLA-A2:HPV16E7 antigen binding proteins of the present invention may be used in combination with immunostimulatory and / or immunosupportive therapy to inhibit tumor growth and / or enhance the survival of cancer patients. Immunostimulatory therapy includes direct immunostimulatory therapy to enhance immune cell activity by either "releasing the brakes" on suppressed immune cells or "stepping on the gas" to activate the immune response. Examples include targeting other checkpoint receptors, vaccination, and adjuvants. Immune supportive modalities can increase tumor antigenicity by promoting immunogenic cell death, inflammation, or have other indirect effects that promote antitumor immune responses. Examples include radiation, chemotherapy, antiangiogenic agents, and surgery.

[0226] In various embodiments, one or more antigen binding proteins of the present invention are administered in combination with a PD-1 inhibitor (e.g., an anti-PD-1 antibody such as nivolumab, pembrolizumab, pidilizumab, BGB-A317, or REGN2810), a PD-L1 inhibitor (e.g., an anti-PD-L1 antibody such as avelumab, atezolizumab, durvalumab, MDX-1105, or REGN3504), a CTLA-4 inhibitor (e.g., ipilimumab), a TIM3 inhibitor (e.g., ipilimumab ... an anti-PD-L1 antibody such as avelumab, atezolizumab, durvalumab, MDX-1105, or REGN3504), a CTLA-4 inhibitor (e.g., ipilimumab), a TIM3 inhibitor (e.g., an anti-PD-L1 antibody such as avelumab, atezolizumab, durvalumab, MDX-1105, or REGN3504), a CTLA-4 inhibitor (e.g., ipilimumab), a TIM3 inhibitor (e.g., an anti-PD-L1 antibody such as avelum agents, BTLA inhibitors, TIGIT inhibitors, CD47 inhibitors, GITR inhibitors, antagonists of another T cell co-inhibitor or ligand (e.g., antibodies to CD-28, 2B4, LY108, LAIR1, ICOS, CD160, or VISTA), indoleamine-2,3-dioxygenase (IDO) inhibitors, vascular endothelial growth factor (VEGF) antagonists [e.g., "VEGF-Trap," e.g., aflibercept or US 7,087,411, or other VEGF inhibitory fusion proteins described therein, or anti-VEGF antibodies or antigen-binding fragments thereof (e.g., bevacizumab, or ranibizumab) or small molecule kinase inhibitors of VEGF receptors (e.g., sunitinib, sorafenib, or pazopanib)], Ang2 inhibitors (e.g., nesbacumab), transforming growth factor beta (TGFβ) inhibitors, epidermal growth factor receptor (EGFR) inhibitors (e.g., erlotinib, cetuximab), CD20 inhibitors (e.g., anti-CD20 antibodies, such as rituximab), antibodies against tumor-specific antigens [e.g., CA9, CA125, melanoma-associated antigen 3 (MAGE3), carcinoembryonic antigen (CEA), vimentin, tumor-M2-PK, prostate-specific antigen (PSA), mucin-1, MART-1, and CA19-9], vaccines (e.g., Calmette-Guerin bacilli, cancer vaccines), adjuvants to increase antigen presentation (e.g., granulocyte-macrophage colony-stimulating factor), bispecific antibodies (e.g., CD3xCD20 bispecific antibodies or PSMAxCD3 bispecific antibodies), cytotoxins, chemotherapeutic agents (e.g., dacarbazine, temozolomide, cyclophosphamide, docetaxel, doxorubicin, daunorubicin, cisplatin, carboplatin, gemcitabine, methotrexate, mitoxantrone, oxaliplatin, paclitaxel, and vincristine), cyclophosphamide, radiation therapy, surgery, IL-6R inhibitors (e.g., sarilumab), IL-4R inhibitors (e.g., dupilumab), IL-10 inhibitors, cytokines such as IL-2, IL-7, IL-21, and IL-15, antibody-drug conjugates (ADCs) (e.g., anti-CD19-DM4 The anti-HLA-A2:HPV16E7 antigen binding proteins of the present invention can be used in combination with other therapeutic agents, such as anti-HLA-A2:HPV16E7 ADCs, and anti-DS6-DM4 ADCs, anti-inflammatory drugs (e.g., corticosteroids and nonsteroidal anti-inflammatory drugs), nutritional supplements such as antioxidants, or any other therapeutic care for treating cancer. In certain embodiments, the anti-HLA-A2:HPV16E7 antigen binding proteins of the present invention can be used in combination with an HPV vaccine. Exemplary HPV vaccines include Gardasil, Gardasil 9, and Cervarix, Lm-LLo-E7 (ADXS11-001; ADXS-HPV; Advaxis,Inc.);GLBL101c(GENOLAC BL Corp);TA-HPV(European Organization for Research and Treatment of Cancer(EORTC));TG4001(Transgene / Roche);MVA E2(Instituto Mexicano del Seguro Social);HPV16-SLP(ISA Pharmaceuticals);GL-0810(Gliknik Inc.);Pepcan+Candin(University of Arkansas);GTL001(ProCervix;Genticel);TA-CIN(Xenova Research Limited);TA-CIN+TA-HPV(Celtic Pharma);pNGVL4a-sig / E7(detox) / HSP70+TA-HPV(Sidney Kimmel Comprehensive Cancer Center);pNGVL4a-CRT / E7(detox)(Sidney Kimmel, Comprehensive Cancer Center; GX-188E (Genexine, Inc.); VGX-3100 (Inovio Pharmaceuticals); dendritic cells pulsed with HPV-16 and HPV-18 E7 and keyhole limpet hemocyanin (National Institutes of Health); DCs pulsed with HPV+ tumor lysate (Department of Biotechnology (DBT, Government of India)); PDS0101 (PDS Biotechnology Corp.); ProCervix (Genticel); GX-188E (Genexine, Inc.); pNGVL4a-CRT / E7(detox) (Sidney Kimmel Comprehensive Cancer Center); pNGVL4a-sig / E7(detox) / HSP70+TA-HPV (Sidney Kimmel Comprehensive Cancer Center); TVGV-1+GPI-0100 (THEVAX Genetics Vaccine Co.); Pepcan+Candin (University of of Arkansas);ISA101(SLP-HPV-01;HPV16-SLP;ISA Pharmaceuticals);ADXS11-001(Lm-LLo-E7;Advaxis,Inc.);ISA101(SLP-HPV-01;HPV16-SLP;ISA Pharmaceuticals);DPX-E7(Dana-Farber Cancer Institute);ADXS11-001(Lm-LLo-E7;Advaxis,Inc.);INO-3112(VGX-3100+INO-9012;Inovio Pharmaceuticals);ADXS11-001(Lm-LLo-E7;Advaxis,Inc.);INO-3112(VGX-3100+INO-9012;Inovio Pharmaceuticals);ISA101(SLP-HPV-01;HPV16-SLP;ISA Pharmaceuticals); and TA-CIN+GPI-0100 (Sidney Kimmel Comprehensive Cancer Center). In certain embodiments, the anti-HLA-A2:HPV16E7 antigen binding proteins of the invention can be used in combination with cancer vaccines, including dendritic cell vaccines, oncolytic viruses, tumor cell vaccines, etc., to enhance anti-tumor responses. Examples of cancer vaccines that can be used in combination with the anti-HLA-A2:HPV16E7 antigen binding proteins of the invention include MAGE3 vaccines for melanoma and bladder cancer, MUC1 vaccines for breast cancer, EGFRv3 (e.g., Rindopepimut) for brain cancer (including glioblastoma multiforme), or ALVAC-CEA (for CEA+ cancers).

[0227] In certain embodiments, anti-HLA-A2:HPV16E7 antigen binding proteins of the present invention can be administered in combination with radiation therapy in methods to generate long-lasting anti-tumor responses and / or enhance survival in patients with cancer. In some embodiments, anti-HLA-A2:HPV16E7 antigen binding proteins of the present invention can be administered to cancer patients before, simultaneously with, or after radiation therapy. For example, radiation therapy can be administered to tumor lesions in one or more doses, followed by administration of one or more doses of anti-HLA-A2:HPV16E7 antigen binding proteins of the present invention. In some embodiments, radiation therapy can be administered locally to tumor lesions to enhance the local immunogenicity of the patient's tumor (adjuvant radiation) and / or to kill tumor cells (ablative radiation), followed by systemic administration of anti-HLA-A2:HPV16E7 antigen binding proteins of the present invention. For example, patients with brain cancer (e.g., glioblastoma multiforme) can undergo intracranial radiation therapy in combination with systemic administration of anti-HLA-A2:HPV16E7 antigen binding proteins of the invention. In certain embodiments, anti-HLA-A2:HPV16E7 antigen binding proteins of the invention can be administered in combination with radiation therapy and a chemotherapeutic agent (e.g., temozolomide) or a VEGF antagonist (e.g., aflibercept).

[0228] In certain embodiments, the anti-HLA-A2:HPV16E7 antigen binding proteins of the invention can be administered in combination with one or more antiviral drugs to treat chronic HPV infection. Examples of antiviral drugs include, but are not limited to, zidovudine, lamivudine, abacavir, ribavirin, lopinavir, efavirenz, cobicistat, tenofovir, rilpivirine, and corticosteroids.

[0229] The additional therapeutically active agent(s) / component(s) may be administered prior to, simultaneously with, or following administration of the anti-HLA-A2:HPV16E7 antigen binding proteins of the invention. For purposes of this disclosure, such administration regimens are considered administration of the anti-HLA-A2:HPV16E7 antigen binding protein "in combination" with the second therapeutically active component.

[0230] The additional therapeutically active component(s) can be administered to a subject prior to administration of an anti-HLA-A2:HPV16E7 antigen binding protein of the invention. For example, a first component can be considered to be administered "before" a second component if the first component is administered 1 week, 72 hours, 60 hours, 48 ​​hours, 36 hours, 24 hours, 12 hours, 6 hours, 5 hours, 4 hours, 3 hours, 2 hours, 1 hour, 30 minutes, 15 minutes, 10 minutes, 5 minutes, or less than 1 minute before administration of the second component. In other embodiments, the additional therapeutically active component(s) can be administered to a subject after administration of an anti-HLA-A2:HPV16E7 antigen binding protein of the invention. For example, a first component can be considered to be administered "after" the second component if it is administered 1 minute, 5 minutes, 10 minutes, 15 minutes, 30 minutes, 1 hour, 2 hours, 3 hours, 4 hours, 5 hours, 6 hours, 12 hours, 24 hours, 36 hours, 48 ​​hours, 60 hours, or 72 hours after administration of the second component. In yet other embodiments, the additional therapeutically active component(s) can be administered to the subject simultaneously with administration of the anti-HLA-A2:HPV16 E7 antigen binding protein of the invention. "Concurrent" administration, for purposes of the present invention, includes, for example, administering the anti-HLA-A2:HPV16 E7 antigen binding protein and the additional therapeutically active component to the subject in a single dosage form (e.g., co-formulated) or in separate dosage forms administered to the subject within about 30 minutes or less of each other. When administered in separate dosage forms, each dosage form can be administered by the same route (e.g., both the anti-HLA-A2:HPV16E7 antigen binding protein and the additional therapeutically active component can be administered intravenously, subcutaneously, etc.); or, each dosage form can be administered by a different route (e.g., the anti-HLA-A2:HPV16E7 antigen binding protein can be administered intravenously and the additional therapeutically active component can be administered subcutaneously). In any event, administration of the components in a single dosage form, administration by the same route in separate dosage forms, or administration by different routes in separate dosage forms are all considered "co-administration" for purposes of this disclosure.For purposes of this disclosure, administration of an anti-HLA-A2:HPV16E7 antigen binding protein "before," "concurrently with," or "after" administration of an additional therapeutically active component (as these terms are defined herein above) is considered administration of the anti-HLA-A2:HPV16E7 antigen binding protein and the additional therapeutically active component "in combination."

[0231] The present invention includes pharmaceutical compositions in which the anti-HLA-A2:HPV16E7 antigen binding proteins of the invention are formulated together with one or more of the additional therapeutically active component(s) described elsewhere herein using various dosage combinations.

[0232] Dosing regimen According to certain embodiments of the invention, multiple doses of anti-HLA-A2:HPV16E7 antigen binding protein (or a pharmaceutical composition comprising a combination of an anti-HLA-A2:HPV16E7 antigen binding protein and any of the additional therapeutically active agents mentioned herein) can be administered to a subject over a defined time course. The method according to this aspect of the invention involves sequentially administering multiple doses of the anti-HLA-A2:HPV16E7 antigen binding protein of the invention to a subject. As used herein, "sequentially administering" means that each dose of the anti-HLA-A2:HPV16E7 antigen binding protein is administered to a subject at different time points, for example, on different days separated by a predetermined interval (e.g., hours, days, weeks, or months). The present invention includes methods comprising sequentially administering to a patient a single initial dose of anti-HLA-A2:HPV16E7 antigen binding protein, followed by one or more secondary doses of anti-HLA-A2:HPV16E7 antigen binding protein, and optionally, thereafter one or more tertiary doses of anti-HLA-A2:HPV16E7 antigen binding protein. The anti-HLA-A2:HPV16E7 antigen binding protein can be administered at a dose of 0.1 mg / kg to 100 mg / kg of the subject's body weight.

[0233] The terms "initial dose," "secondary dose," and "tertiary dose" refer to the temporal order of administration of the anti-HLA-A2:HPV16E7 antigen binding protein of the present invention. Thus, a "initial dose" is a dose administered at the beginning of a treatment regimen (also referred to as a "baseline dose"); a "secondary dose" is a dose administered after the initial dose, and a "tertiary dose" is a dose administered after the secondary dose. The initial, secondary, and tertiary doses may all contain the same amount of anti-HLA-A2:HPV16E7 antigen binding protein, but generally may differ from one another in terms of frequency of administration. However, in certain embodiments, the amount of anti-HLA-A2:HPV16E7 antigen binding protein contained in the initial, secondary, and / or tertiary doses varies from one another (e.g., adjusted upward or downward as needed) during the course of treatment. In certain embodiments, two or more (e.g., 2, 3, 4, or 5) doses are administered at the start of a treatment regimen as a "loading dose," followed by subsequent doses administered less frequently (e.g., "maintenance doses").

[0234] In certain embodiments, the amount of anti-HLA-A2:HPV16E7 antigen binding protein contained in the first dose, second dose, and / or third dose is suboptimal or subtherapeutic. As used herein, the terms "subtherapeutic" or "suboptimal" refer to a dose of antibody administered at a level too low to produce a therapeutic effect or below the level required to treat a disease such as cancer.

[0235] In certain exemplary embodiments of the invention, the secondary and / or tertiary doses are each administered 1 to 26 weeks (e.g., 1 week, 1 1 / 2 weeks, 2 weeks, 2 1 / 2 weeks, 3 weeks, 3 1 / 2 weeks, 4 weeks, 4 1 / 2 weeks, 5 weeks, 5 1 / 2 weeks, 6 weeks, 6 1 / 2 weeks, 7 weeks, 7 1 / 2 weeks, 8 weeks, 8 1 / 2 weeks, 9 weeks, 9 1 / 2 weeks, 10 weeks, 10 1 / 2 weeks, 11 weeks, 11 1 / 2 weeks, 12 weeks, 12 1 / 2 weeks, 13 weeks) after the immediately preceding dose. or later). The phrase "immediately preceding dose," as used herein, refers to the dose of anti-HLA-A2:HPV16E7 antigen binding protein administered to a patient in a multiple administration series immediately prior to the administration of the next dose in the series, with no intervening doses.

[0236] Methods according to this aspect of the invention can include administering any number of secondary and / or tertiary doses of anti-HLA-A2:HPV16E7 antigen binding protein to a patient. For example, in certain embodiments, only a single secondary dose is administered to a patient. In other embodiments, two or more (e.g., 2, 3, 4, 5, 6, 7, 8, or more) secondary doses are administered to a patient. Similarly, in certain embodiments, only a single tertiary dose is administered to a patient. In other embodiments, two or more (e.g., 2, 3, 4, 5, 6, 7, 8, or more) tertiary doses are administered to a patient.

[0237] In embodiments involving multiple secondary doses, each secondary dose can be administered with the same frequency as the other secondary doses. For example, each secondary dose can be administered to the patient 1-2 weeks or 1-2 months after the immediately preceding dose. Similarly, in embodiments involving multiple tertiary doses, each tertiary dose can be administered with the same frequency as the other tertiary doses. For example, each tertiary dose can be administered to the patient 2-12 weeks after the immediately preceding dose. In certain embodiments of the present invention, the frequency with which the secondary and / or tertiary doses are administered to the patient can vary over the course of the treatment regimen. The frequency of administration can also be adjusted by the physician during the course of treatment based on the needs of the individual patient after clinical testing.

[0238] Diagnostic Uses of Antigen Binding Proteins For example, for diagnostic purposes, anti-HLA-A2:HPV16E7 antigen binding proteins of the present invention can be used to detect and / or measure HPV16E7 in a sample. Some embodiments contemplate the use of one or more antigen binding proteins of the present invention in assays to detect HPV-related diseases or disorders, such as HPV16E7-positive cancer, or diseases or disorders, such as HPV infection. An exemplary diagnostic assay for HPV16E7 can include, for example, contacting a sample obtained from a subject (e.g., a patient) with an anti-HLA-A2:HPV16E7 antigen binding protein of the present invention, where the anti-HLA-A2:HPV16E7 antigen binding protein is labeled with a detectable label or reporter molecule or is used as a capture ligand to selectively isolate HPV16E7 from the subject sample. Alternatively, unlabeled anti-HLA-A2:HPV16E7 antigen binding proteins can be used in diagnostic applications in combination with a secondary antigen binding protein, such as an antibody, that is itself detectably labeled. The detectable label or reporter molecule may be a radioisotope, e.g., 3 H, 14 C. 32 P, 35 S, or 1251, etc.; a fluorescent or chemiluminescent moiety, such as fluorescein isothiocyanate or rhodamine; or an enzyme, such as alkaline phosphatase, β-galactosidase, horseradish peroxidase, or luciferase. Specific exemplary assays that can be used to detect or measure HPV16E7 in a sample include enzyme-linked immunosorbent assay (ELISA), radioimmunoassay (RIA), and fluorescence-activated cell sorting (FACS).

[0239] The sample that can be used for the HPV16E7 diagnostic assay of the present invention includes any tissue or body fluid sample that can be obtained from a subject and contains detectable amount of HPV16E7 protein or its fragment under normal or pathological conditions.Generally, the level of HPV16E7 in a specific sample obtained from a healthy patient (for example, a patient who does not suffer from HPV16E7-related disease or disorder, for example, HPV16E7-positive cancer) is measured to first establish baseline or standard HPV16E7 level.Then, this baseline level of HPV16E7 is compared with the level of HPV16E7 measured in the sample obtained from the individual who is suspected of having cancer-related condition or the symptoms associated with such condition.

[0240] The antigen-binding protein specific to HPV16E7 may contain no additional label or moiety, or may contain an N-terminal or C-terminal label or moiety. In one embodiment, the label or moiety is biotin. In binding assays, the location of the label (if any) can determine the orientation of the peptide relative to the surface to which it binds. For example, when the surface is coated with avidin, a peptide containing N-terminal biotin will be oriented so that the C-terminal portion of the peptide is distal to the surface.

[0241] An embodiment of the present invention relates to the use of the disclosed antigen binding proteins as markers for predicting the prognosis of HPV16E7-positive cancer or HPV infection in patients. The antigen binding proteins of the present invention can be used in diagnostic assays to assess the prognosis and predict survival of cancer in patients. [Example]

[0242] The following examples are presented so as to provide those of ordinary skill in the art with a complete disclosure and description of how to make and use the methods and compositions of the present invention, and are not intended to limit the scope of what the inventors regard as their invention. While attempts have been made to ensure accuracy with respect to numbers used (e.g., amounts, temperatures, etc.), some experimental error and deviation should be accounted for. Unless otherwise specified, parts are parts by weight, molecular weight is average molecular weight, temperature is in degrees Celsius, room temperature is about 25°C, and pressure is at or near atmospheric pressure.

[0243] Example 1 HLA-A2: Generation of human antibodies against HPV16E7 Human antibodies against HLA-A2:HPV16E7 were generated using a peptide fragment of HPV16E7 containing either amino acids 11-19 (YMLDLQPET; SEQ ID NO:538) of GenBank Accession No. NP_041326.1 (SEQ ID NO:537) or amino acid residues 82-90 (LLMGTLGIV; SEQ ID NO:539) of GenBank Accession No. NP_041326.1 (SEQ ID NO:537) coupled to HLA-A2. The immunogen was administered directly to VELOCIMMUNE® mice (i.e., engineered mice containing DNA encoding human immunoglobulin heavy and kappa light chain variable regions) along with an adjuvant to stimulate the immune response, as described, for example, in U.S. Patent No. 8,502,018. Antibody immune responses were monitored by HLA-A2:HPV16E7-specific immunoassays. Once the desired immune response is achieved, splenocytes are collected, their viability is preserved, and they are fused with mouse myeloma cells to form hybridoma cell lines.The hybridoma cell lines are screened and selected to identify cell lines that produce HLA-A2:HPV16E7-specific antibodies.Using this technique and the above immunogen, several anti-HPV16E7 chimeric antibodies (i.e., antibodies with human variable domains and mouse constant domains) are obtained.The exemplary antibodies thus produced are named as follows: H4sH17364N; H4sH17368N2; H4sH17930N; H4sH17930N2; H4sH17363N and H4sH17368N3.

[0244] Anti-HLA-A2:HPV16E7 antibodies were also isolated directly from antigen-positive B cells (from one of the immunized mice) without fusion with myeloma cells, as described in U.S. Patent No. 7,582,298, the entire contents of which are expressly incorporated herein by reference. Using this method, several fully human anti-HLA-A2:HPV16E7 antibodies (i.e., antibodies with human variable and human constant domains) were obtained.

[0245] Exemplary antibodies generated according to the above-described methods are named as follows: H4sH17670P; H4sH17672P; H4sH17673P; H4sH17675P; H4sH17680P; H4sH17697P; H4sH17707P; H4sH17715P; H4sH17726P; H4sH17730P; H4sH21051P; H4sH21054P; H4sH210 55P;H4sH21058P;H4sH21064P;H4sH21073P;H4sH21077P;H4sH21079P;H4sH21080P;H4sH21083P;H4sH21086P;H4sH21090P;H4sH21091P;H4sH21093P;H4sH21099P;H4sH21100P;H4sH21103P; and H4sH21104P.

[0246] The biological properties of exemplary antibodies generated according to the methods of this example are described in detail in the Examples below.

[0247] Example 2 Amino acid and nucleotide sequences of the heavy and light chain variable regions Table 1 lists the amino acid sequence identifiers for the heavy and light chain variable regions and CDRs of selected anti-HLA-A2:HPV16E7 antibodies of the invention. The corresponding nucleic acid sequence identifiers are listed in Table 2. [Table 1-1] [Table 1-2] [Table 2-1] [Table 2-2]

[0248] Antibodies are generally referred to herein according to the following nomenclature: an Fc prefix (e.g., "H1M," "H4sH," "H4H," etc.), followed by a numerical identifier (e.g., "17670," "17930," etc., as shown in Table 1), followed by a "P," "N," or "N2" suffix. Thus, according to this nomenclature, antibodies can be referred to herein as, for example, "H4sH17670P," "H4sH17930N," "H4sH17368N2," etc. The H4sH and H4H prefixes in antibody names used herein indicate the particular Fc region isotype of the antibody. For example, an "H4sH" antibody has a human IgG4 Fc with two or more amino acid changes disclosed in U.S. Patent Application Publication No. 20140243504 (incorporated herein in its entirety), an "H4H" antibody has a human IgG4 Fc with a serine to proline mutation (S108P) in the hinge region, an "H1M" antibody has a murine IgG1 Fc, and an "H2M" antibody has a murine IgG2 Fc (all variable regions are fully human, as indicated by the initial "H" in the antibody name). As will be understood by those skilled in the art, an antibody having a particular Fc isotype can be converted to an antibody having a different Fc isotype (e.g., an antibody having a murine IgG1 Fc can be converted to an antibody having a human IgG4 Fc, etc.), but in either case, the variable domains (including the CDRs)—indicated by the numerical identifiers shown in Table 1—remain the same, and the binding characteristics to the antigen are expected to be the same or substantially similar regardless of the nature of the Fc domain.

[0249] In certain embodiments, a selected antibody having a mouse IgG1 Fc was converted to an antibody having a human IgG4 Fc. In certain embodiments, the antibody comprises a human IgG4 Fc with two or more amino acid changes disclosed in U.S. Patent Application Publication No. 20100331527 (incorporated herein in its entirety). In one embodiment, the IgG4 Fc domain comprises a serine to proline mutation (S108P) in the hinge region to promote dimer stabilization.

[0250] Table 3 provides the amino acid sequence identifiers for the heavy and light chain sequences of selected antibodies of the present invention. [Table 3]

[0251] Example 3 Variable gene utilization analysis To analyze the structure of the produced antibodies, the nucleic acids encoding the antibody variable regions were cloned and sequenced. From the nucleic acid sequences and predicted amino acid sequences of the antibodies, the gene usage for each heavy chain variable region (HCVR) and light chain variable region (LCVR) was identified (Table 4). [Table 4-1] [Table 4-2]

[0252] Example 4 Surface plasmon resonance-derived binding affinity and kinetic constants of a human monoclonal anti-HLA-A2:HPV16E7 monospecific antibody The binding affinity and kinetic constants of human anti-HLA-A2 / HPV16E7 antibodies were determined by real-time surface plasmon resonance (SPR; Biacore4000 or BiacoreT-200, GE Healthcare Life Sciences, Pittsburgh, PA) at 25°C. The antibodies were captured on a CM5 Biacore sensor surface (GE Healthcare Life Sciences) derivatized by amine coupling with a monoclonal anti-human Fc antibody (GE, #BR-1008-39). Monomeric HLA-A2:HPV16E7 peptide complexes containing either the E7:11-19 peptide (SEQ ID NO:538) or the E7:82-90 peptide (SEQ ID NO:539) were injected at various concentrations over the surface where the anti-HLA-A2:HPV16E7 antibodies were captured at a flow rate of 50 μL / min (BiacoreT-200) or 30 μL / min (Biacore4000). Antibody-reagent association was monitored for 4-5 min, and dissociation was monitored for 10 min. All binding studies were performed in HBS-ET buffer (0.01 M HEPES, pH 7.4, 0.15 M NaCl, 0.05% v / v surfactant P20).

[0253] Sports meeting (k a ) and dissociation (k d The binding-dissociation equilibrium constant (K) was determined by fitting the real-time sensorgrams to a 1:1 binding model using Scrubber 2.0c curve-fitting software. D ) and dissociation half-life (t1 / 2) were calculated from the kinetic rate constants as follows:

number

[0254] The binding kinetic parameters for the monospecific anti-HLA-A2:HPV16E7 antibodies to the monomeric HLA-A2 / HPV16E7 peptide complex are shown in Tables 5 and 6 below. [Table 5-1] [Table 5-2] [Table 6-1] [Table 6-2]

[0255] The data demonstrate that the majority of the anti-HLA-A2 / HPV16E7 antibodies of the present invention selectively bind to soluble HLA-A2 / HPV16E7 peptide complexes, some with subnanomolar affinity, however, some antibodies showed no binding to HLA-A2 / HPV16E7 complexes.

[0256] Example 5 Prediction of potential off-target peptides Given the target 9-mer peptide-HLA-A2 complex, relevant potential off-target peptides are defined based on the following three criteria: A) the peptide is a 9-mer and predicted to bind to HLA-A2, B) the peptide is similar to the target peptide based on sequence homology, and C) the peptide is derived from a gene expressed in essential normal tissues. Therefore, the following methodology was used to predict potential off-target peptides associated with YMLDLQPET (HPV16 E711-19; SEQ ID NO: 538) and LLMGTLGIV (HPV16 E782-90; SEQ ID NO: 539) (see generally Dhanik, Ankur, et al. (2016) BMC Bioinformatics 17 (1): 286).

[0257] As a first step, we downloaded reference human protein sequences from the UniprotKB database (September 2014 version) (Magrane, Michele, and UniProt Consortium. Database 2011 (2011): bar009) and extracted all 9-mers, resulting in 11,118,076 peptides from 20,014 protein sequences.

[0258] The binding affinity of the peptides to HLA-A2 was then computed using the NetMHCstab webserver (version 1.0) (Jorgensen, Kasper W., et al. (2014) Immunology 141 (1): 18-26). Peptides with affinity values ​​below 500 nM were predicted to bind to HLA-A2, and the rest were discarded, resulting in 338,452 peptides.

[0259] The peptide sequences were then evaluated for sequence homology with the target peptide. For each peptide, its degree of similarity (DoS) to the target peptide was calculated. The DoS value represents the number of identical amino acids at identical positions between the two peptides. Peptides with a DoS value of less than 6 were rejected, resulting in 21 peptides remaining for HLA-A2 / HPV16E7:11-19 and 78 peptides remaining for HLA-A2 / HPV16E7:82-90.

[0260] The expression of genes corresponding to the 21 peptides in essential normal tissues was investigated. Expression was assessed using gene expression data from the GTEx (Gene Tissue Expression) and TCGA (The Cancer Genome Atlas) databases provided by OmicSoft (Hu, Jun, et al. Bioinformatics (2012) 28 (14): 1933-1934). Data were collected from 497 TCGA adjacent normal samples (spanning 15 essential tissue types) and 2,928 GTEx normal samples (spanning 22 essential tissue types) as RPKM (Reads Per Kilobase Per Millimeter). Million values ​​were available. Tissues other than breast, cervix, fallopian tube, testis, uterus, and vagina were considered essential. Genes were considered expressed in essential normal tissues if their maximum 95th percentile expression in each essential normal tissue type was 0.5 RPKM or greater in the GTEx and TCGA databases. For HLA-A2 / HPV16E7:11-19 (YMLDLQPET), 10 of 21 peptides were derived from genes expressed in essential normal tissues. For HLA-A2 / HPV16E7:82-90 (LLMGTLGIV), 49 of 78 peptides were derived from genes expressed in essential normal tissues.

[0261] Ten peptides constitute predicted off-targets associated with the target YMLDLQPET-HLA-A2 complex (Table 7). Of the 49 potential peptides predicted to likely constitute off-targets associated with the LLMGTLGIV-HLA-A2 complex, 13 were randomly selected for experimental validation and are listed in Table 8. [Table 7] [Table 8-1] [Table 8-2]

[0262] Example 6 T2 peptide pulse for determining HLA-A2 / HPV16E7 M specificity To determine the specificity of anti-HLA-A2 / HPV16E7 monoclonal antibodies, peptide-pulsed T2 cells loaded with target or off-target peptides (identified in the previous example) were used. The experiment was performed as follows: For exogenous loading of HPV16E7 target or off-target peptides, T2 cells were rinsed with AIM V® Medium and counted using a Cellometer™ Auto T4 cell counter (Nexcelom Bioscience). Approximately 6 million T2 cells per T-75 flask were cultured in 9 mL of AIM V® Medium containing 10 μg of human b2m and 100 μg of HPV16E7 peptide or off-target peptide at 26°C for 24 hours (Tables 6 and 7). The peptide-loaded T2 cells were washed once with Ca2+ / Mg2+-free PBS and counted. Approximately 10,000 peptide-loaded T2 cells or untreated T2 cells were seeded per well in cell wash buffer onto a 96-well carbon electrode plate (Multi-Array high bind plate, MSD) and incubated at 37°C for 1 hour to allow cells to adhere to the plate. Nonspecific binding sites were blocked with 2% BSA (w / v) in PBS for 1 hour at room temperature. A solution of anti-HLA-A2 / HPV16 E7:11-19, anti-HLA-A2 / HPV16 E7:82-90, or control antibody, as well as a solution without antibody, was added to the plate-bound cells in serial dilutions ranging from 1.7 pM to 100 nM. The plate was incubated for 1 hour at room temperature and then washed using an AquaMax2000 plate washer (MDS Analytical Technologies) to remove unbound antibody. Plate-bound antibodies were detected with a SULFO-TAG™-conjugated goat polyclonal anti-human IgG antibody specific for the Fc gamma fragment (Jackson Immunoresearch, Meso Scale Discovery) for 1 hour at room temperature.After washing, the plate was developed with Read Buffer (MSD) according to the manufacturer's recommended procedure, and the luminescence signal was recorded using a SECTOR Imager 600 (Meso Scale Discovery) instrument. Luminescence intensity, measured in relative luminescence units (RLU), was recorded to indicate the binding strength of each antibody across the concentration range. The ratio of cell binding signal at 11 nM for each anti-HLA-A2 / HPV16E7 antibody compared to the isotype control is reported in Tables 8 and 9, demonstrating specificity. At 11 nM, the majority of antibodies showed minimal binding to T2-untreated cells. Not all antibodies were tested with all corresponding relevant off-target peptides. Those not tested are marked with NT instead of "Not Tested." Antibodies with binding ratios greater than 15 were marked (+++), antibodies with ratios equal to or less than 15 but greater than or equal to 10 were marked (++), antibodies with ratios less than 10 but greater than or equal to 3 were marked (+), and antibodies with binding ratios less than 3 were classified as non-binders and designated (-). Furthermore, direct binding signals (in RLU) were analyzed as a function of antibody concentration, and data were fitted to a sigmoidal (four-parameter logistic) dose-response model using GraphPad Prism™. To indicate the potency of each antibody, where possible, the EC was defined as the concentration of antibody at which 50% of the maximal binding signal was detected in cells. 50 EC values ​​were determined for binding to cell surface HLA-A2 / HPV16E7:11-19 or HLA-A2 / HPV16E7:82-90 alone. 50 The values ​​are also reported in Tables 9 and 10.

[0263] Ten of the thirteen anti-HLA-A2 / HPV16E7:11-19 antibodies of the present invention bind to the HLA-A2 / peptide complex on the surface of T2 cells. Seven of these ten antibodies (H4sH17670P; H4sH17675P; H4sH17363N; H4sH17364N; H4sH17930N; H4sH17930N2; and H4sH21064P) are specific for the HLA-A2 / HPV16E7:11-19 complex. Three antibodies (H4sH17672P, H4sH21079P, and H4sH21080P) showed higher potency and EC 50 The values ​​were below 1.1 nM. Three antibodies (H4sH17673P, H4sH17680P, H4sH17697P) did not bind to T2 peptide-loaded cells and are indicated by (-) in the first column of Table 9.

[0264] Table 9 summarizes the cell binding results for T2 cells loaded with HPV16E7:82-90 targets and predicted off-target peptides. Sixteen of the 21 anti-HLA-A2 / HPV16E7:82-90 mAbs of the present invention bound to the T2 cell surface HLA-A2 / peptide complex. Only two mAbs from this group (H4sH17368N2, H4sH21086P) demonstrated specificity for the HLA-A2 / HPV16E7 82-90 complex. Five antibodies (H4sH17730P, H4sH21051P, H4sH21054P, H4sH21055P, H4sH21077P) did not bind to T2 peptide-loaded cells and are indicated by a (-) in Table 10. [Table 9] [Table 10-1] [Table 10-2]

[0265] As shown in Tables 9 and 10, the anti-HLA-A2:HPV16E7 antigen binding protein of the present invention bound with high specificity only to the specific HPV peptide presented by HLA-A2 (SEQ ID NO: 538 in Table 9, or SEQ ID NO: 539 in Table 10), and did not bind to any off-target peptides presented by HLA-A2.

[0266] Example 7 Binding specificity analysis and FACS analysis using peptide-pulsed T2 cells The relative binding and specificity of HPV16E7 antibodies was assessed by flow cytometry on NIH3T3 cells expressing the HLA-A2 complex, presenting either the HPV11-19 peptide (3T3 / HLA.A2 / hB2M / HPV16E7:11-19) or the HPV82-90 peptide (3T3 / HLA.A2 / hB2M / HPV16E7(82-90)). NIH3T3 cells expressing the HLA complex were transfected with human HLA.A2 (accession number P01892), human B2M (accession number NP_004039.1), and a ubiquitin peptide cassette containing either amino acids 11-19 (SEQ ID NO: 538) or amino acids 82-90 (SEQ ID NO: 539) of HPV16E7 (accession number AKI85233) (Levy F., et al. (1996) Proceedings of the National Academy of Sciences of the United States of America 93 (10): 4907-4912; Valmori D, et al. (1999) Journal of Experimental Medicine 189 (6): 895-906) were transfected using lipofectomine2000 (Invitrogen, Cat. No. 11668) and then generated by selection with 1 μg / ml puromycin, 500 μg / ml G418, and 100 μg / ml hygromycin for at least 2 weeks. For staining, cells were harvested using cell dissociation buffer (Millipore, Cat. No. S-004-C) and counted. Cells were plated at a density of 200,000 cells per well in staining buffer (PBS, calcium and magnesium free (Irving 9240) + 2% FBS (ATCC 30-2020)) in 96-well V-bottom plates and stained with 3-fold serial dilutions of primary antibodies (1.7 pM to 100 nM) for 30 minutes at 4°C. After incubation with primary antibodies, cells were washed once with staining buffer and stained with Alexa-Flour 647 conjugated to secondary antibodies (Jackson ImmunoResearch, Cat. No. 109-606-170) at 10 μg / ml for 30 minutes at 4°C. Cells were then washed and fixed with a 50% solution of BD Cytofix (BD, Cat. No. 554655) diluted in staining buffer. Samples were analyzed by intellicyt The data were run on an iQue flow cytometer, analyzed, and the mean fluorescence intensity (MFI) was calculated. MFI values ​​were calculated using GraphPad Plot a 12-point response curve using a 4-parameter logistic equation in Prism to determine EC 50 For each dose-response curve, secondary antibody alone (i.e., no primary antibody) was also included in the analysis as a series of 3-fold dilutions and is expressed as the lowest dose. EC 50The values ​​(M) and maximum fold binding (fold change from highest dose to lowest dose) are shown in Table 11. Several antibodies specifically bound to either the 3T3 / HLA.A2 / hB2M / HPV16E7:11-19 cell line or the 3T3 / HLA.A2 / hB2M / HPV16E7:82-90 cell line. EC 50 The values ​​ranged from 5 to 500 nM, and the fold binding ranged from 1.0-fold to 43.8-fold. [Table 11]

[0267] The specificity of the six HPV16E7:11-19 antibodies was further characterized by assessing binding to T2 (174 CEM.T2) cells pulsed with HPV16E7:11-19, HPV16E7:82-90, or predicted off-target peptides (Table 7). For pulsing, T2 (174 CEM.T2) cells were cultured at 1 x 10 cells per ml in AIM V medium. 6 The cells were resuspended at a density of 10 μg / ml (Gibco, Cat. No. 31035-025). Cells were pulsed by adding 10 μg / ml of hB2M (EMD Millipore Cat. No. 475828) and 100 μg / ml of the indicated peptide. T2 cells were then incubated overnight at 26°C, washed with staining buffer, and stained with the indicated antibodies at 10 μg / ml according to the protocol described above. MFI values ​​were calculated and expressed as fold change relative to unstained cells. The relative binding of the six HPV16E7:11-19 antibodies to HPV16E7:11-19-pulsed T2 cells ranged from 986- to 1200-fold relative to unstained cells. No significant binding above the isotype control was observed for T2 cells pulsed with other peptides (Table 12). [Table 12]

[0268] Example 8 Epitope analysis using alanine scanning peptides Alanine scanning was performed to determine which residues within the HPV16E7:11-19 peptide were important for antibody binding. T2 cells were pulsed with the alanine scanning peptides and stained with the HPV16E7:11-19 antibody as described above. The following alanine scanning peptides were used (Table 13). [Table 13]

[0269] Conversion of aspartic acid 14 to alanine (D14A) and glutamine 16 to alanine (Q16A) significantly reduced antibody binding for all antibodies tested. Conversion of tyrosine 11 to alanine (Y11A) reduced binding of H4sH17670P, H4sH17675P, H4sH21064P, and H4sH17930N2, but not H4sH17363N or H4sH17364N. Conversion of leucine 13 to alanine (L13A) and proline 17 to alanine (P17A) reduced overall antibody binding (Table 14).

[0270] In summary, D14 and Q16 are important residues for antibody binding. [Table 14]

[0271] Example 9 Reshaping of HLA-A2 / HPV16E7 antibodies into ScFv for use in chimeric antigen receptors Six HLA-A2 / HPV16 E7:11-19 antibodies (17363N, 17364N, 17670P, 17675P, 17930N2, and 21064P) were rearranged into VL-VH single-chain variable fragments (ScFv) and incorporated into chimeric antigen receptor (CAR) constructs using the CD8α hinge and transmembrane domains, 4-1BB costimulatory domain, and CD3ζ stimulatory domain (SEQ ID NOs: 540-545). The HLA-A2 / HPV16 E7:11-19-specific CARs were cloned into a lentiviral expression vector (Lenti-X™ Bicistronic Expression System (Neo), Clontech Cat. No. 632181), and lentiviral particles were generated using the Lenti-X Packaging Single-Shot (VSV-G) system (Clontech Cat. No. 631276) according to the manufacturer's protocol. Jurkat cells (Jurkat / NFATLuc cl.3C7), engineered to express an NFAT-luciferase reporter, were then transduced with six different CAR constructs using RetroNectin® Pre-coated Dishes (Clontech, Cat. No. T110a) according to the manufacturer's protocol. CAR-T cell lines were generated after selection in 500 μg / ml G418 (Gibco, Cat. No. 11811-098) for at least two weeks.

[0272] The activity of the CAR-T lines was evaluated by CAR-T / antigen-presenting cell (APC) bioassay.

[0273] To perform the bioassay, 50,000 Jurkat / NFATLuc cl.3C7 CAR-T cells were added to 50 μl of assay medium (RPMI medium containing 10% FBS and 1% P / S / G) in a Thermo-Nunc 96-well white plate (Thermo Scientific, Cat. No. 136101). Then, 3-fold serial dilutions of APCs (150,000 cells to 200 cells) were added to 50 μl of assay medium. The following APCs were used: CASKI (HLA-A2+ / HPV16+), CASKI cells overexpressing a single-chain version of HLA-A2 presenting the 11-19 or 82-90 peptides, HEK293 (HLA-A2+ / HPV16-), or C33a (HLA-A2+ / HPV16-). The cell mixture was incubated at 37°C in a humidified incubator with 5% CO2 for 5 hours. NFAT-luciferase activity was measured using Promega One-Glo (Cat. No. E6130) and a Perkin Elmer Envision plate reader. Relative luciferase units (RLU) were generated and plotted into an 8-point response curve using a 4-parameter logistic equation in GraphPad Prism to determine the EC 50 Values ​​were calculated. A zero APC condition for each dose-response curve was also included as a series of 3-fold serial dilutions and is represented as the lowest dose. The maximum fold of activation was determined by taking the ratio of the maximum RLU to the minimum RLU on the curve. All six HLA-A2 / HPV16E7:11-19 CAR-T cell lines were activated by CASKI cells overexpressing the HPV16E7:11-19 peptide, with maximum fold activation ranging from 2.5 to 32.3-fold. No CAR-T cell lines were activated by APCs or HEK293 and C33a cells overexpressing the HPV16E7:82-90 peptide. Interestingly, one CAR-T cell line using an ScFv derived from antibody 17675P was activated by native CASKI cells with a fold activation of 4.1, resulting in an EC 50 was 68,654 cells (Table 15). [Table 15]

[0274] Increasing the amount of HLA-A2 presenting the HPV16E7:11-19 peptide should result in increased activation of HLA-HPV16E7:11-19CAR. It has been reported that interferon gamma can increase antigen presentation by MHC class 1 molecules despite upregulation of the proteasome (Fruh K. and Yang Y. (1999) Curr Opin Immunol. 11 (1): 76-81). Based on this finding To determine whether pre-treatment of wild-type CASKI or HEK293 cells with interferon gamma could result in increased activation of CAR-T cell lines, CASKI and HEK293 cells were pre-treated with 500 units / ml of recombinant human IFN-γ (Peprotech Cat. No. 300-02) for 48 hours and then used in the CAR-T / APC bioassay as described above (Table 16). IFNγ-pre-treated CASKI cells activated all six HPV16E7:11-19 CAR-T cell lines, with fold activation ranging from 2.4 to 10.6. [Table 16]

[0275] To further evaluate the specificity of the HPV16E7:11-19 CAR-T strain using luciferase assays, T2 cells were used as APCs and pulsed with predicted off-target peptides (Table 17). Briefly, T2 cells were pulsed with 3-fold serial dilutions of the indicated peptides (1.7 pg / ml to 100 ng / ml). After pulsing, 50,000 CAR-T cells were added to a Thermo-Nunc 96-well white plate (Thermo Scientific, Cat. No. 136101) in 50 μL of assay medium. 50,000 pulsed T2 cells were then added to the plate in 50 μL of assay medium. The cell mixture was incubated for 5 hours at 37°C in a 5% CO2 humidified incubator. NFAT-luciferase activity was determined using a Promega One-Glo™ (Cat. No. E6130) and a Perkin Elmer Envision plate reader. RLUs were plotted into a 12-point response curve using a four-parameter logistic equation in GraphPad Prism to determine EC 50 Values ​​were calculated. For each dose-response curve, an unpulsed condition was also included in the analysis as a series of 3-fold serial dilutions and is represented as the lowest dose. Maximum fold activation was determined as previously described. All CAR-T cell lines were activated by T2 cells pulsed with the HPV16E7:11-19 peptide. The Jurkat / NFATLuc CART line utilizing an ScFv derived from antibody 17364N was nonspecifically activated by T2 cells pulsed with Endophilin-B1 (SH3GLB1:244-252), chondroitin sulfate synthase 2 (CHPF:463:471), and E3 ubiquitin-protein ligase CBL (CBL:83-91). All other CAR-T cell lines were not significantly activated by any off-target peptides. [Table 17-1] [Table 17-2]

[0276] Example 10 Structural analysis of Fab binding to HLA-A2+HPV16E7:11-19 peptide In an effort to better understand the specific interactions between antibodies and HLA-peptide complexes, the X-ray crystal structures of antibody Fab fragments bound to HLA-A2 / b2m displaying the HPV16E7:11-19 peptide were determined. One structure contains the 17670P Fab, and the other contains the 17363N Fab; together, these two structures span the sequence space of the six antibodies described above (e.g., Tables 11 and 12). All nine residues of the HPV16E7:11-19 peptide displayed by HLA are clearly visible in the electron density maps for both the 17670P and 17363N structures. Even at 2.9 Å (the resolution of the 17670P structure), the positions and identities of peptide residues are unambiguous, allowing for precise determination of residue-residue interactions. The 17363P structure is at 2.6 Å, allowing for improved accuracy.

[0277] The 17670P Fab and 17363N Fab bind to the top of the HLA-peptide complex in a manner very similar to that of TCR binding. These Fabs are approximately equally positioned and oriented relative to each other; both align fairly parallel to the "rails" bordering the peptide-binding groove, and both converge on the bound peptide, with the heavy chain CDRs contacting the N-terminal half of the bound peptide and the light chain CDRs contacting the C-terminal half of the peptide. Other published antibody complex structures (e.g., PDB codes 1W72 and 4WUU) reveal that the antibodies do not span the entire peptide displayed by HLA. However, these antibodies, with only partial peptide coverage, have poor specificity and tolerate extensive variation in the portion of the peptide they do not contact, resulting in only a slight loss of binding affinity.

[0278] These structures show that the 17670P and 17363N Fab heavy chains make contacts with residues 11, 14, and 15 of the HPV16 E7 peptide, while the Fab light chains make contacts with residues 15, 17, and 18. The side chains of residues 12, 13, 16, or 19 are directed toward the HLA molecule, and therefore no Fab contacts are made with them. The bound peptides are numbered according to the position of the residues in the original HPV16 E7 protein as follows: [ka]

[0279] The majority of Fab contacts are made with peptide side chains rather than with the backbone.

[0280] Peptide contacts made by 17670P are focused almost exclusively on CDRs LCDR1 and HCDR3, particularly HCDR3. In particular, Fab heavy chain residues 100, 101, 102, 105, 109, 110 of SEQ ID NO: 34 and light chain residues 30, 31, 32, 50 of SEQ ID NO: 42 contact the bound peptide, while Fab heavy chain residues 28, 31, 32, 100, 102, 104, 109, 110, 113 of SEQ ID NO: 34 and light chain residues 31, 50, 52, 53, 54, 55, 92 of SEQ ID NO: 42 contact the HLA. "Contacts" here may involve direct or water-mediated hydrogen bonding, charge-charge interactions, or hydrophobic / van der Waals interactions. For 17363N, Fab heavy chain residues 102, 103, 108, 111, 112 of SEQ ID NO:506 and light chain residues 28, 30, 32, 50, 68 of SEQ ID NO:514 contact the bound peptide, while Fab heavy chain residues 28, 32, 100, 102, 103, 107, 112 of SEQ ID NO:506 and light chain residues 31, 49, 50, 51, 52, 53, 55, 92 of SEQ ID NO:514 contact the HLA molecule.

[0281] Among the six anti-HLA-A2:HPV16E7:11-19 antibodies, 17675P is most similar to 17670P in the CDR sequences that determine peptide binding, and 21064P and 17930N2 also share a high degree of similarity in the peptide-binding CDR regions. The key contacts between 17670P and the HLA-peptide complex are largely conserved in 17675P, 21064P, and 17930N2, and therefore the binding of these antibodies is likely to be similar to that of 17670P.

[0282] In contrast, the CDR H3 of 17363N has a completely different sequence compared to the CDR H3 from 17670P, and this sequence difference translates into a structural difference in CDR H3, which alters contact with the HLA-peptide complex in this region. For example, heavy chain Tyr100 of 17670P contacts Tyr11 of the bound peptide. The equivalent residue in 17363N is Tyr102 (the CDR H3 of this antibody is two residues longer), which does not contact peptide Tyr11. Instead, Tyr102 is reoriented to contact nearby HLA molecules.

[0283] The lead antibody 17364N has a highly similar sequence to 17363N, with all residues that contact the HLA-peptide complex being identical. This antibody is highly similar to 17363N and therefore should have a different binding mode than 17670P, 17675P, 17930N2, and 21064P.

[0284] The present invention is not to be limited in scope by the specific embodiments described herein. Indeed, various modifications of the invention in addition to those described herein will become apparent to those skilled in the art from the foregoing description and accompanying figures. Such modifications are intended to fall within the scope of the appended claims.

Claims

1. A human antibody or antigen-binding fragment thereof that specifically binds to a conformational epitope of human papillomavirus (HPV) 16E7 peptide (HPV16E7 peptide) presented by HLA-A2, wherein the human antibody or antigen-binding fragment thereof comprises three heavy chain complementarity determining regions (CDRs) (HCDR1, HCDR2, and HCDR3) contained within a heavy chain variable region (HCVR) and three light chain complementarity determining regions (CDRs) (LCDR1, LCDR2, and LCDR3) contained within a light chain variable region (LCVR); A human antibody or antigen-binding fragment thereof, wherein the amino acid sequence of the HCVR / LCVR pair comprises SEQ ID NO: 506 / 514.

2. the human antibody or antigen-binding fragment thereof (a) A binding-dissociation equilibrium constant (K) of less than about 20 nM for the monomeric HLA-A2:HPV16E7 11-19 peptide as measured by surface plasmon resonance assay at 25°C. Ｄ ) to join; (b) an EC of less than about 6 nM on cells expressing the HLA-A2:HPV16E7 11-19 peptide, as determined by a luminescence assay; ５０ binds to cells expressing predicted off-target peptides and does not bind to cells expressing predicted off-target peptides; (c) an EC of less than about 30 nM on cells expressing the HLA-A2:HPV16E7 11-19 peptide as determined by flow cytometry assay; ５０ and (d) the conformational epitope comprises one or more amino acids of SEQ ID NO: 537 selected from the group consisting of Y11, D14, L15, P17, and E18. The human antibody or antigen-binding fragment thereof according to claim 1, having a property selected from the group consisting of:

3. The human antibody or antigen-binding fragment thereof of claim 1, wherein the HPV16E7 peptide comprises the amino acid sequence YMLDLQPET (sequence number 538).

4. The human antibody or antigen-binding fragment thereof according to any one of claims 1 to 3, wherein the human antibody or antigen-binding fragment thereof is a full-length antibody, Fab, Fab', (Fab')2, or Fv.

5. The human antibody or antigen-binding fragment thereof according to any one of claims 1 to 3, wherein the human antibody or antigen-binding fragment thereof is a single-chain Fv (scFv).

6. The human antibody or antigen-binding fragment thereof according to any one of claims 1 to 5, wherein the human antibody or antigen-binding fragment thereof is a human monoclonal antibody or antigen-binding fragment thereof.

7. The human antibody or antigen-binding fragment thereof according to any one of claims 1 to 6, wherein the HCDR1, HCDR2, HCDR3, LCDR1, LCDR2 and LCDR3 comprise the amino acid sequence set of SEQ ID NOs: 508, 510, 512, 516, 518 and 520, respectively.

8. A human antibody or antigen-binding fragment thereof according to any one of claims 1 to 7, comprising the HCVR / LCVR amino acid sequence pair of SEQ ID NOs: 506 / 514.

9. 9. The human antibody or antigen-binding fragment thereof of claim 1 , comprising a detectable moiety.

10. A T-body construct comprising a human antibody or antigen-binding fragment thereof according to any one of claims 1 to 9.

11. A pharmaceutical composition comprising a human antibody or antigen-binding fragment thereof that binds to HLA-A2:HPV16E7 according to any one of claims 1 to 9, or a T-body construct according to claim 10, and a pharmaceutically acceptable carrier or diluent.

12. A polynucleotide sequence encoding the HCVR of the human antibody or antigen-binding fragment thereof according to any one of claims 1 to 9; and b) A polynucleotide sequence encoding the LCVR of the human antibody or antigen-binding fragment thereof according to any one of claims 1 to 9.

1. An isolated polynucleotide molecule comprising:

13. A combination comprising a polynucleotide molecule comprising a polynucleotide sequence encoding the HCVR of an antibody or antigen-binding fragment thereof described in any one of claims 1 to 9, and a polynucleotide molecule comprising a polynucleotide sequence encoding the LCVR of an antibody or antigen-binding fragment thereof described in any one of claims 1 to 9.

14. A vector comprising the polynucleotide molecule of claim 12 or the combination of claim 13.

15. A combination comprising a vector containing a polynucleotide molecule comprising a polynucleotide sequence encoding the HCVR of the antibody or antigen-binding fragment thereof described in any one of claims 1 to 9, and a vector containing a polynucleotide molecule comprising a polynucleotide sequence encoding the LCVR of the antibody or antigen-binding fragment thereof described in any one of claims 1 to 9.

16. A cell comprising the polynucleotide molecule described in claim 12, the combination described in claim 13 or 15, or the vector described in claim 14.

17. A composition for treating a subject having a disease or disorder associated with HPV16E7, comprising a human antibody or antigen-binding fragment thereof described in any one of claims 1 to 9, a T-body construct described in claim 10, or a pharmaceutical composition described in claim 11.

18. 18. The composition of claim 17, wherein the HPV16E7-associated disease or disorder is an HPV-associated cancer.

19. 19. The composition of claim 18, wherein the HPV-associated cancer is squamous cell carcinoma.

20. 20. The composition of claim 19, wherein the HPV-associated cancer is cervical cancer, anogenital cancer, head and neck cancer, or oropharyngeal cancer.

21. The composition of any one of claims 17 to 20, wherein the human antibody or antigen-binding fragment thereof, the T-body construct, or the pharmaceutical composition is administered to the subject in combination with a second therapeutic agent.

22. 22. The composition of claim 21, wherein the second therapeutic agent is selected from the group consisting of a PD-1 inhibitor, a CTLA-4 inhibitor, an antibody against a tumor-specific antigen, an antibody against a viral-infected cell antigen, a PD-L1 inhibitor, a CD20 inhibitor, a bispecific antibody against CD20 and CD3, a nutritional supplement such as an antioxidant, a VEGF antagonist, a chemotherapeutic agent, a cytotoxic agent, surgery, radiation, an NSAID, a corticosteroid, an anti-HPV vaccine, and any other treatment useful for ameliorating at least one symptom associated with the disease or disorder.

23. The composition of any one of claims 17 to 22, wherein the human antibody or antigen-binding fragment thereof, the T-body construct, or the pharmaceutical composition is administered subcutaneously, intravenously, intradermally, intraperitoneally, orally, intramuscularly, or intracranially.

24. 24. The composition of any one of claims 17 to 23, wherein the human antibody or antigen-binding fragment thereof is administered at a dose of about 0.1 mg / kg body weight to about 100 mg / kg body weight of the subject.

25. An isolated nucleic acid molecule encoding a chimeric antigen receptor (CAR), the CAR comprising an extracellular binding domain that specifically binds to a conformational epitope of human papillomavirus (HPV) 16E7 peptide (HPV16E7 peptide) presented by HLA-A2, a transmembrane domain, and an intracellular signaling domain; wherein the extracellular binding domain comprises a human antibody or antigen-binding fragment thereof comprising three heavy chain complementarity determining regions (CDRs) (HCDR1, HCDR2, and HCDR3) contained within a heavy chain variable region (HCVR) and three light chain complementarity determining regions (CDRs) (LCDR1, LCDR2, and LCDR3) contained within a light chain variable region (LCVR); An isolated nucleic acid molecule, wherein the amino acid sequence of the HCVR / LCVR pair comprises SEQ ID NO:506 / 514.

26. 26. The isolated nucleic acid molecule of claim 25, wherein the HCDR1, HCDR2, HCDR3, LCDR1, LCDR2 and LCDR3 comprise the amino acid sequence set of SEQ ID NOs: 508, 510, 512, 516, 518 and 520, respectively.

27. 27. The isolated nucleic acid molecule of claim 25 or 26, wherein the human antibody or antigen-binding fragment thereof comprises the HCVR / LCVR amino acid sequence pair of SEQ ID NOs: 506 / 514.

28. 28. The isolated nucleic acid molecule of any one of claims 25 to 27, comprising SEQ ID NO:

540.

29. 29. The isolated nucleic acid molecule of any one of claims 25 to 28, wherein the human antibody or antigen-binding fragment thereof is an scFv.

30. 30. A vector comprising the isolated nucleic acid molecule of any one of claims 25 to 29.

31. 31. An isolated immune effector cell comprising the vector of claim 30.

32. 32. The isolated immune effector cell of claim 31, which is a T-body.

33. 33. A composition for treating a subject having a disease or disorder associated with HPV, comprising the immune effector cell of claim 31 or 32.

34. 34. The composition of claim 33, wherein the HPV-associated disease or disorder is an HPV-associated cancer.

35. 35. The composition of claim 34, wherein the HPV-associated cancer is squamous cell carcinoma.

36. 36. The composition of claim 35, wherein the HPV-associated cancer is cervical cancer, anogenital cancer, head and neck cancer, or oropharyngeal cancer.

37. 37. The composition of any one of claims 33 to 36, wherein the composition is administered to the subject in combination with a second therapeutic agent.

Images